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Proteomic analysis of Mycobacterium tuberculosis: towards the 
etiology of drug resistance
BACKGROUND
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is an airborne and highly 
contagious bacterium. M. tuberculosis generally causes a pulmonary disease, but can also 
manifest itself in other parts of the body. Approximately 90% of the individuals infected by 
M. tuberculosis carry an inactive, asymptomatic, non-contagious, latent form of TB that could 
eventually progress to an active form of TB.(1) Currently, an estimated 2 billion individuals 
worldwide have a latent form of TB, while >10 million cases of active TB are registered each 
year.(2) With a total of 1.4 million individuals that die annually due to this pathogen, TB is the 
global leading cause of death by a single bacterial infection.(2) 
To answer the question how M. tuberculosis has developed into the notorious pathogen we 
experience today, one should go back to the time of early humans, roughly 70,000 years ago. One 
theory suggests that the early modern humans in Africa were already infected by M. tuberculosis.
(3) Since in this theory humans encountered M. tuberculosis at the start of existence, it is believed 
that man and pathogen followed parallel paths during the course of evolution. When early 
humans, accompanied by M. tuberculosis, migrated from Africa into Europe and Asia, isolated 
human populations were formed, leading to separate paths of evolution. Over time, both man 
and pathogen co-evolved in geographically separated populations. This ‘isolated evolution’ 
ultimately resulted in the seven M. tuberculosis lineages that are known today; see Box 1. Each 
of these seven M. tuberculosis lineages adapted to the human population it co-evolved with.
(4) For example, the M. tuberculosis lineages that evolved in high density human populations 
became more infectious and easy to transmit, since large human populations prevent extinction 
of the bacterium once the hosts passes away. In contrast, M. tuberculosis lineages that infected 
low density populations evolved by becoming less aggressive, and included periods of latency 
followed by reactivation to prevent their extinction. Due to this specialized refinement, the 
pathogen was able to manifest itself as one of the greatest killers in history, killing one in five 
European adults between the 17th and 19th century.(5)
Until the 19th century, the cause of TB was unknown. To describe the pathology, the term 
‘consumption’ was used, referring to the dramatic weight loss that occurs in TB patients, i.e. 
the patients were ‘consumed’ by the disease. In 1882 Robert Koch identified  M. tuberculosis 
as the pathogen responsible for the spread of TB, and from that time on mankind knew what 
caused the disease they were fighting.(6) With the introduction of the antibiotic streptomycin 
some 65 years later, humans gained the upper hand and TB could be efficiently treated.(7, 8) In 
the following years, several anti-TB drugs became available, leading to the standard multidrug 
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treatment regimens that are currently being used over the last 50 years.
With the means available to cure TB, the American Medical Association’s Advisory Council for the 
Elimination of TB predicted in 1987 that by 2010 TB would be extinct worldwide.(9) While given 
the unique opportunity to eliminate this deadly disease, limited access to resources, poverty, 
non-adherence to therapy, neglect, and the HIV epidemic prevented eradication of the disease 
and ultimately resulted into the emergence of a new threat; drug-resistant M. tuberculosis.(10) 
BOX 1: Out-of-Africa migration of Mycobacterium tuberculosis
Genetic evidence suggests that the long, 70,000 years of shared history between M. tuberculosis and 
humans led to isolated evolution of seven M. tuberculosis lineages as humans migrated out of Africa; 
see Figure adapted from Hershberg et al., 2008(4) During this time, each of the M. tuberculosis lineages 
have been able to adapt to the various human population structures. 
To date, knowledge about lineage specific diversity within M. tuberculosis is becoming increasingly 
important to understand the observed inter-lineage variation in virulence, transmission and emergence 
of drug resistance.(11) Regarding drug resistance, Lineage 2, largely consisting of the Beijing genotype 
family, is largely responsible for the dissemination of drug resistant TB in Eurasia.(12, 13) Compared to 
the other M. tuberculosis lineages, Beijing strains have been shown to possess, yet to be identified, 
selective advantages to develop antibiotic resistance.(14-17)
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Drug resistance in Mycobacterium tuberculosis
Antibiotics are essential to treat TB patients and prevent further transmission and dissemination 
of the disease. Despite the presence of multiple effective antibiotics, M. tuberculosis is 
increasingly found to be resistant to one or several antibiotics.(18)
The development of antibiotic resistance in M. tuberculosis is a typical example of Darwin’s 
evolution theory. The selective pressure provided by the usage of antibiotics in the 20th and 21st 
century made antibiotic tolerance a favorable trait for M. tuberculosis. The positive selection 
for more antibiotic tolerant bacteria, combined with non-curative treatment, pushed evolution 
to select for drug resistant strains.(19) This positive selection for drug resistant strains led to the 
global occurrence of multidrug resistant strains that are currently isolated from TB patients.
Multidrug resistant TB, also referred to as MDR-TB, is resistant to at least rifampicin and isoniazid, 
two of the most potent drugs in anti-TB therapy. Globally, at least 3.5% of all new TB cases 
are caused by MDR-TB, whereas the reported levels of MDR-TB are around 20% for patients 
previously treated for TB.(18) Despite being resistant to the first-line antibiotics rifampicin and 
isoniazid, MDR-TB can in principle be treated successfully using second-line antibiotics such as 
fluoroquinolone and aminoglycoside. However, there is a progression of MDR-TB to extensively 
drug resistant TB (XDR-TB), which, in addition to resistance for isoniazid and rifampicin, also 
involves resistance to any of the fluoroquinolones and at least one aminoglycoside.(20) Finally, the 
term totally drug resistant TB (TDR-TB) has been introduced in 2009 to describe M. tuberculosis 
that acquired resistance against all known TB drugs available in a particular setting.(21-23) Due to 
the absence of novel anti-TB drugs that can be used to treat drug resistant TB, there is a growing 
concern that the emergence of MDR-TB, XDR-TB and TDR-TB will reverse the gains obtained in 
the last century that aided humans in the enduring fight against M. tuberculosis.(24)  
Massive rates of drug resistant TB have been reported from several central Asian and Eastern 
European countries like for instance Belarus, where MDR-TB was found in 35% of newly infected 
patients and more than 75% in patients previously treated for TB.(25) One explanation for the 
drug resistant TB burden in Belarus and other former Soviet Union states is the collapse of 
healthcare systems following the fall of the Soviet Union.(26) Similarly, the relatively fragile 
healthcare system in India is thought to accelerate the evolution of M. tuberculosis towards drug 
resistance.(27) Due to the absence of sufficient medical knowledge and appropriate means to 
treat TB in multiple high burden countries, it is evident that there is a human factor contributing 
to the development and spread of antibiotic resistance.(28) 
Next to human factors, bacterial factors can also contribute to the emergence of drug resistance. 
In Eurasia, the dissemination of MDR-TB is largely attributable to the M. tuberculosis lineage 2, 
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that largely consist out of the Beijing genotype.(12, 13) Members of the M. tuberculosis the Beijing 
genotype have been reported to be more transmissible than other M. tuberculosis lineages and 
seem to possess selective advantages to development resistance against the first line antibiotic 
rifampicin.(14-17, 29-32) Despite the current knowledge of M. tuberculosis, it remains difficult to 
pinpoint the exact mechanism employed by the pathogen to develop antibiotic resistance. All M. 
tuberculosis lineages have a shared, broad variety of known, and possibly unknown, molecular 
mechanisms that can be utilized to by-pass and ultimately survive antibiotic treatment. These 
mechanisms can express themselves in either the genotype or the phenotype of the pathogen. 
Genotypic resistance, or inheritable resistance, in bacteria can occur either due to chromosomal 
changes of drug target genes or by horizontal transfer of resistance conferring genes between 
bacteria. In M. tuberculosis, genotypic resistance is exclusively caused by chromosomal changes, 
after which drug resistant mutants can outgrow susceptible bacteria under the selective 
pressure of antibiotics.(33) The vast majority of antibiotic resistance in M. tuberculosis is caused 
by a genetic modification of the drug target gene, followed by selection of these mutants in 
the patient. In new patients, MDR-TB can be contracted by an infection of an MDR-TB strain 
(primary resistance) and by a bad quality treatment (acquired resistance). In case of the first-
line antibiotic rifampicin, the drug target rpoB is genetically altered in  approximately 95% of all 
the rifampicin resistant cases.(34)
Next to modifications of the genotype, M. tuberculosis has several intrinsic and phenotypic 
traits that can contribute to antibiotic tolerance already prior exposure to drugs; see Box 2. 
Phenotypic drug resistance mechanisms do usually not provide the level of resistance that is 
conferred by genotypic resistance, hence it is also referred to as phenotypic drug tolerance.
One major obstacle in the design of antibiotics is to get clinically relevant concentrations of 
drugs inside the pathogen. The first hurdle for antibiotics is the remarkable hydrophobic cell wall 
of M. tuberculosis, that consists of unusual long-chain fatty acids, named mycolic acids. These 
fatty acids surround the pathogen and form an impermeable shell that provides resistance to 
a broad variety of antibiotics.(35) The cell wall acts together with specific proteins, referred to 
as porins, that can form channel-like structures in the mycobacterial cell wall. By regulating 
the abundance of porins, mycobacteria can adjust the permeability of their cell wall.(36) The 
presence of porins allows the pathogen to more easily take up hydrophilic nutrients such as 
glucose.(37) In contrast, the absence of porins makes it more difficult for hydrophilic antibiotics 
to cross the cell wall and accumulate inside the pathogen.(36, 38)
Antibiotics that do manage to cross the hydrophobic cell wall of M. tuberculosis can be secreted 
by a specific class of proteins, known as efflux pumps. These proteins actively decrease 
the intracellular drug concentration by exporting antibiotics from the intracellular to the 
extracellular environment.(39-41)  To date,  more than 30 putative efflux pump genes have been 
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described in M. tuberculosis.(40) With this large collection of efflux pumps, M. tuberculosis is 
capable of reducing the intracellular concentration of a variety of antibiotics including, but not 
limited to, tetracycline, fluoroquinolones and aminoglycosides.(42) 
The hydrophobic cell wall, in combination with porins and efflux pumps, brings the intracellular 
concentration of antibiotics to a minimum for specific molecules. Other molecules, such as 
beta-lactams, can be accumulated in the pathogen. However, mycobacteria possess at least 
four enzymes that provide beta-lactamase activity to degrade beta-lactam containing drugs.
(43-45).
Finally, drug tolerance in M. tuberculosis can also be conferred by the slow growth rate of the 
pathogen, since the majority of antibiotics target mechanisms involved in active cell growth 
and division.(46, 47)  Compared to the well-studied bacterium Escherichia coli, the doubling time 
of M. tuberculosis in nutrient rich media is approximately 40 times longer that of E. coli.(48) 
Consequently, it takes approximately 40 times longer to kill 99% of M. tuberculosis in culture 
using antibiotics than it would to kill E. coli.(49) Next to its slow growth rate, M. tuberculosis 
can regulate its metabolic activity. When the pathogen becomes metabolically hypoactive, the 
potency of various antibiotics is lowered.(50)
In vivo, the intrinsic, genotypic and phenotypic drug resistance mechanisms are related. During 
the initial exposure to antibiotics, M. tuberculosis can persist in its host due to intrinsic and 
phenotypic drug resistance mechanisms. As a consequence, the pathogen gains time to develop 
a more durable drug resistant genotype.(51, 52) 
Although intrinsic, genotypic and phenotypic mechanisms are known to exist in M. tuberculosis, 
it is unclear whether these mechanisms are actively induced simultaneously by the pathogen 
when challenged by antibiotics. Since both intrinsic and phenotypic drug resistance mechanisms 
facilitate the development of genotypic resistance, it is of increasing interest to pinpoint which 
biological processes drive the development of drug resistance within the various M. tuberculosis 
lineages. This is not only important to increase our understanding of the ‘traditional’ first line 
antibiotics, but also to prevent the occurrence of resistance for the novel second-line antibiotics 
bedaquiline and delamanid that have proven efficacy for treatment of drug resistant TB.(53, 54)
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BOX 2: The molecular toolbox of Mycobacterium tuberculosis
M. tuberculosis strains possess a variety of tools that allow the pathogen to protect itself against 
antibiotics. Depicted are the four most general phenotypic mechanisms used by M. tuberculosis to 
increase its tolerance towards antibiotics; see Figure adapted from Vranakis et al., 2014 (55).  The first 
barrier, which is conserved throughout the Mycobacterium genus, is the highly hydrophobic cell wall. 
This barrier, in combination with the regulation of porins, increases antibiotic resistance by reducing 
the cells permeability to antibiotics, which makes it difficult to intracellularly accumulate antibiotics to 
a clinically relevant concentration.(35, 36, 38) Antibiotics that manage to cross the cell envelope face a 
second hurdle: efflux pumps that can export a variety of intracellular compounds, such as antibiotics. 
By working together with the cell wall and porins, efflux pumps can keep the intracellular concentration 
of drugs to a minimum.(40) Third, some antibiotics that manage to accumulate inside the pathogen, 
can be degraded by intracellular enzymes. For example, beta-lactam based antibiotics can be actively 
degraded by cytoplasmic enzymes known as beta-lactamases.(43-45) Finally, M. tuberculosis can alter 
its metabolic activity. When the pathogen makes the transition to a metabolically hypoactive state, it 
becomes far less susceptible to a variety of antibiotics.(46, 50)
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Quantitative Proteomics to study Mycobacterium tuberculosis
Current curative anti-TB drug treatment regimens require 6-9 months with multiple antibiotics, 
to avoid re-emergence of the disease.(56) The length of the treatment often leads to adverse 
drug reactions and poor compliance to therapy, which contributes to the occurrence of drug 
resistance.(57) In the case of MDR-TB and XDR-TB, curative treatment requires the use of second-
line antibiotics that are often associated with even more severe adverse events, that could 
ultimately result in discontinuation of treatment and more resistant bacteria.(58) 
Treatment regimens for both drug susceptible and drug resistant TB are based on the 
assumption that the microbial physiology of drug-susceptible M. tuberculosis is similar to that 
of drug-resistant variants and strains that are more prone to develop drug resistance, i.e. our 
understanding of drug resistance is limited to the established relationship between specific 
mutations and resistance to specific anti-TB drugs.(59) However, considering the phenotypic 
drug tolerance mechanisms available to M. tuberculosis, it is to be expected that drug resistant 
strains, and variants that are more likely to develop resistance, differ physiologically from drug 
susceptible strains.
A better knowledge of the mechanisms of action of anti-TB drugs, the evolution of drug 
resistance and the biology of drug resistance development will allow for the identification of 
new drug targets, more strategic use of available antibiotics and improved diagnostic assays to 
detect drug resistance. To fully understand the development of antibiotic resistance, one needs 
tools to monitor and examine the various known and unknown mechanisms that contribute to 
the formation of drug resistance.
Modern ‘omic’ approaches can provide an unbiased, quantitative and holistic view to study 
specific classes of biomolecules. The DNA, which may contain drug resistance conferring 
mutations present in the genome of M. tuberculosis, is studied within the field of genomics. 
The genome itself is generally considered a blueprint for proteins that can be synthesized by 
an organism. The proteins, synthesized as dictated by the genome, that are present at a given 
time point within the cell, are referred to as the proteome. In contrast to the genome, the 
proteome is highly dynamic: the abundance of proteins can vary under different environmental 
conditions; proteins can be modified post- and co-translational; proteins can be secreted or only 
be present within a specific compartment of the cell. The field of proteomics aims to identify 
and quantify the proteome of organisms under various environmental conditions.
The mass spectrometer, or mass analyzer, is a central piece of equipment in mass spectrometric 
based proteomic workflows. Essentially, mass spectrometers determine the mass-to-charge 
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(m/z) ratio of charged peptides and proteins in the gas-phase.  Based on the observed mass-
to-charge ratio, the mass of intact proteins and peptides can be determined. This process is 
referred to as peptide mass fingerprinting.(60) Tandem mass spectrometry, also known as MS/
MS or MS2, is used to determine the amino acid sequence of proteins and peptides.(61) First, 
the intact mass of a molecule is determined using a process similar to that of peptide mass 
fingerprinting. Subsequently, using a single or a combination of fragmentation techniques, 
the peptide backbone of the molecule can be broken. By determining the masses of these 
fragments, one can identify the sequence of building blocks, or amino acids, of which the 
protein or peptide is composed.
The first mycobacterial proteomic studies focused on enriched cellular fractions, including the 
culture supernatant, cell envelope or cytoplasm, using two-dimensional gel electrophoresis 
after which selected “spots” were analyzed using tandem mass spectrometry.(62-71) Using this 
approach, a cumulative number of approximately 300 M. tuberculosis proteins were identified. 
In 1998, the entire M. tuberculosis genome was mapped.(33) In the case of M. tuberculosis, the 
genome contained blueprints for roughly 4,000 proteins. Based on homology studies, nearly 
3,500 proteins could, often weakly, be associated to a function.(72) Equipped with the knowledge 
that less than 10% of the M. tuberculosis proteome was yet observed, it was evident that in 
order to analyze the entire mycobacterial proteome in a single experiment, significant changes 
in workflow and equipment were necessary.
One major step forward was around the turn of the century, with the introduction of novel 
proteomic workflows in which multidimensional liquid chromatography (LC) was hyphenated to 
tandem mass spectrometry, of which the spectra could be automatically matched to a genome 
using proteomic search engines.(73) Currently, proteomic workflows are still based on the same 
principles, albeit with more advanced instrumentation and bioinformatics. 
A schematic, modern proteomics approach for M. tuberculosis is outlined in Box 3. The described 
approach, applied with minor modifications, has resulted in the identification of >3000 mycobacterial 
proteins, which corresponds to 95% of the observable proteome during logarithmic growth of M. 
tuberculosis. (74) The identification of a proteins N-terminal and C-terminal sequence can be used 
to verify and improve genome annotations. This specific field is referred to as proteogenomics. 
Mass spectrometry based proteogenomic analysis of M. tuberculosis led to translational start site 
correction for >30 genes, and identification >40 novel protein coding genes.(74-76) However, to study 
the dynamics of the proteome, and its relation to drug resistance, quantification of proteins is 
often a necessity.(55) This is especially relevant when researchers want to compare the proteome 
composition of a drug-resistant strain with that of a drug susceptible strain or monitor the 
proteomic response of a strain exposed to sub-lethal concentrations of antibiotics. 
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Using mass spectrometry, also quantitative information of the proteome can be obtained.
(77) Although there are multiple quantitative proteomic methods, one can separate label-free 
strategies from isotopically labelled methods.(78) With a label-free proteomic approach, data 
is acquired as presented in Box 3. Subsequently, the abundance of peptides is compared 
between two or multiple runs. The main advantages of label-free proteomic approaches is that 
they are cost-efficient, relatively straight forward and have a high dynamic range.(77, 79) For M. 
tuberculosis, label-free proteomic analyses have been used to compare drug susceptible with 
drug resistant strains, and avirulent to virulent M. tuberculosis strains.(80-83) Although powerful, 
label-free approaches have the disadvantage that they are relatively prone to experimental and 
technical variation.
In order to achieve a more robust proteomic quantification method with more throughput, a 
variety of mass labels, or mass tags, have been introduced.(77, 78) Since mass spectrometers are 
able to determine masses, one can discriminate peptides with a “heavy” or “light” mass label 
in a single analysis. By comparing the intensities of mass labelled peptides, one can determine 
their relative abundance. One elegant technique to label, or tag proteins is to culture cells in 
the presence of stable isotopically labelled amino acids (SILAC).(84) Unfortunately, this type of 
metabolic labeling for M. tuberculosis is challenging because amino acids are used as carbon 
and nitrogen source for the synthesis of new amino acids, causing the isotopic label to end in a 
variety of amino acids.(83, 85)
 
To overcome these limitations, post-metabolic labeling strategies can be used. Post-metabolic 
labeling strategies have the advantage that they do not rely on specific culture media and 
virtually every sample can be labelled, including clinically derived material. Most post-metabolic 
labels are incorporated at the peptide level. Depending on the number of the samples and 
capabilities of the equipment available, one can decide to use isobaric tags or isotope-coded 
tags. Isobaric tags such as tandem mass tags (TMT) or isobaric tags for relative and absolute 
quantitation (iTRAQ) can be used to analyze 2-10 samples in a single analysis. Quantitative data 
is obtained after fragmentation of the peptide and its isobaric label.(86, 87) A major drawback of 
isobaric mass tags is that they are not compatible with all types of mass spectrometers due to 
the low mass of the reporter ion. Furthermore, the occurrence of precursor ions with similar 
masses leads to co-isolation of peptides with inaccurate quantification as a result.(88, 89)  
Finally, quantification can also be performed by dimethylation, also known as reductive 
amination, which uses isotope coded tags.(90) The dimethyl label is incorporated after protein 
digestion, providing the peptides with a “light” (+28 Da), “medium” (+32 Da) or “heavy” (+36 Da) 
methyl tag. Subsequently, the samples are mixed and co-analyzed using LC-MS/MS. Since there 
is no chemical difference between the three dimethyl labels, the labelled peptides will co-elute 
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from the LC system, after which they are analyzed by the mass spectrometer, where the relative 
abundance is calculated based on the precursors ion chromatogram peak area. Compared to 
isobaric mass tags, dimethylation has a lower throughput due to limited multiplexing, and more 
complex mass spectra, which could lead to less peptide identifications. However, isobaric mass 
tags have several advantages compared to dimethylation mass tags including: compatibility with 
all tandem mass spectrometers; more accurate quantification; and more affordable reagents.(91) 
In this thesis, we decided to use dimethylation as the method of choice to quantitatively asses 
the proteome of M. tuberculosis in a robust manner.
Quantitative mass spectrometry can be used to study the abundance of proteins. However, 
more layers of information are present within the proteome. Post-translational modifications 
of proteins can impact the functionality of proteins, their compartmentalization, but also how 
they are organized in complexes and interact with other proteins.(92) Several post-translational 
modifications have been reported within the proteome of M. tuberculosis, including 
phosphorylation, glycosylation, acetylation, lipidation and pupylation.(93-97) Despite their 
presence, there is only a single quantitative phosphoproteomic study that demonstrated the 
potential impact of post-translational modifications on bacterial virulence.(98)
Despite being in its infancy, modern day proteomic approaches are powerful enough to study, 
without bias, phenotypic changes in the M. tuberculosis proteome, which could contribute to 
the development of antibiotic tolerance.
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BOX 3: Interpreting the mycobacterial proteome using mass spectrometry
A typical, schematic, M. tuberculosis proteomic workflow can roughly be divided into three steps: 1. 
Cell culture in a biosafety level 3 laboratory, 2. Sample processing, generally outside of the biosafety 
level 3 laboratory, 3. Analysis of the processed sample. 1) Cell culture is the starting point for a 
majority of bacterial proteomic studies. Since the proteome is highly dynamic, one needs to select 
culture conditions that allow for reproducible culture of the pathogen. Following cell culture, media 
components, including proteins, that can interfere with the downstream processing and analysis of the 
samples need to be removed. Subsequently, the cells need to be killed before they can be moved safely 
from the biosafety level 3 laboratory. 2) For the processing of the samples, the proteins are extracted 
from the cell with a combination of lysis buffer, heat and mechanical disruption to obtain an unbiased 
protein extract of the mycobacterial proteome.(99) The extracted proteins are denatured, reduced 
and alkylated after which they are proteolytically digested: trypsin is the common choice since it often 
yields peptides of favorable length and charge state for analysis by mass spectrometry. At this stage, 
the peptides can be dimethylated for quantitative purposes, or fractionated to reduce the complexity 
of the digest and increase proteomic coverage. 3) The analysis of the protein digest encompasses a 
reverse phase based separation of peptides, followed by analysis using tandem mass spectrometry. 
The recorded fragment spectra are matched against theoretical spectra, generated on the basis of the 
available genomic information by a proteomic search engine.
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Outline of this thesis
Over the last decade, it became apparent that global efforts, which make use of the currently 
available antibiotics, vaccines and diagnostic assays, fall short to reverse the global TB epidemic 
and spread of MDR-TB. In this thesis, we used mass spectrometry based proteomics as a tool to 
study the interplay between the proteome of M. tuberculosis and antibiotic resistance. 
Chapter 1 provides an overview of M. tuberculosis, its family structure, its mechanisms to cope 
with antibiotics and the potential of proteomics to pinpoint which proteins contribute to the 
transition of M. tuberculosis to its multidrug resistant form. 
In chapter 2, we investigate which bacterial factor present in M. tuberculosis Beijing, provides 
a selective evolutionary advantage. The M. tuberculosis Beijing family is often associated with 
drug resistance. Compared to other M. tuberculosis lineages, the Beijing genotype is considered 
to be one of the most prevalent and genetically conserved M. tuberculosis families. Despite 
being genetically conserved, the Beijing family can be divided into the more ancient (atypical) 
and more modern (typical) Beijing strains. Even though the ancient and modern Beijing strains 
are closely related on the genetic level, it is the modern Beijing strain that is responsible for 
the dissemination of drug resistance in Eurasia. Using a pooled proteomics approach, alongside 
traditional individual duplex analyses, we search for proteins that contribute to the successful 
phenotype of modern Beijing strains. Using enzymatic and quantitative polymerase chain 
reaction analysis of selected genes in a large cohort of Beijing strains, we establish a relation 
between the genotype and phenotype of modern Beijing strains that could ultimately provide 
the pathogen with an inheritable selective advantage over other M. tuberculosis strains.
In chapter 3, we determine which phenotypic mechanisms contribute to drug tolerance during 
the initial 24 hrs after antibiotic treatment. Since there is a strong correlation between modern 
Beijing strains and drug resistance, we follow the (phospho)proteome of a clinically relevant 
M. tuberculosis modern Beijing strain during the first 24 hrs of rifampicin exposure. Based on 
the findings generated by the (phosphor)proteomic analysis, we make use of cellular assays to 
confirm the physiological adaptations made by M. tuberculosis Beijing to cope with rifampicin.
In chapter 4, we examine whether other M. tuberculosis strains respond to rifampicin in the 
same manner as M. tuberculosis Beijing strains. We start by comparing the proteome of M. 
tuberculosis Beijing with the proteome of M. tuberculosis H37Rv. Based on the outcomes of this 
study we select differentially regulated proteins that can contribute to antibiotic tolerance in 
M. tuberculosis and quantify these proteins in a large cohort of clinically relevant strains using 
parallel reaction monitoring.
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In chapter 5, the mechanism of action of thioridazine is investigated. Thioridazine is a 
neuroleptic that might be used off-label to treat M. tuberculosis. The anti-mycobacterial potency 
of thioridazine has been reported not to be affected by the selective advantages present in M. 
tuberculosis Beijing. However, the mechanism through which thioridazine is capable of killing 
mycobacteria is yet unknown. By comparing the proteome of M. tuberculosis in the presence 
and absence of thioridazine, we want to generate a first hypothesis of thioridazines mechanism 
of action. Subsequently, this hypothesis is tested using cellular assays, so we can establish a 
model of thioridazines mechanism of action. 
In chapter 6, the potential of tandem mass spectrometry as a highly discriminatory phenotypic 
tool to identify mycobacteria is explored. Using a proteomic workflow in combination with a 
10 minute LC-MS/MS gradient, we examine phylogenetic relationships between various well 
conserved mycobacteria. The outcomes and feasibility of the method is compared with the 
methods that are routinely used in a clinical setting.
In chapter 7, we summarize the outcomes of this thesis. Furthermore, we discuss the relevance 
of our findings, how they should be seen into context with our current knowledge of TB and 
suggest directions for future studies.
1
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Disclosure of selective advantages in the “modern”
 sublineage of the Mycobacterium tuberculosis Beijing
genotype family by quantitative proteomics
Abstract
The Mycobacterium tuberculosis Beijing genotype, consisting of the more ancient (atypical) and 
modern (typical) emerging sublineage, is one of the most prevalent and genetically conserved 
genotype families and has often been associated with multidrug resistance. In this study, we 
employed a 2D-LC-FTICR MS approach, combined with dimethylation of tryptic peptides, to 
systematically compare protein abundance levels of ancient- and modern Beijing strains and 
identify differences that could be associated with successful spread of the modern sublineage. 
The data is available via ProteomeXchange using the identifier PXD000931. Despite the 
highly uniform protein abundance ratios in both sublineages, we identified four proteins as 
differentially regulated between both sublineages, which could explain the apparent increased 
adaptation of the modern Beijing strains. These proteins are; Rv0450c/MmpL4, Rv1269c, Rv3137 
and Rv3283/sseA.  Transcriptional and functional analysis of these proteins in a large cohort of 
29 Beijing strains showed that the mRNA levels of Rv0450c/MmpL4 are significantly higher in 
modern Beijing strains, whereas we also provide evidence that Rv3283/sseA is less abundant 
in the modern Beijing sublineage. Our findings provide a possible explanation for the increased 
virulence and success of the modern Beijing sublineage. In addition, in the established dataset 
of 1817 proteins, we demonstrate the pre-existence of several, possibly unique, antibiotic efflux 
pumps in the proteome of the Beijing strains. This may reflect an increased ability of Beijing 
strains to escape exposure to anti-tuberculosis drugs.
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Introduction
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is one of the most 
successful pathogens worldwide. Nowadays, still about 8-9 million new cases and 1.5 million 
deaths are recorded annually.(1)
DNA fingerprinting of the Mycobacterium tuberculosis complex has revolutionized studies on 
transmission of TB in the last two decades (2), but also disclosed the phylogeny of this important 
grouping of bacteria.(3, 4) In essence there are six major M. tuberculosis lineages. The first one 
was described in 1995 and designated the ‘Beijing’ genotype family, which is highly prevalent in 
Asia, the Former Soviet Union states, and South Africa.(5-8) Recently, the Beijing genotype family 
was identified as the major genotype family in the ‘East Asia clade’ defined on single nucleotide 
polymorphism (SNP) typing.(4) In the years after its disclosure, the Beijing genotype family drew 
attention because it seemed genetically highly conserved on basis of the available genetic 
markers, which could be related to active and recent spread, presumably due to selective 
advantages over other M. tuberculosis genotypes.(5-8) Selective pressure on this group of bacteria 
could be induced by the introduction of mass BCG vaccination and treatment by anti-TB drugs.(9) 
Consequently, in many geographic areas, Beijing strains were found significantly correlated with 
(multi)drug resistance, treatment failure, relapses after curative treatment, and transmission 
of resistant TB.(6, 7, 10-12) In TB mouse models, Beijing strains revealed an upregulated virulence 
and a higher ability to escape BCG vaccination.(13-15) This is particularly alarming since there are 
indications that the Beijing genotype strains are emerging in multiple geographic areas, as they 
are associated with lower ages of patients and, hence, active transmission.(6, 16, 17) Increased 
odds of M. tuberculosis Beijing are also observed for patients with a polymorphism in their 
natural resistance associated macrophage protein 1 (NRAMP1), encoded by the SLC11A1 gene.
(18) This supports the theory of a co-evolution of M. tuberculosis Beijing with their human host.
Initially, mechanisms underlying a higher adaptability were assumed to be related to alterations 
in DNA repair, but polymorphisms in related genes were also observed in strains of other 
genotype families.(19) Although not yet explained in detail, a  study published in 2012 revealed 
that a part of the Beijing strains revealed a much higher frequency of naturally occurring 
rifampicin resistant mutants than the traditionally measured 1 in 108.(20) This important 
observation was recently confirmed by Ford et al, who pointed out that the correlation between 
the Beijing genotype and resistance could indeed be explained by a higher mutation frequency.
(21) Not surprisingly, resistance against anti-TB drugs is especially a major problem in former 
Soviet Union States, China, and South Africa, where the Beijing genotype strains are highly 
prevalent.(22-26)
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In 2002, the Beijing genotype family was divided into the modern (typical) and ancient (atypical) 
lineage.(27) Beijing strains without insertion of IS6110 in the NTF region were referred to as 
ancient Beijing strains and seem to resemble the ancestors of the Beijing family.(27) In most 
countries, modern Beijing strains are much more prevalent than ancient ones, suggesting an 
active spread, except for Japan, where the ancient type of Beijing strains is more wide spread.
(28) The two Beijing lineages were also divided on basis of large genomic deletions, also referred 
to as Regions of Difference (RDs). RD105 is thought to be characteristic of all Beijing strains, 
whereas deletion of RD181 was found associated with modern Beijing strains.(29) Although the 
modern and ancient Beijing strains seem to be closely related on the genetic level(30), differences 
in association with (multi) drug resistance and in the ability to cause and spread disease(31) 
have been described between both sublineages. Moreover, after several studies suggested 
enhanced ability of Beijing strains in general to circumvent BCG-vaccine induced immunity(13, 
14), one study reported that modern Beijing strains were isolated more frequently from BCG-
vaccinated patients than non-vaccinated individuals.(9) The observation that the interaction of 
modern Beijing strains with the immune system is different than that of ancient strains was 
further confirmed by a recent study that described differences in pro-inflammatory cytokine 
induction for both strains.(32) If modern Beijing strains indeed have selective advantages over 
other M. tuberculosis strains and spread more prosperously, this should be reflected in the 
degree of genetic conservation. This assumption was confirmed by whole genome sequencing 
(WGS) of Beijing strains from a wide spread geographic area. Three modern Beijing strains from 
China, Vietnam, and South Africa were found genetically highly conserved in comparison to 
three ancient strains from the same regions.(30) This confirms the evolutionary advantage of 
the modern Beijing genotype over the closely related ancient Beijing and other M. tuberculosis 
strains. In fact, Schürch et al. traced only 31 non synonymous single nucleotide polymorphisms 
(nsSNPs) mutations characteristic of modern Beijing strains.(30) However, the presence of these 
31 nsSNPs is not sufficient to explain the consequences in terms of evolutionary development 
and adaptation.  Therefore, we performed an in-depth comparison of the protein abundances 
of both sublineages. Comparative proteomic analysis of different M. tuberculosis strains has 
been reported before.(33) So far, one study examined the proteomes of a single hyper- and hypo 
virulent M. tuberculosis Beijing strain by a label-free quantitative technique, and reported the 
differential regulation of virulence factors, such as Rv3875/ESAT-6 and other Esx-like proteins.(34) 
However, biological variation limits the value of a traditional individual duplex (one-versus-one) 
experimental approach. In addition, individual characteristics that are not always representative 
of the entire grouping cannot be distinguished from structural differences between the two 
genotypes. To obtain a more reliable insight, multiple measurements of individual samples of 
each grouping are required. Furthermore, to limit the influence of biological and inter-strain 
variation, we generated a sample pool comprising five modern and five ancient Beijing strains, 
which were selected to optimally represent the full spectrum of both M. tuberculosis Beijing 
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sublineages.
Sample pooling was previously successfully applied in proteomic experiments, and used in case 
there was insufficient individual sample material available.(35, 36) Sample pooling has also been 
applied to create an internal reference sample in a so called ‘super-SILAC mix’(37, 38), that can 
be combined with clinical samples. Use of the super-SILAC approach resulted in a narrower 
distribution of protein abundance ratios. The narrower protein ratio distribution increased the 
significance of the altered protein ratios.[35] Next to the pooled sample approach, we compared 
three ancient Beijing strains with three modern Beijing strains using traditional individual 
duplexes. We identified and quantified a cumulative number of 2392 proteins (±60% of the 
M. tuberculosis protein coding genome), of which 1817 were present in all of the analyses 
performed.  We demonstrate the presence of multiple antibiotic extruding efflux pumps in the 
proteome of M. tuberculosis Beijing, notably without exposure of the pathogen to a drug. Three 
of these efflux pumps were previously not quantified in the proteome of M. tuberculosis H37Rv 
by a proteome-wide selected reaction monitoring approach.(39)   
Despite the highly uniform protein ratio distribution in both strains, we identified four proteins 
to be more abundant in the modern Beijing strains that can explain their emergence and 
perhaps higher virulence. We complemented our proteomic data with transcriptional analysis 
of selected genes in a larger cohort of 14 ancient Beijing and 15 modern Beijing strains. To verify 
the differential regulation of a particular virulence factor the experiments were supplemented 
with functional analysis.
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Materials and methods
Molecular typing methods
M. tuberculosis Beijing strains were selected from a previously published selection of 259 Beijing 
strains.(40) Fourteen ancient- and 14 modern Beijing strains were included in the study to optimally 
represent the M. tuberculosis family. In addition, the successful modern Beijing strain B0/W148 
was added to the selection.(41-43) Using the M. tuberculosis Beijing characteristic marker RD105, 
we ensured that all the strains investigated indeed belong to the M. tuberculosis Beijing family. 
Additionally, mutT2/ogt were used to differentiate ancient from modern Beijing strains.(29, 31) To 
exclude the possibility of contamination, or the selection of clonal isolates for proteomic analysis, 
we performed standard MIRU (mycobacterial interspersed repeat units) 24-loci VNTR (variable 
number of tandem repeats) with a few minor modifications.(44) The in-house VNTR method based 
on the protocol of the MIRU-VNTR typing manual was used  with minor modifications: the amount 
of DNA polymerase used was 0.75 units per multiplex PCR, and the initial concentration of labeled 
primers was increased to 8 μM for locus 2165 and locus 2163b. The amplicon sizes were determined 
by using the automated ABI 3730 DNA analyzer (Applied Biosystems, CA). 
Mycobacterial culture conditions
All M. tuberculosis isolates were derived from the reference database of clinical isolates 
at the National Institute for Public Health and the Environment (RIVM) in Bilthoven, the 
Netherlands. Strains were re-cultured from frozen stocks in 5 ml Tween-Albumin liquid culture 
broth (Tritium Microbiologie, the Netherlands) at 36°C without shaking until an O.D. at 600 
nm of 0.4 AU was reached. Of the mycobacterial pre-culture, 1 ml was transferred to a 250 
ml Erlenmeyer flask containing 100 ml Tween-Albumin broth and incubated under shaking 
conditions at 36°C with constant aeration. Once the cultures reached an O.D. at 600 nm of 0.6 
AU, representing the mid-log phase, the cells for proteome analysis were washed three times 
with ice cold PBS, dissolved in 5 ml Lysis-buffer (4% SDS, 100 mM Tris-HCl, pH 7.6) and heat-
killed at 95°C for 10 min. Lysates were stored at -20°C until further usage. M. tuberculosis Beijng 
strains used for qPCR analysis were harvested at early log phase and stored in L6-buffer at -20°C 
until use.(45) 
Minimal inhibitory concentration determination
Susceptibility to the first line anti-mycobacterial drugs; rifampicin, isoniazid, ethambutol 
and pyrazinamid, was determined according to Clinical and Laboratory Standards Institute 
guidelines(46), using the BACTEC MGIT-960 system (Becton, Dickinson and Co., Franklin Lakes, 
NJ). 
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Protein sample preparation and dimethylation isotope labeling
Heat inactivated cells for proteomic experiments were mechanically lysed by bead-beating in 
a mini bead-beater 16 (BioSpec) for 5 min using glass beads. Thereafter, the cells were cooled 
down on ice for 5 min and the procedure was repeated twice. The cell lysates were cleaned 
from cell debris by centrifugation for 1 min at 14,000g and the supernatant was transferred to 
another tube. Proteins were digested using the filter aided sample preparation (FASP) method.
(47) In brief, 100 μg of DTT reduced proteins was loaded on a 30kDa filter. SDS was removed in 
three washes with 8M urea. The proteins were reduced and carbamidomethylated, and the 
excess reagent was removed by three additional washes with 8M urea. Proteins were then 
overnight digested using endoproteinase Lys-C (endoLysC) followed by a four hrs digestion 
using trypsin at RT. Tryptic peptides were desalted on C18 SepPak columns and derivatized on 
column by dimethyl labeling.(48) Peptides derived from ancient Beijing strains were labeled with 
a light label (+28Da), whereas modern Beijing strains were labeled with heavy labels (+36Da). 
In addition, two sample pools consisting of five light labeled ancient Beijing strains and five 
heavy labeled modern Beijing strains were prepared by mixing the respective tryptic digests in 
a 1:1:1:1:1 manner before fractionation. 
Strong Cation Exchange Chromatography
In total 100 μg of labeled peptides were fractionated by strong cation exchange (SCX) on a Agilent 
1100 system equipped with an in-house packed SCX-column (320 µm ID, 15 cm, polysulfoethyl 
A 3 μm, Poly LC), run at 4 μl/min. The gradient started with a 10 min run at 100% solvent A 
70/30/0.1 (water/acetonitrile/formic acid), after which a linear gradient reached 100% solvent 
B (250 mM KCl, 35% acetonitrile, 0.1% formic acid) in 15 min, followed by 100 % solvent C 
(500 mM KCl, 35% acetonitrile 0.1% formic acid) in the following 15 min. The gradient was 
held at 100 % solvent C for 5 min to clean the column, then switched back to 100 % solvent A. 
Thereafter, 15 fractions were collected in 1 min intervals, lyophilized and reconstituted in 30 μl 
95/3/0.1 (water/acetonitrile/formic acid).
NanoLC-MS/MS
Dissolved fractions were analyzed by on-line nano-HPLC MS with a system consisting of a 
Agilent 1100 gradient HPLC system (Agilent, Waldbronn, Germany) as described previously(49), 
and a LTQ-FT Ultra mass spectrometer (Thermo, Bremen, Germany). Of each fraction 5 μl was 
injected onto a home-made pre-column (100 μm×15 mm; Reprosil-Pur C18-AQ 3 µm, Dr Maisch, 
Ammerbuch, Germany) and eluted via a home-made analytical nano-HPLC column (15 cm×50 
µm; Reprosil-Pur C18-AQ 3 μm). The gradient was run from 0% to 30% solvent B (10/90/0.1 
water/acetonitrile/formic acid) in 10-155 min. A tip of approximately 5 µm was drawn at the tip 
of the nano-HPLC column to act as electrospray needle. Full scan mass spectra were acquired 
in the FT-ICR with a resolution of 25,000 at a target value of 5*106. The five most intense ions 
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were selected and fragmented in the linear ion trap using collision-induced dissociation at a 
target value of 10,000.
Search Databases
MSMSpdbb was used to generate concatenated protein databases in FASTA format.(50) Genomic 
sequences and annotational information of M. tuberculosis H37Rv (3996 entries)(51) were used, 
together with the genetic information of M. tuberculosis Beijing strain NITR203 (4071 entries).
(52) This concatenated database contains all previously described mutations that are specific 
for modern Beijing strains, as well as the ancient Beijing “wild-type” sequence (4327 entries).
(30) Protein products larger than 50 amino acids were considered for stop-to-stop translation. 
Peptides describing varying sequences or different translational start sites between both strains 
were only used when the sequence was longer than seven- and shorter than 35 amino acids. 
Proteins that were clustered received the accession number and description of control strain M. 
tuberculosis H37Rv. Translated entries, which did not cluster with any of the annotated genes, 
were discarded. To use the database with MaxQuant software, the artificial J and O amino acid 
residues were replaced by a lysine residue. Alongside the concatenated data base we searched 
FASTA databases based on M. tuberculosis H37Rv(51) and M. tuberculosis Beijing NITR203.(52) 
Data Interpretation
Peptide and protein identification and quantitation was accomplished using MaxQuant 
1.4.0.3.(53) The false discovery rate (FDR) was set to 0.01 for both proteins and peptides. Minimal 
peptide length was set to 6 amino acids. The first search was performed using 20 ppm, while the 
main search was conducted with 10 ppm. Search of MS/MS spectra was performed with 20 ppm 
using the Andromeda search engine.(54) In total 262 common contaminants were included in the 
searches by Andromeda. Enzyme specificity was set as C-terminal to arginine and lysine without 
proline restriction. A maximum of two missed cleavages was allowed. Variable modifications 
included N-terminal protein acetylation, methionine oxidation and corresponding dimethyl 
labels.
Carbamidomethylation of cysteine was selected as a fixed modification. Proteins considered for 
quantification required a minimal peptide count of two, including unique and razor peptides. 
Proteins identified by site, matched against the reverse database or identified as a contamination, 
were excluded for further analysis. Statistical analysis of the outcomes was performed by Perseus 
using the significance B test with a Benjamini-Hochberg FDR <5%. Data files have been deposited 
in the publicly available ProteomeXchange Consortium (proteomecentral.proteomexchange.
org) and can be accessed through the code: PXD000931. General properties of the proteome 
were examined using “Batch MW and pI Finder” tool and the gravy index was calculated using 
the “gravy-calculator.de” web tool, whereas PSORTb v3.0(55) was used to determine protein 
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localization and the TMHMM Server V.2.0(56) for the determination of transmembrane helixes.
Transcriptional analysis of selected genes by quantitative Real Time PCR
RNA was isolated and purified from bacteria using the PureLink RNA Mini Kit (life technologies) 
according to the manufacturer’s instructions. In addition, on column digestion was 
performed with RNAse free DNAse (Qiagen). The quality and quantity of RNA was examined 
by spectrophotometric measurements (260/280 nm). Thereafter, 0.5 μg of purified RNA was 
reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (life technologies). 
Genomic DNA control samples were incubated without reverse transcriptase. Primers were 
designed using Primer3Plus(57) or derived from previous studies.(34) The following forward and 
reverse primer sequences were used: 16s forward 5’-TCCCGGGCCTTGTACACA-3’; reverse 5’- 
CCACTGGCTTCGGGTGTTA-3’, Rv0450c/MmpL4 forward 5’-GTGTTCAAGGAAGGCGATTC-3’; 
reverse 5’-CAAGGGGTTGGTTACCCTCT-3’, Rv1269c forward 5’-CAAGGTGCTCACCAGTTTCA-3’; 
reverse 5’- CTGGTATGCCCTATCGTTGG-3’, Rv3137 forward 5’- GGTTGACCGATACCGTGTG-3’, reverse 
5’ -GCCACCAGGCAGTAAGACAG-3’, Rv3283/sseA forward 5’-ATACCTGGTTCGTGCTCACA-3’; 
reverse 5’-AGCCGTCGTAGTTCCGTACA-3’.  LightCycler 480 SYBR Green I Master (Roche Applied 
Sciene) was used as qPCR master mix. Samples were analyzed in a LightCycler 480 (Roche Applied 
Science). The following cycling conditions were used: The thermal cycler program was initiated 
by 10 min at 95°C followed 35-40 cycles for 10 s at 95°C, 10 s at 60°C and 10 s at 72°C. High 
Resolution Melt analysis was performed after each program. mRNA quantities were determined 
in triplicate and normalized on 16s rRNA levels using the 2-∆Ct method. Mann-Whitney U-test 
was used to determine p-values.
Prediction of protein stability upon mutation
Three independent algorithms were used to predict the effect of a previously described 
mutation(30) on the stability of Rv3283/sseA: PolyPhen-2(58), I-Mutant3.0 (sequence mode)(59) 
and (Protein ANalysis THrough Evolutionary Relationships) PANTHER.(60) The respective protein 
sequence was derived from tbdb.org(61), using the conversion of a glutamic acid residue to a 
lysine residue in position 276.
 
Quantitative rhodanese activity assay
To perform quantitative rhodanese activity analysis, all chemicals were derived from Sigma-
Aldrich Chemie B.V. (Zwijndrecht, Netherlands). Rhodanese activity was examined as described 
previously with minor modifications.(62) In brief, cells were cultured to early-log phase and 
disrupted by bead-beating. Unbroken cells and cell debris was separated by centrifugation 
and discarded. The collected supernatant was filtered twice through a 0.2 μm filter and stored 
until use at -70˚C in PBS-containing 20% glycerol. The reaction mixture contained 50 μl of 125 
mM sodium thiosulfate, 25 μl of 250 mM potassium cyanide, and 30 μl of 200 mM potassium 
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phosphate buffer, pH 8.6. 20 μl of cell lysate was added to this reaction mixture. The reaction 
was carried out for 15 min at room temperature and was stopped by the addition of 25 μl of 
38% formaldehyde. In the control set, formaldehyde was added prior to the addition of the cell 
lysate. The concentration of thiocyanate was determined by the addition of 125 μl 410 mM 
ferric nitrate in 14% (w/v) nitric acid. Rhodanese activity is reported as specific activity (unit/mg 
protein) of which the biological replicates were averaged for each of the isolates examined. One 
unit of enzyme activity was defined as micromoles of thiocyanate formed per min at pH 8.6. 
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Results
Selection of M. tuberculosis Beijing genotype isolates
To quantify differences in the proteomes of modern and ancient M. tuberculosis Beijing 
sublineages we set out to generate two sample pools containing five strains of each genotype. 
Therefore, 14 ancient Beijing and 15 modern Beijing strains were selected from a published 
collection of 259 Beijing strains.(40) The selected strains were representative of 13 countries on 
four continents i.e. the strains were isolated in that country or isolated from a patient born in the 
respective country. RD105 was determined to ensure all strains represent the M. tuberculosis 
Beijing genotype. MutT2/ogt were determined to differentiate between modern and ancient 
M. tuberculosis Beijing strains.(31) MIRU-24 VNTR was determined to ensure a heterogeneous 
selection M. tuberculosis Beijing isolates; Figure S1. 
Qualitative proteome analysis of M. tuberculosis Beijing strains
We set out to identify proteins that are differentially regulated in either modern Beijing or 
ancient Beijing strains. To this end, we utilized a pooled approach, in which we mixed the 
digests of five ancient Beijing strains and five modern Beijing strains. We also analyzed three 
individual duplexes, in which single ancient Beijing strains were compared to single modern 
Beijing strains. In each individual duplex, different strains were selected at random from our set 
of Beijing strains described above. 
Three different search databases were used to analyze the peptides yielded; 1. a FASTA database 
based on the genome of M. tuberculosis H37Rv(51), a well annotated M. tuberculosis laboratory 
strain. 2. a database based on the genome of M. tuberculosis Beijing strain NITR203(52), which 
contains all modern Beijing specific nsSNPs, and 3. a concatenated database comprising both 
H37Rv and NITR203; Figure S2B. The combined analyses yielded a total of 30,748 unique peptides 
with a FDR <1% for all samples measured; see Table S1. None of the searched databases clearly 
outperformed the others in terms of peptide identifications. Therefore, we continued with the 
concatenated database, as it contains all major sequence variation caused by SNPs.
The cumulative number of unique protein identifications and quantifications was 2392; of which 
1817 proteins were identified and quantified in all proteome experiments, constituting >75% 
of all the quantified proteins; see Figure S2A and Table S2. These results represent the most 
comprehensive proteome description of a clinical M. tuberculosis genotype to date. When we 
compared the identified proteins of the individual duplexes with the pooled duplex, an overlap 
of >80% was achieved using our shotgun proteomics approach. 
To confirm the quality of our proteomic dataset, we investigated if specific proteins were 
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underrepresented on the basis of several physicochemical properties; see Figure S3A-C. As 
can be concluded from the distribution of proteins based on mass, pI, or hydrophobicity (i.e, 
gravy index) which follows the theoretical database distribution. All categories are represented 
to the same extent. In addition, there is no bias on the basis of protein localization(55) and 
transmembrane proteins(56), even for proteins predicted to contain 13 predicted transmembrane 
helices; see Figure S3D-E. In summary, from the above we conclude there is no skewing of the 
proteome we obtained.
Functional classification of proteins and efflux pumps
We categorized the proteins that were quantified in all four analyses, according to their functionality 
as given by Tuberculist.(63) Proteins that were considered to be specific for M. tuberculosis Beijing 
NITR203(52) by MSMSpdbb(50) were categorized as “other”; see Figure 1A. The proteins of different 
functional categories are represented to the same extent, except for the PE/PPE family, the insertion 
sequences and phages and the proteins that we categorized as “other”.(63) 
Beijing strains are linked to (multi)drug resistance in many geographical areas.(16, 22-26) Initially, the 
DNA repair mechanism was thought to be involved in the development of antibiotic resistance.
(19) Although not based on studying the DNA repair in detail, two recent studies confirmed this 
hypothesis by showing that several Beijing strains have a much higher frequency of rifampicin 
resistant mutants.(20, 21) However, proteins such as efflux pumps can also play a crucial part in 
reduced susceptibility to antibiotics by lowering the intra bacterial concentration of drugs and 
hence creating a higher tolerance to particular compounds. To determine whether such pre-
existing factors are present in the proteome of M. tuberculosis Beijing, we categorized putative 
efflux pump genes and transporters that play a role in drug resistance in M. tuberculosis, as 
previously listed.(64) As presented in Figure 1B, indeed several antibiotic transporting efflux 
pumps were disclosed in the proteome of in vitro cultured M. tuberculosis Beijing strains. 
The pre-existence of these efflux pumps can potentially be caused by the analysis of multidrug 
resistant strains. We therefore determined the MICs for the first line antibiotics (rifampicin, 
isoniazid, ethambutol and pyrazinamide) of the analyzed strains. Both the modern and ancient 
Beijing strains used in this study were susceptible to all first line drugs (data not shown).
The pre-existing presence of efflux pumps is not a unique characteristic of M. tuberculosis 
Beijing strains. Efflux pumps were also identified in the proteome of M. tuberculosis H37Rv by 
a proteome-wide selected reaction monitoring approach.(39) We compared this comprehensive 
dataset of 2195 M. tuberculosis H37Rv proteins with the proteins we identified. Three of these 
proteins (Rv0341/iniB, Rv2688c&Rv3728) were exclusively identified by our proteomic analysis 
of M. tuberculosis Beijing.
2
44 | CHAPTER 2
FIGURE 1: Functional distribution of the proteome of M. tuberculosis Beijing 
Proteins present in our MS-database (filled black bars) and our dataset (white bars) were categorized 
by:
A) Functional class categories as given by Tuberculist
B) Bacterial efflux transporter families
ABC: ATP Binding Cassette, MFS: Major Facilitator Superfamily, RND:  Resistance Nodulation cell 
Division, SMR: Small Multidrug Resistance
Quantitative proteomic profiling of modern and ancient M. tuberculosis Beijing strains
WGS revealed that the modern- and ancient Beijing strains are highly conserved on the genetic 
level.(30) However, multiple studies have shown that modern Beijing strains are more “successful” 
in terms of transmission and development of antibiotic resistance.(13, 14, 31, 65, 66) Moreover, in 
most geographic areas with a higher density of Beijing strains the modern Beijing strain are 
predominant, except for Japan.(28) To determine whether bacterial factors on the protein level 
may be associated with the emergence of modern Beijing strains, we quantitatively compared 
the proteomes of five modern Beijing and five ancient Beijing strains. Therefore, we performed 
a pooled approach and three individual duplex analyses. The protein ratio distribution was only 
slightly narrower when the samples were pooled; see Figure S4. 
Forty-seven proteins were identified as differentially abundant using our pooled approach. The 
three individual duplex experiments identified respectively 74, 111 and 55 proteins of which the 
abundance was significantly different; see Table S3. We categorized all differentially abundant 
proteins according to their functionality, as given by Tuberculist.(63) To identify proteins that are 
specifically more abundant in either the modern, or the ancient Beijing strains, we selected 
proteins that were over represented in the three individual approaches and the pooled 
approach; see Table 1. Rv0450c/MmpL4 and Rv3137 were significantly more abundant in 
the modern Beijing strains, whereas Rv1269c, and Rv3283/sseA were identified to be more 
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abundant in the ancient Beijing strains examined.
TABLE 1: Differentially abundant proteins between modern Beijing and ancient Beijing strains
Rv identifier Gene name Description PEP Fold Unique peptides
Rv0450c MmpL4 Transmembrane transport protein 0 3,3-3,8 34
Rv1269c - Conserved probable secreted protein 3.96E-34 <0,1-0,3 5
Rv3137 - Probable monophosphatase 8.69E-143 3,1-4,3 12
Rv3283 sseA Probable thiosulfate sulfurtransferase 0 <0,1-0,2 22
Transcriptional analysis of selected genes in a large cohort of M. tuberculosis Beijing strains
To evaluate whether the mRNA levels of Rv0450c/MmpL4, Rv1269c, Rv3137 and Rv3283/sseA 
are differentially regulated throughout the entire modern Beijing or ancient Beijing genotypes, 
we complemented our MS-based proteomic observations with qPCR analysis in a larger cohort 
of M. tuberculosis Beijing strains by qPCR. Therefore, 14 ancient Beijing strains and 15 modern 
Beijing strains, including the strains used for the proteome analyses, as presented in Figure S1, 
were analyzed. 
For Rv0450c/MmpL4 both the mRNA and the protein product were more abundant in the 
modern Beijing strains examined; see Figure 2. In contrast, Rv1269c and Rv3137 did not 
show significant differences in the larger cohort of M. tuberculosis Beijing strains examined. 
Nevertheless, Rv3137 showed a trend in line with the obtained protein ratios, but the effect 
observed on the protein level was larger than the fold change observed on the mRNA level.
An opposite trend between mRNA levels and protein levels was observed for  Rv3283/sseA. 
Our proteome analysis showed a 5-10 fold higher abundancy of Rv3283/sseA in ancient Beijing 
strains. Contrary to these observations,  higher transcriptional levels were observed for Rv3283/
sseA in modern Beijing strains compared to ancient Beijing strains. 
Functional prediction of amino-acid residue substitution in Rv3283/sseA
To investigate if the observed lower protein abundance of the protein Rv3283/sseA in modern 
Beijing strains could be caused by destabilization of the protein stucture by the altered amino 
acid at position 276, due to the nsSNP, reported to be specific for modern Beijing lineage 
strains(30), we applied the protein stability prediction programs, PolyPhen-2(58) and I-Mutant3.0(59) 
and the protein functionality prediction program PANTHER.(60)
The 3D structure of 3HZU, a homologue of Rv3283/sseA was used by PolyPhen-2  among 
other information.  Based on the calculation, PolyPhen-2 designates the mutation as being 
“benign”, “possibly damaging”, and “probably damaging”. The conversion of the glutamic acid 
residue towards a lysine residue in position 276 of Rv3283/sseA is considered to be “probably 
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damaging” by PolyPhen-2.
FIGURE 2: Observed mRNA levels for selected genes
mRNA levels of the selected protein candidates were analyzed in 14 ancient Beijing strains and 15 
modern Beijing strains using qPCR. Each sample was analyzed in triplicate. Data are expressed as mean 
± standard error of the mean.
As a second independent control, we also determined the impact of the mutation using the 
sequence option of I-Mutant3.0(59), which evaluates changes in stability of proteins based upon 
a single site mutation. The amino acid subsitution in the active domain of Rv3283/sseA was 
predicted to result in a free energy change of 1.02 Kcal/mol. This is calculated from the unfolding 
Gibbs free energy change of the mutated protein minus the unfolding free energy value of the 
native protein (Kcal/mol). A change of 1.02 Kcal/mol in predicted free energy is considerable, 
and therefore expected to largely decrease the stability of Rv3283/sseA.
Finally, we predicted the functionality of the mutant and wild-type version of Rv3283/sseA 
using PANTHER.(60) This software considers site-specific variation between evolutionary related 
proteins to calculate substitution position-specific evolutionary conservation(subPSEC) score. 
When we calculated the functional consequence of a mutation in Rv3283/sseA the subPSEC 
score was -4.74 and the corresponding Pdeleterious (probability of functional impairment) 
was 0.85. All together,  three independent prediction algorithms predict that the mutation in 
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Rv3283/sseA will have a large impact on the proteins’ function and stability. 
To support the observation that Rv3283/sseA is less abundant in modern Beijing strains than 
in ancient Beijing strains, we determined its activity. Rv3283/sseA is one of the at least four 
rhodanese domain containing proteins in our proteomic dataset of M. tuberculosis Beijing. 
Two of the proteins with potential rhodanese activity, Rv0815c/cysA2 & Rv3117/cysA3, could 
not be distinguished from one another, due to their high sequence similarity, but could be 
distinguished from Rv3283/sseA in the proteome analysis. Rv0815c/cysA2, Rv3117/cysA3 and 
Rv2291/sseB were not identified to be differentially abundant in all of the ancient or modern 
Beijing strains examined. Rhodanese proteins can detoxify cyanide by converting thiosulfate to 
thiocyanate and sulfite (EC 2.8.1.1). This reaction can be monitored in a quantitative manner by 
the formation of a blood red iron(III) thiocyanate complex.(62)
Rhodanese activity of cell lysates, containing all proteins with potential rhodanese activity, was 
determined in triplicate of the strains used for the proteomic analysis; see Figure 3. The average 
rhodanese activity observed in the cell lysate of ancient Beijing strains was  approximately 23% 
higher than the rhodanese activity observed in the modern Beijing strains. 
FIGURE 3: Rhodanese activity in M. tuberculosis Beijing sublineages
Rhodanese activity was determined in whole cell lysates of five ancient Beijing and five modern Beijing 
strains. Biological triplicates were taken and samples were analyzed in triplicate. The median is shown 
by the horizontal black line, with vertical whiskers representing the range.
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Discussion
The Beijing lineage of M. tuberculosis is one of the most successful M. tuberculosis genotypes 
worldwide, as indicated by its degree of genetic conservation and emergence.(67, 68) Previous 
studies showed an increase of TB incidence caused by M. tuberculosis Beijing, combined with 
higher odds on drug resistance for these strains.(6) Characterization of the Beijing strains revealed 
the presence of two sublineages, the modern and ancient Beijing strains.(27) Although the two 
sublineages  are highly conserved on the genetic level, epidemiological studies suggested a 
possible evolutionary advantage of the modern Beijing strains, as this lineage is most prevalent 
in many geographic areas, except for Japan. In addition, whole genome analysis demonstrated 
the presence of only 31 nsSNPs that are characteristic of modern Beijing lineage strains from 
China, Japan and South Africa and this suggests a relative short time of divergence and successful 
spread.(30) To understand the evolutionary success of these pathogens, it is essential to identify 
factors that contribute to their high transmissibility and propagation in the human population, 
possibly associated with enhanced antibiotic resistance and ability to circumvent BCG induced 
immunity.(10, 13, 14, 31, 65, 66) We employed a pooled proteomics approach alongside three traditional 
individual duplex analyses to identify proteins that contribute to the successful phenotype of 
modern Beijing strains. 
Selection of a heterogeneous set of M. tuberculosis Beijing genotype strains
To cover the full spectrum of the genotype family, we selected 14 ancient and 14 modern Beijing 
strains from a previous selection of 259 M. tuberculosis strains.(40) Furthermore, we included the 
successful modern Beijing strain B0/W148, that comprises one-fourth of the M. tuberculosis 
Beijing isolates in different parts of Russia.(41-43) The Beijing strains in our selection originated from 
13 countries distributed over four continents. We determined RD105 to assure that all strains in 
our selection truly belonged to the M. tuberculosis Beijing genotype.(29) A deletion of RD181 is 
considered to be characteristic of the modern sublineage.(29) However, deletions of RD181 were 
also identified in “late” ancient Beijing strains.(69, 70) Therefore, stringent differentiation between 
modern and ancient Beijing strains was accomplished using the M. tuberculosis modern Beijing 
genetic markers of putative DNA repair genes mutT2 and ogt.(31) To exclude the possibility of 
mixed strains, contamination or the selection of clonal isolates we performed MIRU-24 VNTR-
typing; see Figure S1. Five modern and five ancient Beijing strains were randomly selected from 
this heterogeneous set of M. tuberculosis Beijing strains.
Description of the M. tuberculosis proteome
The combined analysis of pooled and individual duplex approaches yielded a total of 2392 
unique proteins, the highest reported number of quantified proteins in any clinical strain of M. 
tuberculosis to date. Comparison of the individual duplexes with the pooled duplex approach 
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showed an overlap of 80-95% in identified proteins; see Figure S2A.  In total 1817 proteins were 
quantified in all four analyses using a concatenated database. A high overlap, achieved by a 
shotgun proteomics approach is typically achieved when one reaches high proteome coverage. 
Furthermore, this high overlap of protein identifications and quantifications in all four analyses 
suggests a low inter-strain and low biological variation in the strains examined.
In mycobacterial proteomics, the solid, thick cell wall of mycobacteria presents a major obstacle 
to full proteome recovery. In particular reproducible extraction of cell wall and membrane bound 
proteins can be difficult. Therefore, we examined the general physicochemical properties of the 
obtained proteome to assure a representative coverage of the proteome, and to prevent a bias 
towards easy-to-extract proteins. The concatenated search database was utilized to represent 
the theoretically maximal observable proteome; see Figure S3. In the general properties that 
we assessed (Protein MW/pI//hydrophobicity), the observed proteome followed a distribution 
highly similar to that of the theoretically observable proteome, from which we conclude that 
our workflow is not biased regarding proteins with certain physiochemical properties. This was 
further confirmed by TMHMM(56) and protein localization analysis; see Figure S3 D-E.(55) 
Approximately 42% of the proteins present in our database were reproducibly quantified in the 
four analyses. Two third of the proteins that were predicted to be localized in the thick cell wall 
were included in this dataset. In addition, we were able to reproducibly quantify proteins with 
≥13 transmembrane helixes. The high coverage of even the highly hydrophobic cell wall bound 
proteins suggests that our dataset provides a reliable representation of the M. tuberculosis 
Beijing proteome without discrimination of the more hydrophobic proteins.
Categorization of the identified proteins
Functional categorization, as given by Tuberculist(63), showed a homogeneous distribution of 
the 1817 proteins present in our dataset for most of the listed categories, except for the PE/
PPE family and the insertion sequences and phages; see Figure 1A. The categories containing 
the PE/PPE-family and insertion sequences and phages are notoriously difficult to identify. A 
recent study using ‘proteome-wide selected reaction monitoring’ also suffered from an under 
representation of the PE/PPE-family.(39) The PE/PPE family is named after their PE proline-
glutamic acid and PPE proline-proline-glutamic acid N-terminal motif. Members of this family are 
characterized by a high number of glycine and alanine residues in combination with repetitive 
sequences.  As a result, there are relatively few tryptic cleavage sites.(39) This lack of tryptic 
digestion sites makes our workflow with endoLys-c and trypsin digestion less suitable for the 
detection of members from this protein family. A reported method for the optimal identification 
of PE/PPE proteins includes the extraction of proteins from the mycobacterial cell wall followed 
by a double tryptic digestion and a triple chymotrypsin digestion.(71)
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Identification of pre-existing efflux pumps in the Beijing genotype
Throughout many geographic areas, Beijing strains were reported to significantly correlate 
with (multi) drug resistance, treatment, relapses after curative treatment and transmission 
of resistant TB.(6, 7, 10-12) Initially, altered DNA repair mechanisms in the M. tuberculosis Beijing 
genotype family were assumed to be responsible for the strong correlation with antibiotic 
resistance, due to mutations in three putative mutator genes in modern Beijing strains.(19) 
More support for this hypothesis was gained after a recent study showed that Beijing strains in 
Vietnam have an increased frequency of rifampicin resistant mutants compared to strains of the 
East African Asian (EAI) genotype family.(20) Unfortunately, the effects of variations in the DNA 
repair mechanism of M. tuberculosis Beijing has not been studied in full detail. Our systematic 
study did not reveal any quantitative difference for the genes involved in DNA repair, i.e. mutT2, 
mutT4 and ogt. This suggests that mutations or post-translational mutations, but not protein 
abundance, are important for the aberrant DNA repair mechanism in M. tuberculosis Beijing.
 
The role of efflux pumps, which are able to transport antibiotics over the cell wall, has only 
been slightly touched upon in M. tuberculosis Beijing strains.(72, 73) We examined whether efflux 
pumps are present in the proteome of M. tuberculosis Beijing strains in the absence of selective 
pressure of antibiotics. We therefore used a previously listed selection of M. tuberculosis efflux 
pumps to categorize the proteins included in our dataset.(64) As presented in Figure 1B, several 
types of efflux pumps are present in the proteome of in vitro cultured M. tuberculosis Beijing. 
To ensure that this observation is not caused by the presence of (multi)drug resistant strains 
potentially present in our selection, we determined the MICs of first line antibiotics for the 
strains analyzed. None of the M. tuberculosis strains examined were identified to be resistant 
for any of the tested drugs. This observation shows that the presence of the efflux pumps 
alone, present in the proteome of M. tuberculosis Beijing, is not sufficient to cause antibiotic 
resistance. However, expression of these antibiotic extruding proteins can potentially cause 
a higher tolerance to drugs or makes it more difficult to eliminate all pathogens by antibiotic 
therapy. Moreover, a reduced susceptibility to drugs such as rifampicin, as observed previously, 
may be responsible for more durable persistence and hence the selection of drug resistant 
bacteria.(20) As recently reported, a much higher dosage of rifampicin was required to achieve a 
100% killing of M. tuberculosis Beijing strains.(20) Taken together, this suggests a potential role for 
efflux pumps in the development of (multi)drug resistance in M. tuberculosis Beijing strains. The 
pre-existing presence of efflux pumps is, however, not necessarily a unique characteristic for M. 
tuberculosis Beijing. Therefore, we compared the presence of efflux pumps in our dataset with 
those that were recently identified and quantified in the proteome of M. tuberculosis H37Rv.
(39) The used comprehensive M. tuberculosis H37Rv dataset was generated using proteome-
wide selected reaction monitoring and contains 2195 proteins. Three efflux pumps, Rv0341/
iniB, Rv2688c and Rv3728, were exclusively identified in our dataset on Beijing strains. However, 
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a proteogenomic approach that studied the proteome of M. tuberculosis H37Rv identified the 
respective proteins, Rv0341/iniB, Rv2688c and Rv3728.(74) It should be noted that 123 LC-MS/MS 
analyses were performed, which resulted in the identification of Rv2688c by a single peptide. 
In contrast, we identified ≥4 unique peptides in each of the duplex analyses performed. This 
combined information is a strong indication that Rv2688c is more abundant in M. tuberculosis 
Beijing strains than in the proteome of M. tuberculosis H37Rv. Rv3728 was reported to be 
present in the proteome of M. tuberculosis H37Rv as well.(74) Howbeit, peptides corresponding 
to Rv3728 were only identified by the Sequest algorithm, whereas Mascot and MassWiz 
failed to identify any peptide belonging to Rv3728. Therefore, as these proteins may preexist 
exclusively in the M. tuberculosis Beijing proteome, or be more abundant in the proteome of 
M. tuberculosis Beijing, they might contribute to the success of the Beijing family as a whole in 
the development of antibiotic resistance.
Identification of differentially abundant proteins within the Beijing genotype
With the pooled sample approach alongside three individual duplex approaches, we achieved 
reproducible high proteome coverage using shotgun proteomics. Furthermore, we demonstrated 
a highly uniform ratio distribution for a majority of the proteins in the M. tuberculosis Beijing 
strains analyzed. On average, the pooled approach and the individual comparisons yielded 
approximately the same number of differentially abundant proteins (pooled duplex 47, individual 
duplexes 74, 111 and 55, Table S3). Therefore, it is conceivable that not only the modern and 
ancient Beijing strains are highly similar on the genetic level (30), but that also protein regulation 
is conserved throughout the M. tuberculosis Beijing family as a whole; Figure S4.  
As expected, not all proteins identified as differentially abundant in the pooled approach were 
also identified as differentially abundant in the individual duplexes. A logical explanation is 
that very abundant proteins in single isolates cannot be averaged out. Furthermore, individual 
duplex approaches are prone to false positives due to inter-strain and biological variation.  It is 
important to keep in mind that both the pooled approach and the individual approaches can 
still yield false positives and are best used in parallel to identify sublineage specific differences. 
From our dataset of 1817 proteins that were reproducibly quantified in each analysis, only four 
proteins showed to be differentially regulated in all strains examined; see Table 1. This further 
confirms that most traits are highly conserved in the M. tuberculosis Beijing family. Therefore, 
our data suggests that the success of the modern Beijing strains compared to the ancient Beijing 
strains is caused by only a limited number of virulence factors.
Transcriptional analysis of differentially abundant proteins in a large cohort of M. tuberculosis 
Beijing strains
Of the 1817 proteins present in our dataset only four proteins were differentially abundant in 
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all four proteomic analyses (Rv0450c/MmpL4, Rv1269c, Rv3137, Rv3283/sseA). To determine 
whether the mRNA levels of the corresponding proteins are differentially regulated throughout 
the entire modern Beijing or ancient Beijing genotypes, we complemented our MS-based 
proteomic observations with quantitative mRNA analysis in a larger cohort of M. tuberculosis 
Beijing strains by qPCR. Although mRNA does not always correlate with protein abundance 
levels present within the cell, it provides insight into the regulation of these specific genes.(75-77) 
The strains listed in Figure S1 were selected to represent the full repertoire of M. tuberculosis 
Beijing strains. This selection consisted out of 14 ancient Beijing and 15 modern Beijing strains 
and included the strains used for proteomic analysis.
The probable secreted protein Rv1269c was identified by MS to be >3 fold more abundant in 
ancient Beijing strains. However, we analyzed the cell lysate of M. tuberculosis Beijing, not the 
secretome. Quantitative mRNA analysis revealed that Rv1269c is equally transcribed by both 
modern and ancient Beijing strains; see Figure 2. Therefore, we cannot rule out the possibility 
that Rv1269c is more efficiently secreted by modern Beijing strains as the proteomic data clearly 
pointed out that Rv1269c is less abundant in modern Beijing strains.
Subsequently, we analyzed the mRNA levels for Rv3137, a probable monophosphatase that 
is essential for the in vitro growth of M. tuberculosis H37Rv.(78, 79) A trend similar to the ratios 
obtained by our proteomic experiments was detected. However, the average difference was 
much smaller on the mRNA level than observed on the protein level. Further separation of 
the modern Beijing strains from our selection with several genetic markers(31) will potentially 
allow us to identify a sub species of modern Beijing strains that contains high levels of Rv3137. 
However, this indicates that Rv3137 is not a virulence factor that is upregulated throughout the 
modern Beijing genotype as a whole.
The relative mRNA quantities of Rv0450c/MmpL4 were in agreement with the results obtained 
by our proteomic experiments. Previous studies identified Rv0450c/MmpL4 as a potential 
virulence factor of M. tuberculosis by signature-tagged transposon mutagenesis.(80) In addition, 
this protein has been reported to be essential for growth in mouse models of TB.(81) A recent study 
reported Rv0450c/MmpL4, together with Rv0451c/MmpS4 or Rv0677c/MmpS5 and Rv0676c/
MmpL5, are needed for the secretion of iron-scavenging siderophores in M. tuberculosis.(82) Our 
results demonstrate a clear upregulation of both protein and mRNA throughout the modern 
Beijing genotype. Taken together with the previously reported modern Beijing specific mutation 
in Rv0676c/MmpL5(30), this suggests that siderophores could be differentially expressed in the 
two Beijing sublineages. If the increased  levels of Rv0450c/MmpL4 work as a compensating 
mechanism for the mutated Rv0676c/MmpL5 gene in modern Beijing strains remains to be 
determined. Nevertheless, the results point to differences in iron metabolism between both 
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M. tuberculosis Beijing genotypes. This hypothesis is reinforced by a study which revealed that 
patients with a mutation in SLC11A1/NRAMP1, a divalent transition metal transporter involved 
in iron metabolism, have been associated with higher odds of TB caused by M. tuberculosis 
Beijing.(18) The altered quantities of Rv0450c/MmpL4 in association with the modern Beijing 
specific mutation in Rv0676c/MmpL5 is possibly the missing link that explains the success of 
M. tuberculosis Beijing strains within individuals that possess a mutation in SLC11A1/NRAMP1. 
Therefore, our findings support the idea of M. tuberculosis coevolution with their human host. 
Next to the secretion of siderophores, Rv0450c/MmpL4 & Rv0676c/MmpL5 has been identified 
as differentially regulated in rifampicin-resistant M. tuberculosis strains upon rifampicin 
exposure.(83) Build around the already known function of these MmpL genes and the upregulation 
of MmpL mRNA in a M. tuberculosis-rifampicin microarray model the authors suggested an 
involvement of Rv0450c/MmpL4 & Rv0676c/MmpL5 in the rifampicin efflux out of the cell.(83)
For Rv3283/sseA, the mRNA levels showed a trend opposite to the results we obtained by 
proteomics. Where the protein appeared to be strongly upregulated, and was quantitated by 
as much as 22 unique peptides on the protein level of ancient Beijing strains, we observed 
a slightly, but not significant, increase in the mRNA levels of modern Beijing strains. The 
discrepancy between the results obtained by proteomics and qPCR might be explained by the 
presence of a nsSNP in the genome of modern M. tuberculosis Beijing strains.(30)
Enzymatic activity of Rv3283/sseA
Several studies have linked the expression of Rv3283/sseA to a virulent M. tuberculosis phenotype. 
One study demonstrated the differential regulation of Rv3283/sseA by M. tuberculosis within 
the host cell.(84) The association between the protein and an increase in virulence was further 
supported by a study that showed how a mutation in Rv3283/sseA leads to enhanced growth 
of M. tuberculosis in macrophages relative to in vitro growth of M. tuberculosis.(85) Finally, the 
predicted rhodanese activity of Rv3283/sseA potentially helps to cope with oxidative stress, as 
the knock-out of a rhodanese domain containing protein in Azotobacter vinelandii altered their 
sensitivity towards oxidative damages.(86)  
In contrast to our proteomic data, the transcription levels of the Rv3283/sseA were higher, on 
average, in modern Beijing strains compared to ancient Beijing strains. We set out to determine 
whether a previously reported modern Beijing specific mutation could contribute to this 
discrepancy. This nsSNP confers a glutamic acid residue to a lysine residue which has been 
shown to be specific for modern Beijing strains.(30) Three independent bioinformatic algorithms 
were used to determine the effect of the mutation on the stability and function of the respective 
protein. PolyPhen-2, which uses the 3D crystal structure of Rv3283/sseA homologue 3HZU 
among other information, predicted that the mutation is “probably damaging” for the protein.
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(58) Next to PolyPhen-2, we also used I-Mutant 3.0 in sequence mode.(59) The calculated free 
energy change upon substitution of glutamic acid by a lysine residue was -1.02 kcal/mol, which 
indicates a significant loss of stability of Rv3283/sseA in modern Beijing strains. Analysis of the 
protein and the corresponding mutation by PANTHER pointed towards a functional impairment 
of the mutated protein (subPSEC=-4.74& Pdeleterious=0.85).(60) The predicted instability, and 
thereby a potential short half-life time of Rv3283/sseA in modern Beijing strains can explain 
the lower level of Rv3283/sseA observed in modern Beijing strains compared to ancient Beijing 
strains. 
To further confirm our results we measured the rhodanese activity in whole cell lysates of the 
ten M. tuberculosis Beijing strains used for the comparative proteomic analysis. Besides Rv3283/
sseA there are at least three additional proteins (Rv0815c/cysA2, Rv2291/sseB & Rv3117/cysA3) 
that contain a rhodanese domain. The presence of these proteins makes our rhodanese activity 
assay on whole cell lysate level not rhodanase enzyme specific. However, as the additional 
rhodanese domain containing proteins appeared to occur in equal quantities in most modern 
and ancient Beijing strains, this is not expected to yield any difference in the total rhodanese 
activity. We observed approximately 23% more rhodanese activity in the ancient Beijing strains 
examined compared to modern Beijing strains. The relative predicted instability of the mutated 
Rv3283/sseA, together with the observed rhodanese activity, supports the results obtained by 
proteomics. In summary; our data suggests that modern Beijing strains possess, on average, 
less Rv3283/sseA than ancient Beijing strains.   
Comparative study
We compared the results of our systematic approach with a previous comparative proteomic 
study that described the differences between a hyper- and a hypovirulent Beijing strain.(34) In 
that study 23 proteins were reported to be more abundant in the hypo virulent strain. Of these 
23 proteins, 17 were quantified in all four of our analyses, but none showed to be specifically 
more abundant in either the modern or the ancient Beijing strains; see Table S4. When we 
compared the 54 proteins that were reported to be more abundant in the previously reported 
hypervirulent strain, we identified 39 of those 54 proteins in all four of our analyses. Only one 
protein, Rv2680, showed to be more abundant in several modern Beijing strains. Two out of our 
three individual duplex approaches and the pooled approach demonstrated the upregulation 
of Rv2680 in modern Beijing strains. Together these observations show that comparison of 
two individual isolates can be useful to identify virulence factors, but not to describe specific 
differences between the two Beijing sublineages. The proteins Rv0450c/MmpL4, Rv1269c, 
Rv3137 and Rv3283/sseA were identified as differentially abundant in both our pooled approach 
and our three individual duplex analyses. Of these proteins, Rv3137 was solely identified in 
the previously reported M. tuberculosis Beijing proteome dataset.(34) However, Rv3137 was not 
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reported to be upregulated in the hypervirulent strain. This observation supports our hypothesis 
that Rv3137 is upregulated in several, but not all modern Beijing strains.
Other differentially regulated proteins 
The W-Beijing strain, a distinct phylogenetic branch within the modern Beijing genotype mainly 
observed in the early 1990s in the USA(87), is known for the expression of a glycosylated variant 
of phthiocerol dimycocerosate (PDIM), the phenolic glycolipid (PGL-tb). W-Beijing strains are 
capable of synthesizing PGL-tb due to a mutation in their pks15/1 gene.(88) Production of PGL-
tb is thought to be one of the success factors of the W-Beijing strains.(89) However, not all M. 
tuberculosis Beijing strains produce PGL-tb, even when they possess a functional pks15/1 gene.
(90) In our dataset, Rv2946c/pks1 is significantly less abundant in both the pooled approach 
and two out of three separate duplexes. This observation suggests that M. tuberculosis Beijing 
strains do not necessarily express equal amounts of PDIM and PGL-tb.
In this study we identified Rv2688c in the proteome of M. tuberculosis Beijing, whereas this 
protein was not observed in the extensively studied proteome of M. tuberculosis H37Rv.
(39) Rv2688c is often described as a fluoroquinolones (FQ) export ATP-binding protein.(91) 
The presence of Rv2688c was not only observed in the proteome of M. tuberculosis Beijing 
strains, but was also relatively high abundant in several of the modern Beijing strains studied. 
Interestingly, Beijing genotype isolates that are resistant to FQs occur significantly more than FQ-
resistant isolates of other genotypes in Vietnam.(92) A mutation in the gyrA gene was associated 
with this high-level FQ-resistance. However, an increased abundance of the FQ efflux pump, 
Rv2688c, possibly leads to a better tolerance of modern M. tuberculosis Beijing strains against 
FQs, which can eventually result in mutations that cause resistance.
Our study showed that Rv2946c/PKS1 and Rv2688c are not upregulated in all modern Beijing 
strains. However, further characterization of the modern Beijing family might yield subfamilies 
in which this trait is conserved.
The DosR regulon, which is transcribed during the latent stage of infection, is reported to be 
constitutively upregulated in W-Beijing strains.(90) Our combined pooled and individual approach 
did not reveal differential abundance of proteins from the DosR regulon between modern and 
ancient Beijing strains. This suggests that upregulation of DosR might be conserved throughout 
all M. tuberculosis Beijing strains in general compared to other M. tuberculosis lineages.
2
56 | CHAPTER 2
Conclusions
We identified an important virulence factor for modern Beijing strains in the form of Rv0450c/
MmpL4. This observation is the first link between the proteome of modern M. tuberculosis 
Beijing strains and the higher odds of M. tuberculosis Beijing in individuals with a mutation in 
their SLC11A1/NRAMP1 gene. We further provide evidence for the lower abundance of Rv3283/
sseA in modern Beijing strains, which seems to be a direct consequence of a previously described 
nsSNP. In addition, we listed several proteins previously reported as potential virulence factors, 
such as Rv2946c/PKS1 and FQ efflux pump Rv2688c, which could contribute to the success of 
modern Beijing strains. Taken together our observations contribute to a better understanding of 
the successful spread of modern Beijing strains, and may assist in combatting this serious threat 
in TB control. If the spread of Beijing strains is not controlled the current epidemic of TB may 
transform into an epidemic of resistant TB.
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journal: http://www.mcponline.org/content/13/10/2632/suppl/DC1
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FIGURES
SUPPORTING INFORMATION FIGURE S1: Characterization of selected M. tuberculosis Beijing 
strains
The selected clinical isolates(40) were differentiated between modern and ancient Beijing using RD105 
and mutT2/ogt.(29, 31)  
Strains selected for proteomic analysis are indicated by a black dot in front of their NLA number. 
*Zero repeats were identified for VNTR2163b of NLA000501814
2
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SUPPORTING INFORMATION FIGURE S2: Venn diagrams (93) showing the overlap between 
A) The proteins identified in the pooled approach and the three individual approaches
Pooled:  Ancient Beijing strains: NLA000017583, NLA1010701604, NLA1010200230,
NLA1010501814, and NLA1019801252 versus modern Beijing strains: NLA1010700873, 
NLA1011100782, NLA1019401707, NLA1019401709, NLA1019402019 
Duplex 1: Ancient Beijing: NLA000017583 versus modern Beijing: NLA1010700873
Duplex 2: Ancient Beijing: NLA1010200230 versus modern Beijing: NLA109401709
Duplex 3: Ancient Beijing: NLA1019801252 versus modern Beijing: NLA101100782
B) Peptides identified with three different databases (30748 peptides in total)  
M. tuberculosis H37Rv = FASTA database derived from genomic sequence of M. tuberculosis 
H37Rv(51) 
M. tuberculosis Beijing = FASTA database derived from genomic sequence of M. tuberculosis Beijing 
NITR203(52) 
Concatenated = concatenated FASTA database derived from both M. tuberculosis H37Rv and M. 
tuberculosis Beijing NITR203 made using MSMSpdbb(50)
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SUPPORTING INFORMATION FIGURE S3: General physiochemical properties and localization of the 
observed (white bars) and theoretical proteome (filled black bars). 
 
A-C) Physiochemical characteristic of M. tuberculosis Beijing proteome and our concatenated database.
D-E) Protein localization and number of predicted transmembrane helixes for each of the proteins 
present in our dataset and the concatenated database.(55, 56)
2
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Mechanisms of phenotypic rifampicin tolerance in 
Mycobacterium tuberculosis Beijing genotype strain 
B0/W148 revealed by proteomics
3
Abstract
The “successful” Russian clone B0/W148 of Mycobacterium tuberculosis Beijing is well known 
for its capacity to develop antibiotic resistance. During treatment, resistant mutants can occur 
that have inheritable resistance to specific antibiotics. Next to mutations, M. tuberculosis has 
several mechanisms that increase their tolerance to a variety of antibiotics. Insights in the 
phenotypic mechanisms that contribute to drug tolerance will increase our understanding of 
how antibiotic resistance develops in M. tuberculosis.
In this study, we examined the (phospho)proteome dynamics in M. tuberculosis Beijing 
strain B0/W148 when exposed to a high dose of rifampicin; one of the most potent first-
line antibiotics. A total of 2,534 proteins and 191 phosphorylation sites were identified, and 
revealed the differential regulation of DosR regulon proteins, which are necessary for the 
development of a dormant phenotype that is less susceptible to antibiotics. By examining 
independent phenotypic markers of dormancy, we show that persisters of in vitro rifampicin 
exposure entered a metabolically hypoactive state, which yields rifampicin and other antibiotics 
largely ineffective. These new insights in the role of protein regulation and post-translational 
modifications during the initial phase of rifampicin treatment reveals a shortcoming in the anti-
tuberculosis regimen that is administered to 8-9 million individuals annually. 
3
72 | CHAPTER 3
Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is one of the most devastating 
infectious diseases. Currently, 8-9 million new TB cases and 1.5 million deaths to this disease 
are recorded annually.(1)
The M. tuberculosis complex can be delineated into six lineages, which differ in their worldwide 
distribution, capacity to cause and spread active disease, and correlation with resistance.(2-4) 
The in 1995 described ‘Beijing’ genotype is among the most frequently studied M. tuberculosis 
lineages due to its remarkable dominance in Asia, the former Soviet Union, parts of Europe 
and South Africa.(5-8) Based on the available genetic markers, the Beijing genotype was 
reported to be genetically highly conserved, which is associated to active and recent spread. 
(5-8) Throughout several geographic areas, but specifically in Eastern-Europe,(9) Beijing strains 
were found to correlate with (multi and extensively) drug resistance, treatment failure, relapses 
after treatment and transmission of antibiotic resistant TB.(6, 7, 9-11) In line with the spread and 
prevalence of the M. tuberculosis Beijing strains, resistance against anti-TB drugs is a major 
problem in China, South Africa, Eastern Europe; especially the former Soviet Union States.(9, 12-17)
In Russia, half of the M. tuberculosis isolates belong to the Beijing family, of which one-fourth 
belongs to the highly clonal Beijing B0/W148 cluster.(18) Compared to other Beijing isolates, 
members of the Beijing B0/W148 genotype display an increased virulence in macrophage 
infection models,(19) a stronger correlation with multidrug resistance,(18, 20-22) and an increased 
transmissibility.(22, 23) 
Standard treatment regimens of TB includes rifampicin, one of the cornerstones of anti-TB 
treatment, which targets the mycobacterial RNA-polymerase. The survival of M. tuberculosis and 
the relatively high chance of resistance development is, however, favored by the sub-optimal 
dose that is currently used in a standard TB treatment.(24-31) Therefore, trials are organized in 
Africa to validate the application of significantly higher doses of drugs.(32) Under the current 
treatment regimen mutations can occur in the rpoB gene, which alters the structure of the 
RNA-polymerases β-subunit. Genetic alteration of the rpoB gene is responsible for >95% of all 
the rifampicin resistant cases.(33)
Next to the acquisition of DNA mutations associated with resistance, M. tuberculosis has a variety 
of features which can contribute to rifampicin tolerance already during the initial exposure.
(34) One of the most remarkable features is the hydrophobic cell wall of M. tuberculosis, they 
consist of unusual long-chain fatty acids that surround the mycobacteria and provide a high 
level of resistance to antibiotics.(35)
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Intrinsic antibiotic resistance in M. tuberculosis is further provided by the slow growth rate 
of the pathogen. Especially in the metabolically hypoactive, non-replicative dormant state of 
M. tuberculosis, induced by the bacilli to evade the host immune response and survive inside 
the hostile macrophage environment,(36) the pathogens becomes more tolerant to several 
antibiotics, including rifampicin.(37-42) The bacteria are far less susceptible during dormancy 
because the majority of the currently used anti-TB drugs target processes that are involved 
in cell growth and division.(40) Next to intrinsic antibiotic resistance, there is a wide variety of 
efflux pumps that can translocate toxic compounds from the cytoplasm back into the external 
environment.(43) In fact, in the proteome of Beijing genotype strains specific efflux pumps have 
been identified, to pre-exist in higher quantities than other studied M. tuberculosis genotypes.(44) 
The proteome of M. tuberculosis has been explored by several groups to gain information about 
genomic annotation, protein subcellular localization, virulence factors, environmental stress 
responses and the impact of rifampicin resistance conferring mutations.(44-53) In this study, we 
examined the proteome to determine whether a drug susceptible isolate of M. tuberculosis 
Beijing B0/W148 uses any of the above mentioned phenotypic mechanisms to cope with 
rifampicin induced stress during the initial 24 hrs of drug exposure, i.e. the relative impermeable 
cell wall, adjustment of the metabolic activity and antibiotic extruding efflux pumps. To this 
end, we determined the temporal dynamics of the proteome and corresponding Ser/Thr/
Tyr phosphorylations of M. tuberculosis Beijing strain B0/W148 in response to rifampicin. 
Thereby, we provide evidence that not only resistance acquired by genomic mutations, but also 
phenotypic drug tolerance mechanisms contribute to in the increasing problem of rifampicin 
resistance.
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Materials and Methods
Mycobacterial culture conditions 
M. tuberculosis B0/W148 was derived from the reference database of clinical isolates at the 
National Institute for Public Health and the Environment (RIVM) in Bilthoven, the Netherlands 
(isolate number NLA001100782). Mycobacterial cells were re-cultured from frozen stocks in 5 
ml Tween-Albumin liquid culture broth (Tritium Microbiologie, the Netherlands) at 36°C without 
shaking until an O.D. of 0.4 AU at 600 nm was reached, as described previously.(44) One ml of 
the pre-culture was transferred to a 250 ml Erlenmeyer flask containing 100 ml Tween-Albumin 
broth and incubated under shaking conditions at 36°C to provide constant aeration. Once the 
cultures reached an O.D. of 0.6 AU at 600 nm, representing the mid-log phase, the cells were 
exposed to rifampicin at a concentration of 16 µg/ml or DMSO. Cells were harvested after 1.5, 3, 
6, 15 and 24 hrs of exposure by washing three times with ice-cold PBS (Brau, Germany), in 5 ml 
Lysis-buffer (4% SDS, 100 mM Tris-HCl, pH 7.6) and heat-killed at 95°C for 10 min. Lysates were 
stored at -20°C until further usage. Biological duplicates and technical replicates were analyzed 
for each of the assessed time points.
Rifampicin susceptibility determination
Susceptibility to rifampicin (Sigma Aldrich, the Netherlands) was determined according to 
Clinical and Laboratory Standards Institute guidelines,(54) using the BACTEC MGIT-960 system 
(Becton, Dickinson and Co., Franklin Lakes, NJ). Mutations in the rifampicin resistance 
determining region (RRDR) of rpoB, the hotspot for drug resistance, were assessed using the 
MTBDRplus assay according to the manufacturers’ recommendations, as described previously.(55) 
Mycobacterial viability and culturability determination
To determine mycobacterial viability and ability to multiply after being exposed to rifampicin, 
2 ml of mycobacterial cells were taken from a 100 ml culture with varying concentrations of 
rifampicin. The cells were washed thoroughly to remove rifampicin from the supernatant and 
dissolved in 2 ml of PBS. Of this suspension, a 200 µl sample was incubated into mycobacterial 
growth indicator tubes (MGIT) and the time to detection (TTD) was determined using the BACTEC 
MGIT-960 system (Becton, Dickinson and Co., Franklin Lakes, USA). The remaining cells were 
heat-killed at 80˚C and the ATP content of mycobacterial cells was assessed using the BacTiter-
Glo Microbial Cell Viability Assay (Promega, the Netherlands) following the manufacturers’ 
instructions. Biological duplicates and technical triplicates were analysed.
Protein sample preparation and dimethylation isotope labeling
Two biological duplicates and two technical replicates were analyzed for each of the 
assessed time points. Proteins were prepared in parallel as described previously.(44) In brief, 
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mycobacterial cell lysates were mechanically disrupted by bead-beating in a mini bead-beater 
16 (BioSpec, USA) for 5 min using glass beads. Thereafter, the cells were cooled down on ice 
for 5 min and the procedure was repeated twice. The cell lysates were cleaned from cell debris 
by centrifugation for 1 min at 14,000 g and the supernatant was transferred to another tube. 
Proteins were digested using the filter aided sample preparation (FASP) method.(56) In brief, DTT 
reduced proteins were loaded on a 30 kDa filter. SDS was removed in three washes with 8M 
urea. The proteins were carbamidomethylated, and the excess reagent was removed by three 
additional washes with 8M urea. Proteins were then digested overnight using endoproteinase 
Lys-C (endoLysC), followed by a four hrs digestion using trypsin at RT. Tryptic peptides were 
desalted on C18 SepPak columns and on column labeled by dimethylation using the “light-” 
(+28Da) and “medium-label” (+32Da).(57) Quantitative proteomic comparisons were performed 
between cells that were exposed to either DMSO or rifampicin for the same amount of time. 
A label swap was performed between the biological replicates. An overview of the labelling 
strategy can be found in Table S1. A total of 100 μg of labeled peptides were fractionated by 
fractionated by strong cation exchange (SCX) on a Agilent 1100 system equipped with an in-
house packed SCX-column (320 µm ID, 15 cm, polysulfoethyl A 3 μm, Poly LC), run at 4 μl/
min. The SCX gradient started for 10 min at 100% solvent A (water/acetonitrile/formic acid; 
70/30/0.1), after which a linear gradient reached 100% solvent B (250 mM KCl/acetonitrile/
formic acid 70/30/0.1) in 15 min, followed by 100% solvent C (500 mM KCl/acetonitrile/formic 
acid 70/30/0.1) for 15 min. To clean the column, the gradient was held at 100% solvent C for 5 
min. Next the column was washed with 100% solvent A. Fifteen fractions were collected in 1 min 
intervals, lyophilized and reconstituted in 30 μl (water/acetonitrile/formic acid 95/3/0.1) for 
nanoLC-MS/MS. Analysis was performed by on-line nano-HPLC MS consisting of a Agilent 1100 
gradient HPLC system (Agilent, Waldbronn, Germany), and a LTQ-FT Ultra mass spectrometer 
(Thermo, Bremen, Germany). Of each fraction 5 μl was injected onto a home-made pre-column 
(100 μm×15 mm; Reprosil-Pur C18-AQ 3 µm, Dr Maisch, Ammerbuch, Germany) and eluted 
via a home-made analytical nano-HPLC column (15 cm×50 µm; Reprosil-Pur C18-AQ 3 μm). 
The gradient was run from 0% to 30% solvent B (10/90/0.1 water/acetonitrile/formic acid) in 
10-155 min. The end of the nano-HPLC column was drawn to a tip of 5 µm internal diameter 
and acted as electrospray needle. Full scan FT-ICR MS spectra were collected from 300-1400 
m/z with a resolution of 25,000 at a target value of 5*106. Data-dependent CID MS/MS was 
performed of the five most abundant precursors using a normalized collision energy of 35.0 and 
an isolation width of 2.0 Th. The minimum signal required to trigger an MS2 scan was set to 
500. Charge state screening was enabled to reject the acquisition of MS/MS spectra for singly 
charged precursor ions. A dynamic exclusion duration of 45 seconds was used.
Phosphopeptide enrichment
Phosphorylated peptides were enriched using Titansphere (GL Sciences, Japan) affinity material 
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as previously described.(58) In short, micro columns were pre-equilibrated by loading 50 µl of TiO2 
loading buffer twice (80% acetonitrile, 6% trifluoroacetic acid and 50 mg/ml dihydroxybenzoic 
acid). Dimethylated peptides were suspended in 50 µl of loading buffer and loaded onto the 
micro columns. The columns were sequentially washed with 50 µl of loading buffer followed 
by two washes with 50% acetonitrile, 0.1% trifluoroacetic acid. The bound peptides were 
eluted with 25 µl of 5% ammonia which was directly neutralized with 25 µl of 10% formic acid. 
The samples were cleaned by solid phase extraction on C18 SepPak columns and analyzed by 
nanoLC-MS/MS as described above. 
Data interpretation
Peptides and proteins were identified and quantified using MaxQuant 1.4.0.3.(59) The false 
discovery rate (FDR) was set to 0.01 for both proteins and peptides. Minimal peptide length 
was set to six amino acids. A first search was conducted using 20 ppm precursor tolerance, 
after which the data was corrected for systematic errors by MaxQuant. This re-calibrated 
dataset was analyzed with 10 ppm precursor mass tolerance in the MaxQuant main search. 
The MS/MS spectra search was performed with 0.5 Da tolerance using the Andromeda search 
engine.(60) A total of 262 common contaminants were included in the searches by Andromeda. 
Trypsin specificity was set as C-terminal to arginine and lysine without proline restriction. A 
maximum of two missed cleavages was allowed. Variable modifications included N-terminal 
protein acetylation, methionine oxidation, corresponding dimethyl labels, Asn to Asp & Gln 
to Glu for deamidated peptides and phospho(STY) for the enriched phosphopeptide fractions. 
Carbamidomethylation of cysteine was selected as a fixed modification. Proteins identified have 
a minimal peptide count of two unique peptides. All spectra were matched against a FASTA 
database of M. tuberculosis H37Rv (3996 entries).(61) Statistical analysis of the outcomes was 
performed by Perseus using the significance B test with a Benjamini-Hochberg FDR 5%. Proteins 
considered to be differentially expressed have at least a 1.5-fold ratio(62) and a significance B 
score ≤0.05. In addition, phosphopeptides required a delta score ≥5, Andromeda score ≥60 and 
a site localization probability ≥0.75. Over 300 raw data files and the MaxQuant output files, 
which provide access to all annotated spectra, have been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository that can be accessed with the dataset identifier 
PXD002402.
In solution Auramine-O/Nile Red dual fluorescent staining 
Nile Red and auramine-O staining were performed essentially as described previously with some 
modifications.(63) Mycobacterial cells were washed in ice-cold PBS. Subsequently, the pellet was 
incubated with Phenolic auramine Solution (Sigma Aldrich, the Netherlands) for 15 minutes. 
The cells were thoroughly washed with PBS and destained using acidic ethanol for 2 min, 
followed by thorough washes. After auramine-O staining the cells were incubated in Nile Red 
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(Sigma Aldrich, the Netherlands) followed by thorough washes with PBS and directly analysed 
using a Glomax-Multi Jr Single tube MultiMode Reader (Promega, USA) with excitation at 525 
nm and emission at 580-640 nm for Nile Red staining and excitation at 460nm and emission at 
515-570nm for the auramine-O stain.
Fluorescence microscopy
From a mycobacteria culture in mid-logarithmic phase, 25 µl was mixed with 75 µl of PBS and 
evenly smeared over the surface of glass slides. The sample was allowed to air dry and 200 µl 
of 70% ethanol was added to fix the bacteria. The slides were flooded with Phenolic auramine 
Solution (Sigma Aldrich, the Netherlands) for 15 min without drying. Next, the slides were rinsed 
with distilled water and the excess liquid was shaken off. The slides were flooded with acidic 
ethanol to decolorize for 2-3 min and thoroughly washed with water. Subsequently, the slides 
were flooded with Nile Red (Sigma Aldrich, the Netherlands) and incubated for 15 min, followed 
by a thorough wash with water. Finally, the slides were flooded with potassium permanganate 
for 3-4 min and rinsed with water. The slides were air dried in the dark and mounted for 
fluorescence microscopy. Slides were examined with a Zeiss Axioskop 2 fluorescence microscope 
with an Axiocam HRc camera and Zeiss Axiovision 4.4 software (Zeiss, Germany).
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Results/discussion
High tolerance to short-term rifampicin treatment in M. tuberculosis Beijing B0/W148
Patients with a drug susceptible variant of M. tuberculosis are usually treated with rifampicin, 
one of the most potent first-line anti-TB drugs that is currently available. Rifampicin is 
administered once a day at a dose of 600 mg for at least six months. Considering its serum half-
life of approximately 3 hrs, only ±0.5% of the initial serum concentration will remain after 24 hrs 
of rifampicin intake.(64) As a consequence, M. tuberculosis will essentially be repeatedly pulsed 
by rifampicin. The initial response of M. tuberculosis in the first hours of antibiotic treatment is 
thereby presumably essential to cope with rifampicin-induced stress. 
The administration of high rifampicin doses of 900 mg a day, instead of the commonly 
prescribed 600 mg, has already been examined in 1968.(65) These studies revealed that daily 
administration of 900 mg rifampicin results in serum concentrations of 16.2 µg/ml 3 hrs after 
intake. To determine whether M. tuberculosis Beijing B0/W148 is capable of surviving high 
doses of 16 µg/ml rifampicin, we exposed the pathogen to various concentrations of rifampicin 
for 24 hrs. After 24 hrs of treatment we quantified the intracellular ATP concentrations to assess 
cell viability; Figure 1. Surprisingly, even doses far above 16 µg/ml were tolerated for 24 hrs. 
To assure that the cells remained culturable(66), and were not beyond survival, we cultured 
the cells after 24 hrs of rifampicin exposure in MGIT-tubes without antibiotic pressure; Figure 
1. To ascertain that the high levels of antibiotic tolerance were not conferred by a mutation 
in the rpoB gene, the primary target of rifampicin, we performed a MTBDRplus assay which 
did not reveal any mutation after 24 hrs exposure to 16 µg/ml rifampicin. These observations 
demonstrate that M. tuberculosis Beijing strain B0/W148 can survive 24 hrs treatment with 16 
µg/ml of rifampicin. Since no mutations were identified that confer high levels of rifampicin 
tolerance, our data suggest that phenotypic tolerance mechanisms play an important role in 
the initial response to rifampicin. 
Induction of DosR regulon proteins upon exposure of M. tuberculosis Beijing B0/W148 to 
rifampicin
To determine the initial proteomic response of M. tuberculosis Beijing B0/W148 upon 
rifampicin treatment, we exposed the pathogen to a concentration of 16 µg/ml rifampicin. As 
described above, this concentration is similar to the serum concentrations that can be reached 
using high dosages of rifampicin during treatment.(65) Furthermore, as presented in Figure 1, 
a concentration of 16 µg/ml does not yield large numbers of dead cells that can compromise 
our view on the proteome of this pathogen. After 1.5, 3, 6, 15 and 24 hrs of exposure to either 
rifampicin, or DMSO as a control, the cells were harvested and processed for proteomic analysis 
as described in the methods section.
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FIGURE 1: M. tuberculosis Beijing B0/W148 remains culturable after 24 hrs exposure to high concentrations 
of rifampicin
Viability(ATP) & culturability(TTD) of M. tuberculosis Beijing B0/W148 after 24 hrs exposure to rifampicin, 
after removal of the antibiotic pressure. The culture viability was assessed by quantification of ATP whereas 
the culturability was determined by inoculating MGIT-tubes with rifampicin treated M. tuberculosis in the 
absence of the drug and measuring the TTD. Biological duplicates and technical triplicates were taken for 
each of the data points. Error bars represent the standard error of the mean (SEM). Note: the error bars are 
too small to be visualized for several data points.
We identified and quantified a cumulative number of 30,740 peptides and 2,534 proteins based 
on at least two unique peptides/proteins, of which 1,828 proteins were quantified at all-time 
points in both biological replicates; Table S1 & S2. All biological replicates showed a >90% 
overlap between the proteins identified and quantified. An asymmetrical distribution of protein 
ratios was observed over time for rifampicin-exposed mycobacteria, i.e. we identified more 
proteins to be down regulated than up regulated, as an expected consequence of rifampicin 
dependent RNA-polymerase inhibition; Figure 2 and Figure S1. Since protein stability data 
for M. tuberculosis are not present to date, we cannot state whether proteins are truly down 
regulated or less abundant due to rifampicin treatment as a result of protein turnover combined 
with a limited supply of newly synthesized proteins. For example, the relatively rapid decline of 
Rv3283/sseA could be explained by the predicted relative instability of the protein due to the 
presence of a, modern Beijing lineage, specific nsSNP as we have described previously; Figure 
S2.(44, 67)
Sixty-three proteins were identified to be less abundant after 24 hrs exposure to rifampicin, 
whereas 10 proteins were up regulated; Table S3. Proteins that were differentially abundant 
upon 24 hrs of rifampicin treatment were categorized based on their function;(68) Figure S3. None 
of the categories showed to be significantly over- or underrepresented after Chi-square analysis. 
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FIGURE 2: Asymmetrical distribution of protein ratios upon treatment of M. tuberculosis Beijing B0/
W148 with rifampicin
A violin-plot(110) representing the average Log2 ratio of 1,828 proteins that were quantified at each of the 
time points analyzed.
Of the 10 proteins that were more abundant upon 24 hrs of rifampicin treatment, six belonged to 
the DosR dormancy regulon.(69) In total, we identified and quantified 23 members of this regulon 
at all time-points in each of the biological duplicates. The temporal abundance dynamics of 17 
of these 23 proteins followed a similar trend; Figure S4. 
Most notably is the differential abundance of Rv2031c/hspX/acr, which was particularly up 
regulated within the first 24 hrs of rifampicin treatment. It is known that Rv2031c/hspX/acr is 
one of the earliest and strongest induced DosR genes.(51, 69, 70) Furthermore, in a mouse model 
the Rv2031c/hspX/acr knock-out strain showed an increased susceptibility to anti-TB drugs 
compared to wild-type strains, once treatment was started 3 weeks after infection so dormancy 
could be established.(71) 
It has often been speculated that the dormant state of M. tuberculosis, which can be induced by 
the DosR regulon, plays an important role in tolerance towards antibiotics during treatment.(40, 71-
75) It is however important to note that the induction of dormancy has so far only been observed 
for environmental stimuli and that this has not been reported for anti-TB drugs in M. tuberculosis. 
A majority of the currently available anti-TB drugs target processes involved in cell growth and 
division, which can explain why these drugs work less well against metabolically hypoactive, 
non-replicating mycobacterial cells.(40) Next to the lowered effectiveness of antibiotics in 
metabolically hypoactive mycobacterial cells, it has also been reported that mycobacteria alter 
their cell envelope during dormancy, which reduces the accumulation of antibiotics.(76)
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The induction of the DosR regulon proteins upon rifampicin exposure might represent a 
mechanism of M. tuberculosis Beijing B0/W148 to circumvent antibiotic induced stress. 
However, even though dormancy can be beneficial for M. tuberculosis to overcome antibiotic 
stress, induction of the DosR regulon is not the only and primary mechanism for antibiotic 
tolerance in the mouse infection models.(77) Therefore, we also assessed the abundance of other 
proteins that could contribute to a more drug tolerable phenotype.
A POTENTIAL ROLE FOR EFFLUX PUMPS IN RIFAMPICIN TOLERANCE
Other proteins that can play a major role in tolerance and development of antibiotic resistance 
are antibiotic extruding efflux pumps. A broad variety of these pumps has been identified and 
can contribute to the active secretion of different types of antibiotics in M. tuberculosis.(43) In the 
case of rifampicin, it has been mentioned that the level of drug tolerance can even be defined 
by the activity of efflux pumps.(34) We determined whether any of the efflux pumps that have 
previously been demonstrated to be induced by rifampicin on the mRNA level or any other of 
the previously listed efflux pumps(43) are differentially regulated upon rifampicin treatment in 
M. tuberculosis B0/W148. 
In our dataset of 1,828 proteins we quantified 12 of the previously listed 31 efflux pumps, 
including Rv1747 & Rv1002c, which were reported to be involved in the response to rifampicin.
(34) However, none of these efflux pumps showed to be differentially abundant after up to 24 hrs 
of rifampicin treatment; Table S1.
As we previously proposed, efflux pumps might pre-exist at higher levels of activity in several 
modern Beijing strains, including the modern Beijing strain B0/W148 used in this study.(44) The 
fact that none of these efflux pumps are differentially regulated does, therefore, not necessarily 
indicate that efflux mediated rifampicin tolerance does not play a role in M. tuberculosis 
Beijing B0/W148. When we examined the B0/W148 cluster specific nsSNPs that were reported 
previously regarding their possible influence on protein expression,(78) we identified two efflux 
pump coding genes to possess a nsSNP that can affect the function or stability of these proteins; 
Rv1877&Rv3728. Taken together, on the basis of our data we can neither exclude, nor include 
efflux pumps to play an important role in rifampicin tolerance in Beijing B0/W148. However, 
based on the proteins that we identified to be differentially regulated it seems that the synthesis 
of DosR regulated proteins is prioritized by the pathogen.
RIFAMPICIN INDUCED CHANGES IN PROTEIN PHOSPHORYLATION
Reversible phosphorylation is a major regulatory modification which allows both eukaryotic and 
prokaryotic cells to sense and respond to their environment. In M. tuberculosis, the existence 
of phosphorylation on Ser, Thr, and recently also Tyr has been described, although the function 
and regulation of specific phosphorylation sites is lacking.(79-81) Therefore, we performed a large-
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scale quantitative study to investigate the role of Ser/Thr/Tyr phosphorylation in M. tuberculosis 
in response to rifampicin.
In this study, we identified a cumulative number of 191 phosphorylation sites corresponding 
to 180 phosphopeptides, which mapped to 132 unique proteins; Table S4. Approximately 93% 
of the identified phosphopeptides contained a single phosphorylated residue, whereas 7% 
contained two phosphorylation sites; Figure S5. This might be due to the use of TiO2, which 
has a preference for monophosphorylated peptides.(82) The observed ratio Ser/Thr/Tyr was 
22/76/2. This confirms that phosphorylation in M. tuberculosis is biased towards Threonine,(79) 
whereas phospho-Serine is predominant in eukaryotes, Bacillus subtilis, Escherichia coli and 
Pseudomonas species.(58, 83-87) 
We observed that phosphorylation of Rv2187, Rv2534, Rv2986c and Rv3458c changed over 
time, independent of their respective protein kinetics; Figure 3. To confirm the identity of these 
phosphopeptides we compared the fragmentation spectra with those acquired from synthetic 
peptides; Figure S6A-H.
FIGURE 3: Protein and phosphorylation dynamics during rifampicin exposure. 
Protein (black filled dots) and phosphorylation (white squares) dynamics of Rv2187(Thr-437), 
Rv2536(Thr-160), Rv2986c(Ser-90) and Rv3458c(Thr-147) during rifampicin exposure. Error bars represent 
the SEM. *Was identified in a single biological replicate for T=15hr. Note: the error bars are too small to be 
displayed for several data points.
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The phosphorylation on both Rv2187 & Rv2536 was observed to be down regulated during 
rifampicin treatment. Rv2187 & Rv2536 have been reported to be differentially regulated 
upon treatment with erythromycin and streptomycin.(88) Both streptomycin and erythromycin 
are translational inhibitors, whereas rifampicin is known to be a transcriptional inhibitor. As 
transcription and translation are both essential for protein synthesis we hypothesize that the 
differential phosphorylation of Rv2187 & Rv2536 is involved in a general response to inhibitors 
of protein synthesis.
HupB/Rv2986c was the first histone-like protein to be described in M. tuberculosis and is 
capable of binding mycobacterial DNA.(89) In this study, we demonstrate that HupB/Rv2986c is 
increasingly phosphorylated on Ser-90 upon rifampicin treatment; Figure 3. In the presence of 
iron, HupB/Rv2986c binds the mbtB/Rv2383c promoter.(90) Thereby, HupB/Rv2986c, also known 
as iron-regulated protein (Irep-28),(91) can positively regulate the biosynthesis of siderophores 
which are necessary for the uptake of iron by mycobacteria. We previously established a 
connection between the success of Beijing strains and the uptake of iron by siderophores.(44) 
Secretion of siderophores is carried out by either Rv0450c/MmpL4, together with Rv0451c/
MmpS4, or Rv0677c/MmpS5 together with Rv0676c/MmpL5 in M. tuberculosis.(92) It is known 
that modern Beijing strains contain a unique nsSNP in Rv0676c/MmpL5 and consistently over-
express Rv0450c/MmpL4.(44, 93) The increasing phosphorylation of HupB/Rv2986c fits the overall 
picture that iron metabolism plays a role in the success of M. tuberculosis Beijing. Finally, 
iron-sequestration has previously been linked to antibiotic tolerance, as the growth inhibitory 
effects of rifampicin is slightly reversible in the presence of high concentrations of iron and 
the concentration of siderophores increases in the presence of rifampicin.(94) In line with the 
induction of the dormancy regulon, it has been proposed that M. tuberculosis attempts to 
increase iron-storages for long periods of dormancy.(95) 
Next to the role of HupB/Rv2946c in the storage of iron and its possible role in dormancy, 
we also observed increased levels of phosphorylated rpsD/Rv3458c. Similar to HupB/Rv2946c, 
rpsD/Rv3458c is important to cope with high levels of iron.(96) Finally, rpsD/Rv3458c is induced 
when M. tuberculosis enters stationary phase.(97)   
Rifampicin induces a more dormant phenotype in M. tuberculosis Beijing B0/W148
The differential regulation of DosR regulon proteins and the increased phosphorylation of HupB/
Rv2986c & rpsD/Rv3458c both point towards a role for dormancy during rifampicin exposure. 
Previous studies have identified host and environmental factors that can induce dormancy in 
M. tuberculosis.(39, 98) However, our (phospho)proteomic data suggest that a drug, rifampicin, 
itself, can induce dormancy, which would be a completely novel stimulus for the induction of 
dormancy. The confirmation of this observation would be of direct clinical relevance, since 
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modern day antibiotic susceptibility testing assays focus on the growth inhibitory concentration 
of drugs. However, these methods do not take into account that growth can be brought to a 
halt due to the induction of dormancy. As a consequence, the capability of strains to survive 
high levels of rifampicin due to dormancy will not be noticed using standard drug susceptibility 
testing protocols.
The increased abundance of DosR proteins is a strong indication that the pathogen transitioned 
to a dormant phenotype upon exposure to rifampicin. However, the regulation of DosR 
proteins is not sufficient to conclude that the cell will enter a non-replicative dormant state. 
To independently confirm the induction of dormancy upon rifampicin treatment we examined 
long term persisters of rifampicin treatment, e.g. cells that remained viable after a week of 
rifampicin treatment. The accumulation of intracytoplasmic lipid inclusions, as indicated by Nile 
Red, the loss of acid fastness as measured by Auramine-O, the arrest of bacterial multiplication 
(OD600nm, TTD) and the decrease in ATP levels are considered to be hallmarks of dormancy, 
and were therefore previously assessed in rifampicin-treated M. tuberculosis.(39, 63, 99, 100) 
Treatment of M. tuberculosis Beijing B0/W148 with rifampicin brought the growth to a halt, 
as assessed by optical density; Figure S7A. As examined by the MGIT-assay, culturable cells 
remained. Striking is the fact that the MIC of 0,0625 µg/ml observed in this study is, even 
after seven days exposure, not sterilizing. When we increased the MIC 256-fold to 16 µg/ml 
and exposed the mycobacteria for seven days, we could still detect viable and culturable cells 
that did not contain a mutation in rpoB, which is a strong indication for phenotypic antibiotic 
tolerance.
If M. tuberculosis truly enters dormancy, it would not only bring replication to a halt, but also 
the concentration of ATP is reported to be 5-fold lowered in the Wayne dormancy model.(101) 
In our approach, we observed a ±10-fold reduction in ATP after a seven-day long treatment with 
≥ 0.25 µg/ml rifampicin; Figure S7C. These results strengthen our hypothesis that rifampicin 
treatment induces dormancy in this strain. The witnessed 10-fold reduction in ATP-levels 
during rifampicin treatment is not lethal for M. tuberculosis. A further reduction of these ATP-
levels can be achieved with the use of bedaquiline, which will eventually be fatal for dormant 
mycobacteria.(102, 103) 
To further confirm that a dormant phenotype is established by M. tuberculosis Beijing B0/
W148, we examined the loss of acid-fast staining and accumulation of Nile Red-staining lipid 
droplets, a well-studied phenotype of dormancy in M. tuberculosis.(39, 63, 99, 100) Similar to the ATP 
concentrations determined, there was no dose-response observed in the Nile Red/Auramine 
stain for rifampicin concentrations ≥ 0.25 µg/ml; Figure S7D. The relative increase of lipid bodies 
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supports our hypothesis that dormancy is indeed induced upon exposure to rifampicin in this 
particular pathogen. 
Interestingly, actively dividing, mid-logarithmic mycobacterial cells of M. tuberculosis Beijing 
B0/W148 already retained Nile Red; Figure 4. This pre-existent dormant phenotype in the 
examined M. tuberculosis W-Beijing strain adds to a previous study that reported increased 
levels of triglycerides and elevated levels of mRNA for DosR regulon genes within this specific 
genotype.(104) Therefore, it seems that M. tuberculosis W-Beijing strains can more easily enter a 
phase of dormancy once it encounters stress factors. Moreover, a less complicated transition to 
dormancy could explain why Beijing strains are more tolerant to transient drug treatment than 
M. tuberculosis H37Ra and East African-Indian strains.(105) 
FIGURE 4: Pre-existence of a dormant phenotype in M. tuberculosis Beijing B0/W148. 
A) Acid-fast Auramine-O staining of M. tuberculosis Beijing B0/W148.
B) Nile Red staining of intracellular lipid droplets in M. tuberculosis Beijing B0/W148.
C) Overlay of Auramine and Nile Red staining shows the pre-existence of a dormant phenotype in all M. 
tuberculosis B0/W148 cells.
Taken together, our study provides evidence that a clinically relevant dose of rifampicin is not 
sufficient to kill these Beijing genotype mycobacteria, even at high concentrations. Instead, a 
dormant phenotype is established upon treatment. Metabolic shutdown, as part of dormancy, 
severely hampers the success of antibiotic treatment for this pathogen and it is questionable 
whether higher dosage of rifampicin will overcome this effect. The induction of dormancy by 
M. tuberculosis Beijing B0/W148 might thereby be a successful route to cope with antibiotic 
pressure.
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The observation that not only environmentally induced stress, but also drug induced stress 
can lead to dormancy suggest that the DosR-regulon functions as a general stress response 
mechanism. This hypothesis is further strengthened by a previous study which showed the 
induction of DosR proteins upon bedaquiline exposure.(103) Therefore this findings might be 
extended to other (first-line) antibiotics. 
The correlation between an established dormant phenotype and antibiotic tolerance is well 
accepted, but it remains speculative how dormancy can contribute to the development of 
a rifampicin resistant genotype. It has long been assumed that rifampicin resistance occurs 
spontaneously due to chromosomal mutations.(106) Surprisingly, the mutation rates of M. 
tuberculosis are similar during active and latent disease in a macaques model.(107) These 
mutation rates were similar to those identified by sequencing of human isolates.(108) Since 
the M. tuberculosis mutation rate per-time is similar between active and latent disease, rpoB 
mutations can be acquired during prolonged periods of dormancy, a phase that could last for 
years in which the pathogen is highly tolerant to antibiotics.(109)
Conclusions
Modern, state of the art molecular diagnostics focus on the identification of genotypic markers 
of antibiotic resistance. In this study we demonstrated that the initial high rifampicin tolerance of 
the successful Russian M. tuberculosis Beijing B0/W148 strain is not acquired due to a mutation 
in the rpoB gene. Instead, the outcome of our (phospho)proteomic- and cellular studies show 
that phenotypic drug tolerance, caused by the induction of dormancy, plays an important role 
in M. tuberculosis Beijing B0/W148 during the initial phase of rifampicin exposure. Knowledge 
of the phenotypic mechanisms operative in M. tuberculosis will contribute to a more effective 
form of treatment for the 8-9 million individuals that receive anti-TB therapy annually.
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Supporting information
SUPPORTING INFORMATION TABLE S1: Overview of the proteins identified in all of the samples analyzed. 
This table can be downloaded on the website of the journal: https://pubs.acs.org/doi/suppl/10.1021/acs.
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SUPPORTING INFORMATION TABLE S2: Overview of all the peptides identified. This table can be 
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SUPPORTING INFORMATION TABLE S3: Proteins identified to be differentially regulated after 24 h of 
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SUPPORTING INFORMATION TABLE S4: Overview of the phosphopeptides and phosphoproteins identified. 
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FIGURE S1: Protein ratio distribution comparison in rifampicin exposed M. tuberculosis Beijing B0/W148. 
Normalized Log2 transformed protein ratio’s plotted against the summed Log2 protein intensity for both 
biological replicates. The peptides derived from rifampicin exposed mycobacteria was provided with a 
“medium”-label in biological replicate 1 and a “light”-label in biological replicate 2. Data points are coloured 
based on their significance B values. Turquois is >0.5, blue >0.25, red >0.1, yellow >0.05 and green <0.05. 
Note: a label swap was performed between both biological replicates. 
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FIGURE S2: Abundance kinetics of Rv3283/sseA during rifampicin exposure. Error bars represent SEM.
FIGURE S3: Proteins significantly down regulated or upregulated after 24 hr of rifampicin treatment. None 
of the functional categories(68) showed to be significantly over/underrepresented after Chi-square analysis.
3
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FIGURE S4: Differential regulation of DosR regulon proteins upon rifampicin exposure. Error bars represent 
SEM.
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FIGURE S5: Percentage of phosphosites identified per phosphopeptide(A) and the percentage of Ser/Thr/
Tyr phosphorylation. Error bars represent SEM. 3
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A: MS/MS-spectrum of the phosphopeptide of Rv2187(Thr-437)
B: MS/MS-spectrum of the synthetic phosphopeptide for Rv2187(Thr-437)
C: MS/MS-spectrum of the phosphopeptide of Rv2536(Thr-160)
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D: MS/MS-spectrum of the synthetic phosphopeptide for Rv2536(Thr-160)
E: MS/MS-spectrum of the phosphopeptide of Rv2986c(Ser-90
F: MS/MS-spectrum of the synthetic phosphopeptide for Rv2986c(Ser-90) 
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FIGURE S6: MS/MS-spectra of selected phosphopeptides
A) MS/MS-spectrum of the phosphopeptide of Rv2187(Thr-437)
B) MS/MS-spectrum of the synthetic phosphopeptide for Rv2187(Thr-437)
C) MS/MS-spectrum of the phosphopeptide of Rv2536(Thr-160)
D) MS/MS-spectrum of the synthetic phosphopeptide for Rv2536(Thr-160)
E) MS/MS-spectrum of the phosphopeptide of Rv2986c(Ser-90
F) MS/MS-spectrum of the synthetic phosphopeptide for Rv2986c(Ser-90) 
G) MS/MS-spectrum of the phosphopeptide of Rv3458c(Thr-147)
H) MS/MS-spectrum of the synthetic phosphopeptide for Rv3458c(Thr-147)
G: MS/MS-spectrum of the phosphopeptide of Rv3458c(Thr-147)
H: MS/MS-spectrum of the synthetic phosphopeptide for Rv3458c(Thr-147)
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FIGURE S7: Development of a dormant phenotype upon rifampicin treatment. Error bars represent the 
SEM. The concentrations are reported in µg/ml.
A) The optical density measured at 600nm.
B) The time till detection (TTD) determined after 0,1,4 and 7 days of rifampicin treatment.
C) Viability of the cells was assessed by determination of the concentration of ATP after treatment with 
different concentrations of rifampicin for 7 days.
D) The normalized Nile Red/Auramine ratio after 7 days of treatment with multiple concentrations of 
rifampicin.
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Parallel reaction monitoring of clinical Mycobacterium tu-
berculosis lineages reveals pre-existent markers of rifampicin 
tolerance in the emerging Beijing lineage
4
Abstract
The spread of multidrug resistant Mycobacterium tuberculosis is one of the major challenges 
in tuberculosis control. In Eurasia, the spread of multidrug resistant tuberculosis is driven by the 
M. tuberculosis Beijing genotype. In this study, we examined whether selective advantages are 
present in the proteome of Beijing isolates that contribute to the emergence of this genotype. 
To this end, we compared the proteome of M. tuberculosis Beijing to that of M. tuberculosis 
H37Rv, both in the presence and absence of the first-line antibiotic rifampicin. During rifampicin 
exposure, both M. tuberculosis genotypes express proteins belonging to the DosR dormancy 
regulon, which induces a metabolically hypoactive-, drug tolerant phenotype. However, these 
markers of rifampicin tolerance were already more abundant in the M. tuberculosis Beijing 
isolate prior to drug exposure. To determine whether the a priori high abundance of specific 
proteins contribute to the formation of antibiotic resistance in M. tuberculosis Beijing, we 
quantified the abundance of 33 selected proteins in 27 clinical isolates from the five most 
common M. tuberculosis lineages using parallel reaction monitoring. The observed pre-existing 
high abundance of dormancy proteins in Beijing strains provides an evolutionary advantage that 
allow these strains to persist for prolonged periods during rifampicin treatment.
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Introduction
Mycobacterium tuberculosis has recently been declared the most important worldwide cause 
of death by a single infectious disease.(1) In 2014 tuberculosis (TB) caused the death of 890,000 
men, 480,000 women and 140,000 children.(1) Of major concern is the spread of multidrug 
resistant tuberculosis (MDR-TB), a form of TB that is resistant to at least rifampicin and 
isoniazid, the cornerstones in anti-TB treatment. In Eurasia, the dissemination of MDR-TB is 
largely attributable to the M. tuberculosis Beijing genotype.(2, 3)
Strains of the M. tuberculosis Beijing lineage seem to possess selective advantages to acquire 
rifampicin resistance,(4-7) to circumvent BCG-vaccine induced immunity (8-10) and hyper-
transmissibility compared to other M. tuberculosis lineages.(11-14) Not surprisingly, the M. 
tuberculosis Beijing genotype is correlated with (multi)drug resistance, hyper-virulence and 
relapses after curative treatment in many geographical areas.(15-20)
Although it is well accepted that M. tuberculosis Beijing manifests itself differently from other 
M. tuberculosis lineages regarding transmission, drug resistance and virulence, there is some 
discrepancy between the various studies published. This heterogeneity is partly attributable 
to differences between M. tuberculosis sub-lineages in the Beijing genotype family.(21) 
Phylogenetically, the Beijing genotype can be delineated into the more “ancient” or atypical and 
the more “modern” or typical Beijing sub-lineage. However, both sub-lineages are genetically 
highly similar.(22, 23) In fact, only 31 non synonymous single nucleotide polymorphisms (nsSNP) 
have been identified that discriminate both sub-lineages.(24) Although genetically similar, the 
degree of genetic conservation is much higher within the typical Beijing sub-lineage, which 
suggests that these strains acquired selective advantages over atypical Beijing strains in 
relatively recent years.(24) This hypothesis is further strengthened by the fact that it is mainly 
the modern typical Beijing sub-lineage that is associated with (multi)drug resistance and the 
ability to spread and cause disease.(25) Currently, there is no unequivocal model that can clarify 
the evolutionary success of M. tuberculosis (typical) Beijing strains.(26) However, the key to the 
evolutionary success of M. tuberculosis (typical) Beijing might be traced within the proteomic 
composition of strains in this lineage. 
Over a decade ago, a two-dimensional gel electrophoresis approach was used to identify 
proteins that are differentially abundant in M. tuberculosis Beijing, a second “non-Beijing” 
clinical isolate, and M. tuberculosis H37Rv, a frequently studied mycobacterial laboratory strain.
(27) One protein was identified to be more abundant in M. tuberculosis Beijing (Rv2031c/hspX), 
whereas three other proteins were identified to be less abundant (Rv0440/GroEL2, Rv0934/
PstS1 and Rv1860/47kDa). In a recent study, we quantitatively compared the proteomes of 
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typical with that of atypical Beijing strains, in which we found that Beijing sub-lineages are 
extremely conserved in terms of protein abundance.(28) In fact, the two proteomes were so 
similar that we could only identify two proteins to be differentially regulated between both 
sub-lineages; Rv0450c/mmpL4 and Rv3283/sseA. Subsequently, when we examined the initial 
response of a typical Beijing isolate to rifampicin, we found the so-called DosR dormancy 
regulon to be induced within 24 hrs after treatment.(29) The DosR dormancy regulon induces a 
non-replicative, metabolically inactive and drug tolerant mycobacterial phenotype which may 
severely compromise treatment efficacy.(30) We demonstrated that dormancy can be actively 
induced by the pathogen to protect itself from toxic compounds, whereas it was previously only 
known that environmental factors can induce dormancy.(31, 32) If M. tuberculosis Beijing strains 
possess an increased ability to induce dormancy upon exposure to rifampicin, this could possibly 
reflect the mechanism through which Beijing genotype bacteria developed a higher tolerance 
to antibiotics within patients, which consequently leads to a longer persistence, development 
of resistance and higher relapse rates even after curative treatment. However, the induction 
of the dormancy regulon upon rifampicin exposure has so far only been demonstrated in M. 
tuberculosis Beijing.
Therefore, we here address the question of what proteins typify the proteome of M. tuberculosis 
Beijing and what proteins contribute to the emergence of drug-resistant M. tuberculosis Beijing. 
To this end, we used a data-dependent acquisition (DDA) approach to compare the proteome of 
the M. tuberculosis Beijing B0/W-148, which resembles the “successful” Russian typical Beijing 
strain,(33) with the proteome of the M. tuberculosis laboratory-strain H37Rv, both with and 
without exposure to rifampicin. Based on the proteins quantified by DDA proteomics, we made 
a selection of 33 proteins and examined their abundance using parallel reaction monitoring 
(PRM) in multiple lineages of well characterized clinical M. tuberculosis isolates; typical Beijing, 
atypical Beijing, East-African Indian (EAI), Haarlem and Central Asian Strain (CAS) lineages.
Following this approach, we provide a thorough inter-lineage comparison of protein abundance 
in well characterized M. tuberculosis genotypes. The results presented in this manuscript show 
that proteins required to circumvent rifampicin-induced killing are already highly abundant in 
strains of the M. tuberculosis Beijing genotype, prior to drug exposure.
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Materials & Methods
Culture conditions
Mycobacterial cells were re-cultured from frozen stocks in 5 ml Tween-Albumin liquid culture 
broth (Tritium Microbiologie, the Netherlands) at 36°C to an O.D. of 0.4 AU at 600 nm, as 
described previously.(28) One ml of this pre-culture was transferred to a 250 ml Erlenmeyer 
flask containing 100 ml Tween-Albumin broth and incubated under constant rotation at 36°C 
to provide aeration. Once the cultures reached an O.D. of 0.6 AU at 600 nm, representing the 
mid-log phase, the cells were exposed to 1 µg/ml rifampicin (Sigma Aldrich, the Netherlands) or 
DMSO as a control. Cells were harvested after 24 hrs of incubation and washed three times with 
ice-cold PBS (Braun, Germany), the resulting pellet was suspended in 5 ml Lysis-buffer (4% SDS, 
100 mM Tris-HCl, pH 7.6) and heat-killed at 95°C for 10 min. Lysates were stored at -20°C until 
further usage. Biological duplicates were grown, processed and analyzed in parallel.
Rifampicin susceptibility determination
To exclude the selection of rifampicin resistant mycobacteria we analysed the rifampicin 
resistance determining region (RRDR) of rpoB, the hotspot for drug resistance, for presence 
of mutations using the MTBDRplus assay according to the manufacturers’ recommendations, 
as described previously.(34) Phenotypic rifampicin susceptibility, as determined by the minimal 
inhibitory concentration (MIC), was determined according to Clinical and Laboratory Standards 
Institute guidelines,(35) using the BACTEC MGIT-960 system (Becton, Dickinson and Co., Franklin 
Lakes, NJ). 
Sample preparation
Protein digests were prepared as described previously.(28) In brief, mycobacterial cell lysates 
were mechanically disrupted by bead-beating in a mini bead-beater 16 (BioSpec, USA) after 
which the lysates were transferred to a fresh tube. Proteins in the lysate were digested using 
the filter aided sample preparation (FASP) method, including reduction, removal of SDS by 
urea and carbamidomethylation of cysteines.(36) The tryptic digest was desalted on C18 SepPak 
columns (Waters Corporation, Massachusetts, USA) and on column labeled by dimethylation.
(37) Samples analyzed by data dependent acquisition (DDA) were fractionated into 15 fractions 
by strong cation exchange (SCX) on a Agilent 1100 system equipped with an in-house packed 
SCX-column (320 µm ID, 15 cm, polysulfoethyl A 3 μm, Poly LC, Columbia, USA), run at 4 μl/
min. The SCX gradient started for 10 min at 100% solvent A (water/acetonitrile/formic acid; 
70/30/0.1), after which a linear gradient reached 100% solvent B (250 mM KCl/acetonitrile/
formic acid 70/30/0.1) in 15 min, followed by 100% solvent C (500 mM KCl/acetonitrile/formic 
acid 70/30/0.1) for 15 min. To clean the column, the gradient was held at 100% solvent C for 5 
min. Next, the column was washed with 100% solvent A. Fifteen fractions were collected in 1 
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min intervals, lyophilized and reconstituted in 30 μl (water/acetonitrile/formic acid 95/3/0.1) 
for nanoLC-MS/MS. 
Data acquisition
Samples prepared for DDA analysis were analyzed on a nanoLC-MS/MS system consisting of an 
Easy nLC 1000 gradient HPLC system (Thermo scientific, Bremen, Germany), and a Q-Exactive 
mass spectrometer (Thermo scientific, Bremen, Germany). SCX fractions were injected onto an 
in-house packed precolumn (100 μm × 15 mm; Reprosil-Pur C18-AQ 3 μm, Dr. Maisch, Germany) 
and eluted via a homemade analytical nano-HPLC column (15 cm × 50 μm; Reprosil-Pur C18-AQ 
3 μm). The gradient was run from 0% to 30% solvent B (10/90/0.1 water/acetonitrile/formic 
acid) in 120 min. A tip of ~5 μm was drawn at the end of the nano-HPLC which acted as the 
electrospray needle of the MS source. The Q-Exactive mass spectrometer was operated in 
top10-mode. Parameters were; resolution 70,000 at an AGC target value of 3e6, a maximum fill 
time of 20 ms (full scan), and resolution 17,500 at an AGC target value of 1e5 with a maximum 
fill time of 60 ms for MS/MS. For PRM analysis the Q-Exactive mass spectrometer was operated 
in PRM-mode: a cycle comprised one full scan and ten transitions. Full scans were acquired at 
17,500 resolution, and AGC target value of 3e6, a maximum fill time of 20 ms. Tandem mass 
spectra were acquired with a resolution of 35,000 at an AGC target value of 2e5 and a maximum 
fill time of 128 ms. The isolation window was set at 1.5 m/z.
Data dependent acquisition data processing
Peptides and proteins were identified and quantified using MaxQuant 1.4.0.3.(38) The false 
discovery rate (FDR) was set to 0.01 for both proteins and peptides. The first search was 
conducted using 10 ppm, while the main search was performed with 4.5 ppm using the 
Andromeda search engine.(39) MS/MS spectra were searched using 20 mmu mass tolerance. 
A total of 262 common contaminants were included in the searches by Andromeda. Trypsin 
specificity was set as C-terminal to arginine and lysine without proline restriction. A maximum 
of two missed cleavages was allowed. Variable modifications included N-terminal protein 
acetylation, methionine oxidation, and corresponding dimethyl labels. Carbamidomethylation 
of cysteine was selected as a fixed modification. A minimal unique peptide count of two was used 
for protein identification. All spectra were matched against a FASTA database of M. tuberculosis 
reference strain H37Rv (3996 entries).(40) Statistical analysis of the outcomes was performed by 
Perseus using the significance B test with a Benjamini-Hochberg FDR 5%.(39) Proteins considered 
to be differentially abundant have significance B score of ≤0.05. Principal component analysis 
and the generation of a heat map based on the protein ratios was performed in Perseus.(39)  The 
RAW data files and the MaxQuant output files, which provide access to all annotated spectra, 
have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository 
that can be accessed with the dataset identifier PXD003474.
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Parallel reaction monitoring data analysis
PRM data analysis and data integration was performed in Skyline 3.1.0.7382.(41) 
Quantitative analysis was performed using synthetic stable isotypically labelled (SIL) peptides 
that were dimethylated (+36Da). Ten fmol per peptide was injected together with 500 ng 
dimethylated (+28Da) tryptic digest. The intensity rank order and chromatographic elution 
of the transitions were required to match those of a synthetic standard for each peptides 
measured. Summed peak areas from the selected peptide transitions were compared to that of 
the SIL peptide. Statistical evaluation of the outcomes was performed using a one-way ANOVA 
with post hoc Dunnet test to compare the mean of all lineages with the mean of the typical 
Beijing genotype. All RAW-files and the corresponding Skyline files have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository that can be accessed with the 
dataset identifier PXD003474.
Molecular characterization of M. tuberculosis isolates
M. tuberculosis isolates were derived from the reference database of clinical isolates at the 
National Institute for Public Health and the Environment (RIVM) in Bilthoven, the Netherlands. 
The genotypes of the selected isolates were determined as described previously.(42) Phylogenetic 
relationships between the different strains were analysed using mycobacterial interspersed 
repeat units (MIRU) 24-loci variable number of tandem repeats (VNTR) typing with a few minor 
modifications.(42) The in-house VNTR method is based on the protocol of the MIRU-VNTR typing 
manual with minor modifications: the amount of DNA polymerase used was 0.75 units per 
multiplex PCR, and the initial concentration of labelled primers was increased to 8 μM for locus 
2165 and locus 2163b. The amplicon sizes were determined by using the automated ABI 3730 
DNA analyser (Applied Biosystems, California, USA).
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Results and discussion
M. tuberculosis isolates reveal a large diversity in proteome composition
Members of the M. tuberculosis Beijing genotype differ from other M. tuberculosis strains 
in terms of transmission, virulence and capacity to develop antibiotic resistance.(11, 15-20) To 
determine whether the relative proteomic composition of M. tuberculosis Beijing contributes 
to these phenomena, we compared the proteome of M. tuberculosis Beijing B0/W148, a typical 
Beijing strain, with the proteome of M. tuberculosis reference strain H37Rv, both in the presence 
and absence of rifampicin; Figure 1A & B. 
A total of 2,903 unique proteins were identified of which 2,429 proteins were relatively quantified 
against the internal control in each of the analyses, based on at least two unique peptides per 
protein; Figure 1C & Table S1, S2. A high reproducibility was observed between the biological 
replicates (Pearson r >0.9), which shows that the technical and biological reproducibility is 
high and that the detected differentially abundant proteins reflect true heterogeneity in the 
proteomic composition of both lineages; Figure S1 & Figure S2. 
FIGURE 1: Quantitative proteome analysis of rifampicin treated M. tuberculosis lineages.
A) In-depth proteome analysis was performed by parallel processing of the samples using the FASP 
procedure.(36) After trypsin digestion the samples were labelled by dimethylation and mixed in a 1:1:1 
ratio.(37) The resulting peptides were fractionated using SCX chromatography and analysed by high-
resolution nanoLC-MS/MS.
B) Experimental design for the proteomic analysis of M. tuberculosis lineages with and without 24 hrs of 
rifampicin treatment. A label-swap was performed between biological replicates.
C) Venn diagram of the number of proteins quantified in the different conditions examined. 
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A clear segregation between both M. tuberculosis lineages and antibiotic treatment was found 
using principal component analysis; Figure 2A. Similarly, hierarchical clustering of these samples 
showed that the inter-lineage variation is much more profound than the variation introduced 
by exposure to a bactericidal dose of rifampicin; Figure 2B. Due to the substantial inter-lineage 
variation we first focussed on the proteins that were differentially regulated between M. 
tuberculosis Beijing and M. tuberculosis H37Rv after 24hr of DMSO treatment. 
FIGURE 2: Characterization of the relative proteomic variation between M. tuberculosis typical Beijing and 
M. tuberculosis H37Rv. 
A) Principal component analysis of the log2-transformed abundance changes of the 2429 proteins that were 
quantified in both genotypes in both conditions tested.
B) Protein ratios were log2-transformed and z-score normalized. The different samples in the columns were 
hierarchically clustered and rows containing quantified proteins entries were clustered by k-means.
PhoPR and DosR regulon proteins differ in abundance between the Beijing- and the H37Rv strain
In our proteomic DDA dataset of 2,429 proteins, we identified a total of 287 proteins to be more 
abundant in the M. tuberculosis typical Beijing strain compared to H37Rv; Table S1. Among 
the proteins we identified to be more abundant in the typical Beijing lineage was Rv2031c/
hspX, a protein that has previously been identified to be more abundant in a clinical isolate of 
M. tuberculosis Beijing.(27) In that same study, three other proteins were identified to be less 
abundant in that specific M. tuberculosis Beijing isolate compared to H37Rv; Rv0440/GroEL2, 
Rv0934/PstS1 and Rv1860/47kDa. Although all three proteins were present in our dataset, 
none of these proteins was less abundant in M. tuberculosis Beijing; Table S1. This discrepancy 
is possibly caused by the genomic variation in H37Rv strains that are maintained in different 
mycobacterial research laboratories.(43)
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One regulon of which we found the proteins to be more abundant in the M. tuberculosis Beijing 
strain is the DosR dormancy regulon; Table S3. The DosR regulon in the pathogen is necessary to 
enter a latent, non-replicative state for prolonged periods of time up to decades.(44) This latent, 
metabolically hypoactive dormant state makes the pathogen highly tolerant to drugs, since 
most antibiotics inhibit active metabolic processes.(45) Diverse stimuli, including nitric oxide, 
acidity, nutrient deprivation and hypoxia can induce this dormant phenotype.(46-49) Next to 
these environmental stimuli, we have recently shown that an active duplicating clinical typical 
Beijing strain develops a dormant phenotype during exposure to rifampicin.(29) In addition, by 
knocking-out the dormancy protein Rv2031c/hspX, M. tuberculosis becomes more susceptible 
for rifampicin and relapses less often after treatment with anti-TB drugs, compared to wild-type 
strains.(50) 
We identified a total of 23 DosR regulon proteins, of which ten proteins were significantly more 
abundant in the M. tuberculosis typical Beijing strain analysed; Table S3. Previous mRNA analysis 
of five selected DosR genes demonstrated that M. tuberculosis Beijing strains maintain higher 
levels of these DosR gene transcripts than non-Beijing strains.(51) From these five proteins, we 
could confirm the increased abundance of Rv2031c/hspX, Rv3133c/devR and Rv3130c/tgs1 in a 
direct comparison with the H37Rv strain. 
The second regulon we identified to be enriched for differentially abundant proteins is the 
PhoPR regulon; Figure 3.(52) Especially PhoPR regulated proteins involved in lipid metabolism 
were found to be more abundant in the proteome of M. tuberculosis H37Rv. The virulence 
of PhoPR knock-outs is impaired to such an extent that M. tuberculosis PhoPR mutants are 
considered safe enough to be used as vaccine strains.(53, 54) The differential abundance of PhoPR 
proteins might reflect a not yet explored mechanism of M. tuberculosis Beijing related to a 
distinct virulent phenotype. Regarding rifampicin susceptibility, PhoPR knock-outs display a MIC 
similar to that of wildtype M. tuberculosis, indicating that PhoPR does not directly contribute 
to drug tolerance.(54)
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FIGURE 3: The PhoPR regulon network. PhoPR regulated genes that are related to intracellular survival and 
virulence are visualized and grouped by function as described previously.(52) The selected proteins of the 
PhoPR network are coloured by their fold change, proteins in red are more abundant in M. tuberculosis 
typical Beijing whereas red coloured proteins were identified to be less abundant in M. tuberculosis typical 
Beijing compared to H37Rv. The significance of the proteins, as determined with the significance B-test, is 
presented as follows: * <0.05, ** <0.01, ***<0.001. Grey lines correspond to protein-protein interactions as 
reported in the STRING database, with a minimal confidence of 0.7.(66) 
Dormancy proteins are induced by M. tuberculosis H37Rv and Beijing after exposure to rifampicin
When we compared the proteomes of both M. tuberculosis genotypes after exposure to 
rifampicin, we observed a shared response to the antibiotic; Table S1. Rv1942c/mazF5 was the 
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strongest induced protein in both lineages. The DosR regulon associated proteins Rv2031c/
hspX and, to a lesser extent, RV2032/acg, were more abundant in both lineages after exposure; 
Figure S2. Thereby, we show that the induction of DosR proteins upon rifampicin exposure 
is shared by multiple M. tuberculosis lineages. However, the observed absolute increase of 
Rv2031c/hspX induced by rifampicin was more than three-fold higher in the M. tuberculosis 
typical Beijing strain than in H37Rv; Figure S3.
The increased abundance and stronger induction of DosR regulon proteins in M. tuberculosis 
typical Beijing, compared to H37Rv, possibly reflects an increased ability of Beijing strains to 
swiftly develop a dormant phenotype when stressed. This potentially more rapid transition to 
dormancy will make the pathogen less susceptible to rifampicin, thus providing a prolonged 
period for the selection of mutants, which will reduce the efficacy of this drug to sterilize tissues 
containing bacteria. It is thereby conceivable this will lead to more relapses after curative 
treatment.
Furthermore, the observation that environmental factors and rifampicin can induce dormancy 
proteins, suggests that the DosR-regulon is induced as part of a general stress response.(31) The 
increased abundance and stronger induction of DosR regulon proteins might therefore provide 
a selective advantage to multiple (first-line) antibiotics.
Taken together, the outcomes of our proteomic study demonstrate that both M. tuberculosis 
typical Beijing and H37Rv induce DosR proteins as a response to rifampicin-induced stress, 
however, the base-line level of these proteins is higher in Beijing genotype strains. This 
observation suggests that the a priori high abundance of DosR proteins contributes to the 
“success” of M. tuberculosis typical Beijing. However, strain H37Rv is, although considered 
virulent, a laboratory strain. Therefore, we cannot state whether the differences in proteomic 
composition reflect differences between M. tuberculosis typical Beijing and all other clinical 
strains. 
M. tuberculosis typical Beijing proteome signature
To extend our DDA derived findings to a larger cohort of M. tuberculosis isolates of different 
genotypes, we designed a large-scale PRM assay with spiked-in SIL peptides. Based on our DDA 
proteomic dataset and the available literature, we made a selection of 33 proteins, including 
PhoPR proteins, DosR proteins, the antigens esxA/B/W and efflux pumps, that potentially 
contribute to the success of M. tuberculosis Beijing lineage. For a list of the proteins and 
peptides selected and the corresponding rationale for selection, see Table S4. The selection 
of appropriate proteotypic peptides for PRM was performed either manually, based on the 
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DDA data obtained intensity and fragmentation pattern, or from an online repository of M. 
tuberculosis targeted proteomic assays.(55) SIL peptides were labelled with a ‘heavy’ dimethyl 
label (+36Da), whereas the tryptic digest was ‘light’ labelled (+28Da). The selected 33 proteins 
were monitored by 83 peptides and a total of 348 transitions per isotopic mass label.
The abundance of these 33 proteins was determined in the proteomes of 27 clinical isolates 
derived from four of the most prevalent M. tuberculosis lineages; Figure S4 and Table S5. In 
addition, we selected members of the atypical Beijing lineage; a sub-lineage genetically closely 
related to typical Beijing strains, but less conserved.(24) The M. africanum lineage was excluded 
as cases are restricted to West-Africa(56) and M. bovis was excluded as it causes <3% of all 
pulmonary TB cases worldwide.(57)
Protein ratios obtained by PRM showed to be highly reproducible; Figure S5 and Table S6. Two 
proteins, Rv0450c/mmpL4 and Rv3283/sseA were only identified to be differentially abundant in 
the M. tuberculosis typical Beijing strains; Figure 4 and Figure S6. We have previously described 
that the abundance of these two proteins differ between typical and atypical Beijing lineages.
(28) However, in this study we demonstrate that this observation extends to all the other M. 
tuberculosis genotypes examined.
FIGURE 4: Proteins identified to be differentially abundant in the typical Beijing sub-lineage. Rv0450c/
mmpL4 is more abundant in M. tuberculosis typical Beijing (A), whereas Rv3283/sseA is less abundant in 
the typical Beijing sub-lineage (B). All protein ratios are relative to the protein abundance determined in 
M. tuberculosis H37Rv. The box-plot representation shows the median value of protein abundance (middle 
bold line), the lower and upper limits of each box representing the first and third quartiles, respectively. 
Whiskers represent the min/max protein abundance determined (*P=<0.05, **P=<0.01).
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Rv0450c/mmpL4 is generally an essential virulence factor for M. tuberculosis, as demonstrated 
by knock-out experiments.(58, 59) Within M. tuberculosis, the function of RV0450c/mmpL4 
appears to be complementary to Rv0676c/mmpL5, both secreting iron-scavenging siderophores.
(60) However, Rv0676c/mmpL5 contains a nsSNP specific to typical Beijing, whereas we here 
describe that Rv0450c/mmpL4, and not Rv0676c/mmpL5, is more abundant in typical Beijing 
strains than in any of the other M. tuberculosis genotypes examined; Figure 4A and Figure S6A.
Both the specific presence of a nsSNP in Rv0676c/mmpL5 of typical Beijing strains and the 
increased abundance of Rv0450c/mmpL4 indicate a unique role for iron metabolism in typical 
Beijing strains. In relation to dormancy, M. tuberculosis has been suggested to increase iron 
storages prior to this phase of non-replicating persistence.(61) The high abundance of Rv0450c/
mmpL4 in M. tuberculosis typical Beijing is most likely a pre-existent dormancy related factor 
within this specific sub-lineage.
Both Rv0450c/mmpL4 and Rv3283/sseA contain a nsSNP specific to M. tuberculosis typical 
Beijing.(24, 28) For Rv3283/sseA, a thiosulfate sulfurtransferase, we have previously demonstrated 
that the typical Beijing specific nsSNP yields the protein unstable.(28) As a consequence, we 
have observed that RV3283/sseA is less abundant in members of the typical Beijing genotype; 
Figure 4B and Figure S6B. Generally, the loss of functional proteins in M. tuberculosis promotes 
an attenuated phenotype. However, mycobacteria deficient of a functional Rv3283/sseA show 
improved growth in an in vitro macrophage model.(62) Thereby, it is conceivable that the average 
±50-fold lower abundance of Rv3283/sseA in typical Beijing strains contributes to the increased 
virulence of this sub-lineage.
Regulators of dormancy are more abundant in Beijing strains
One of the regulatory networks of which the protein abundance differed between the typical 
Beijing and the H37Rv strain was PhoPR, a major virulence regulon within M. tuberculosis; 
Figure 3(52, 53) Our PRM data show that the abundance of PhoPR regulated proteins is conserved 
throughout the various M. tuberculosis isolates examined; Figure S7. Thereby, we demonstrate 
that the abundance of PhoPR differs between clinical isolates and the laboratory reference 
strain H37Rv. This difference in PhoPR regulon protein abundance between the H37Rv reference 
and M. tuberculosis clinical isolates could be responsible for the described deviant virulence 
associated characteristics in the H37Rv strain, including the uptake by monocyte-derived-
macrophages and early pro-inflammatory cytokine induction.(63)
A second regulatory network, of which we identified the proteins to be more abundant in the 
typical Beijing isolate compared to H37Rv, is the DosR dormancy regulon; Table S3. Of the 
eight DosR regulon proteins that we quantified in the clinical isolates examined, we identified 
Rv3132c/devS and Rv3133c/devR, the proteins that compromise the DosR two-component 
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regulatory system, to be more abundant in both M. tuberculosis Beijing sub-lineages; Figure 5 
and Figure S8 & S9. Furthermore, the DosR controlled proteins Rv0079, Rv2031c/hspX, Rv2032/
acg, Rv2627c, Rv3130c/tgs1 and Rv3131 showed to be less abundant in M. tuberculosis CAS 
than in M. tuberculosis typical Beijing; Figure 5 & Figure S8.
FIGURE 5: Heat map of selected differentially regulated DosR proteins quantified by PRM in various M. 
tuberculosis genotypes. The selected proteins were coloured by the average fold change of the genotype, 
relative to M. tuberculosis H37Rv.
Our DDA data demonstrate that dormancy proteins are induced in both the typical Beijing- 
and the M. tuberculosis reference strain H37Rv, showing that this response is shared by 
multiple members of the M. tuberculosis grouping. Based on this observation, combined with 
our PRM data that demonstrates that M. tuberculosis Beijing strains maintain higher levels of 
the dormancy regulator, we can conclude that early markers of the response to rifampicin are 
constitutively more abundant in Beijing strains compared to other clinically relevant strains.
M. tuberculosis typical Beijing strains contain a specific mutation in Rv2027c/dosT, the sensor 
part of the two-component dormancy regulatory system.(64) The presence of this mutation 
correlated with the expression of Rv3133c/devR transcripts in the same study. As a consequence, 
it has been suggested that typical Beijing strains express on average a 12-fold more Rv3133c/
devR-mRNA than atypical Beijing strains.(64) Our PRM based quantification of Rv3133c/devR 
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shows that this protein is equally abundant in both typical and atypical Beijing sub-lineages 
and four-fold more abundant in the Beijing strains examined compared to the other genotypes 
analysed; Figure 5 and Figure S8. Thereby, we reject the hypothesis that this mutation correlates 
with differential abundance of Rv3133c/devR on the protein level. However, this finding does 
not preclude the possibility that the mutation in Rv2027c/dosT plays a (in)direct role in the 
biology of more modern lineages of M. tuberculosis Beijing. In fact, the presence of a typical 
Beijing specific mutation in the DosR regulon strengthens our hypothesis that there is a unique 
role in the dormancy pathway in this specific pathogenic sub-lineage. 
Bacteria that are capable to establish dormancy during antibiotic treatment, extent their window 
of opportunity to acquire drug resistance conferring mutations. Moreover, M. tuberculosis cells 
that enter a fully dormant state of non-replicating persistence, maintain the same mutation 
rate as actively growing cells.(65) Therefore, we argue that the constitutive high abundance of 
DosR, as described specifically for M. tuberculosis Beijing strains in this study, contributes to an 
accelerated development of antibiotic resistance for compounds targeting metabolically active 
cells. 
Conclusion
In this study, we searched for specific bacterial factors that may account for the epidemiological 
and in vitro phenomena that have been described for the Beijing genotype of M. tuberculosis. 
Our DDA study shows that the typical Beijing- and H37Rv strain both induce DosR dormancy 
proteins as a shared response to rifampicin exposure. However, we observed that these proteins 
are more abundant in typical Beijing strains than in the reference strain H37Rv already prior to 
drug exposure. Subsequent PRM based quantification of these dormancy proteins in multiple, 
clinically relevant M. tuberculosis lineages demonstrated that the regulators of dormancy 
are more abundant in members of M. tuberculosis Beijing genotype than in any of the other 
lineages examined. The here described pre-existing high abundance of dormancy regulators 
in Beijing strains can provide these strains an edge over other strains to persist for prolonged 
periods of time during rifampicin treatment. The identification of this M. tuberculosis Beijing 
specific trait will eventually contribute to improved diagnostics and treatment for the millions 
of individuals that receive anti-TB therapy annually. Consequently, this finding may contribute 
to the global management of MDR-TB.
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Supporting information
SUPPORTING INFORMATION TABLE S1: Overview of the protein identified and quantified in both 
biological replicates. This table can be downloaded on the website of the journal:
https://www.sciencedirect.com/science/article/pii/S1874391916303992?via%3Dihub
SUPPORTING INFORMATION TABLE S2: Overview of the peptides identified and quantified in both 
biological replicates. This table can be downloaded on the website of the journal:
https://www.sciencedirect.com/science/article/pii/S1874391916303992?via%3Dihub
SUPPORTING INFORMATION TABLE S3: Overview of the dosR regulon proteins identified with their 
corresponding ratio and significance B score.






B e i j i n g / H 3 7 R v 
DMSO#1 Sig. B
Rv0079 Rv0079 4,906 0,000 5,150 0,000
Rv0081 Rv0081 2,169 0,010 1,391 0,368
Rv0569 Rv0569 1,517 0,195 1,380 0,382
Rv0570 nrdZ 1,505 0,202 1,381 0,381
Rv0571c Rv0571c 1,161 0,545 1,415 0,300
Rv1812c Rv1812c 1,717 0,003 1,920 0,003
Rv1996 Rv1996 1,727 0,014 1,695 0,047
Rv1998c Rv1998c 0,915 0,956 1,209 0,638
Rv2004c Rv2004c 1,248 0,404 1,266 0,542
Rv2006 otsB1 1,068 0,734 1,136 0,795
Rv2028c Rv2028c 1,323 0,352 1,281 0,518
Rv2031c hspX 9,206 0,000 5,090 0,000
Rv2032 acg 4,798 0,000 8,121 0,000
Rv2623 TB31.7 1,484 0,031 1,690 0,019
Rv2624c Rv2624c 1,085 0,696 1,341 0,432
Rv2627c Rv2627c 2,559 0,007 2,759 0,003
Rv2629 Rv2629 1,553 0,126 1,570 0,161
Rv3130c tgs1 4,919 0,000 2,608 0,005
Rv3131 Rv3131 2,300 0,016 2,047 0,037
Rv3132c devS 3,294 0,000 3,612 0,000
Rv3133c devR 3,994 0,000 4,587 0,000
Rv3134c Rv3134c 1,509 0,200 1,597 0,187
Rv3137 Rv3137 0,998 0,971 0,952 0,677
SUPPORTING INFORMATION TABLE S4: Overview of the proteins and their corresponding peptides 
selected for parallel reaction monitoring. This table can be downloaded on the website of the journal:
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https://www.sciencedirect.com/science/article/pii/S1874391916303992?via%3Dihub
SUPPORTING INFORMATION TABLE S5: Overview of the clinical isolates of Mycobacterium tuberculosis 
analysed by parallel reaction monitoring. This table can be downloaded on the website of the journal:
https://www.sciencedirect.com/science/article/pii/S1874391916303992?via%3Dihub
SUPPORTING INFORMATION TABLE S6: Overview of the protein ratios, relative to M. tuberculosis H37Rv, 
determined by parallel reaction monitoring. This table can be downloaded on the website of the journal:
https://www.sciencedirect.com/science/article/pii/S1874391916303992?via%3Dihub
FIGURES
FIGURE S1: Density plot of the reproducibility between biological replicates. Biological variability was 
analysed by quantitative comparison of the protein abundances between both biological replicates after 
24hrs treatment with DMSO (A) or rifampicin (B).
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FIGURE S2: Scatterplot of protein ratios compared to the internal control for M. tuberculosis H37Rv with 
DMSO (A&B) or rifampicin (C&D) treatment and for M. tuberculosis typical Beijing with DMSO (E&F) or 
rifampicin (G&H) treatment. The protein intensity is plotted on the y-axis and the ratio relative to the internal 
control is plotted on the x-axis. The dormancy proteins Rv2031c/hspX and Rv2032/acg are highlighted in 
red.
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FIGURE S3: Delta fold-change induction of Rv2031c/hspX and Rv2032/acg relative to the internal control. 
The delta fold change was calculated using the following formula: 
P-values were determined between the fold change induced by rifampicin treatment using an unpaired 
t-test.
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FIGURE S4: Phylogenetic relations between the clinical isolates analysed by PRM. A radial UPGMA tree 
based was constructed based on the copy numbers of 24 MIRU-VNTR loci in our selection of M. tuberculosis 
clinical isolates; typical Beijing (n=5), atypical Beijing (n=6), EAI (n=5), Haarlem (n=6) and CAS (n=5). The tree 
was calculated using the MIRU-VNTRplus server.
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Figure S5: Scatter plot of the reproducibility between technical replicates. Biological variability 
was analysed by quantitative comparison of the protein ratios between both technical replicates.
FIGURE S6: Calibration curve of protein ratios derived after injection of a five-fold dilution series of SIL 
peptides (+36Da) in a complete proteome matrix derived from M. tuberculosis Beijing B0/W148 (500ng). 
The derived protein ratios for Rv0450c/mmpL4(A) and Rv3283/sseA(B) in the clinical isolates examined are 
within the linear range of the calibration curve.
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FIGURE S7: Quantification of selected PhoPR regulon interaction network proteins in five M. tuberculosis 
genotypes. The significance of the protein fold-change compared to M. tuberculosis Typical Beijing, but 
none of the proteins ratios deviated significantly. 
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FIGURE S8: Quantification of selected dosR dormancy regulon proteins in five M. tuberculosis genotypes. 
The significance of the protein fold-change compared to M. tuberculosis typical Beijing is presented as 
follows: * <0.05, ** <0.01.
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FIGURE S9: calibration curve of protein ratios derived after injection of a five-fold dilution series of heavy 
labelled peptides (+36Da) in a complete proteome matrix derived from M. tuberculosis Beijing B0/W148 
(500ng). The derived protein ratios for Rv3132c/devS(A) and Rv3133c/devR(B) in the clinical isolates 
examined are within the linear range of the calibration curve.
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The increasing occurrence of multidrug resistant tuberculosis exerts a major burden on 
treatment of this infectious disease. Thioridazine, previously used as a neuroleptic, is active 
against extensively drug resistant tuberculosis when added to other second and third line 
antibiotics. By quantitatively studying the proteome of thioridazine treated Mycobacterium 
tuberculosis, we discovered the differential abundance of several proteins that are involved in 
the maintenance of the cell envelope permeability barrier. By assessing the accumulation of 
fluorescent dyes in mycobacterial cells over time, we demonstrate that long term drug exposure 
of M. tuberculosis indeed increased the cell envelope permeability. The results of the current 
study demonstrate that thioridazine induced an increase in cell envelope permeability, and 
thereby the enhanced uptake of compounds. These results serve as a novel explanation to the 
previously reported synergistic effects between thioridazine and other anti-tuberculosis drugs. 
This new insight in the working mechanism of this anti-tuberculosis compound could open 
novel perspectives of future drug administration regimens in combinational therapy.
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Introduction
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is one of the most 
successful pathogens worldwide. Currently, 8-9 million TB cases and close to 1.5 million deaths 
due to M. tuberculosis are recorded annually.(1) 
 
A major obstacle in the control of TB is the emergence of multidrug resistant TB (MDR-TB), i.e. 
M. tuberculosis strains that are resistant to at least rifampicin and isoniazid, two of the most 
potent drugs used in anti-TB regimens. In 2013, 3.7% of all new TB cases were reported as 
MDR-TB, but this is most likely an under estimation.(2) Alarmingly, the reported levels of MDR-
TB are around 20% for patients previously treated for TB.(2) Moreover, there is a progression 
of MDR-TB towards extensively drug resistant TB (XDR-TB), which, in addition to resistance for 
isoniazid and rifampicin, also involves resistance to any of the fluoroquinolones and at least one 
aminoglycoside.(3) Finally, the term totally drug resistant TB (TDR-TB) has been introduced to 
describe resistance against all known TB drugs available at a particular setting. The existence of 
MDR-TB, XDR-TB and TDR-TB underlines that there is an urgent need for new effective anti-TB 
compounds.
Thioridazine (THZ), a compound belonging to the class of phenothiazines, is a drug that has 
previously been used to treat psychotic disorders such as schizophrenia.(4) Over fifteen years ago 
the in vitro effect of THZ on the respiration of M. tuberculosis has been reported.(5) The current 
increase in the frequency of MDR-TB infections and increased level of resistance against anti-
TB drugs has renewed the interest in phenothiazines and their anti-mycobacterial properties.
(6) In mouse models, a clear positive effect on the killing of M. tuberculosis was noticed when 
THZ was used alone(7) or added to other drugs in treatment regimen.(8) Despite the promising 
reports of anti-TB treatment with THZ, it should be noted that the anti-mycobacterial effects of 
THZ, also in combination with other antibiotics, vary between published animal model based 
studies.(9),(10),(11),(12) Nevertheless, in a clinical setting, THZ has been used for therapy of 17 XDR-TB 
patients in Buenos Aires, Argentina with remarkable success.(13) As shown by this latter study 
and others, THZ does not produce significant negative side effects when patients are monitored 
for possible cardiac effects during treatment.(14) 
Three mechanisms have been proposed to explain the mode of action of phenothiazines: 1) 
accumulation of phenothiazines in macrophages and lung homogenate to concentrations that 
are equal to those which are bactericidal in vitro together with the promotion of intracellular 
killing by macrophages,(15),(16),(17),(10) 2) potential inhibition of antibiotic extruding efflux pumps 
that might be over-expressed in MDR-TB infections(18),(19),(20),(21) and which can be experimentally 
upregulated by exposure to increasing concentrations of anti-TB drugs such as isoniazid(20, 22) 
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and 3) direct in vitro killing of M. tuberculosis.(23),(24) 
Efflux pumps that possess the ability to transport antibiotics across the cell envelope are 
thought to play a major role in the development of drug tolerance next to genomic mutations.
(25) Moreover, an increased abundance of efflux pumps can stimulate the accumulation of 
resistance mutations, by enhancing drug tolerance for prolonged time periods.(26) The genome 
of M. tuberculosis encodes for several efflux pumps that may contribute to the development 
of drug resistance(27) and these have been suggested to be inhibited by phenothiazines.(20) 
Thus, the use of an efflux pump inhibitor in combination with other antibiotics can prevent 
the development of efflux pump induced antibiotic resistance and even result in an enhanced 
activity of other antibiotics. Indeed, synergistic effects between THZ and the first-line antibiotics 
rifampicin and isoniazid have been reported, as well as synergism between THZ and the anti-
mycobacterial drug streptomycin.(10),(20),(28) 
Notably, rifampicin and isoniazid best target replicating, metabolically active cells.
(29),(30),(31),(32),(33),(34) To the contrary, THZ also displays bactericidal activity against starved cells.
(29) Furthermore, THZ monotherapy could cure both drug susceptible and MDR-TB in a mouse 
model and in vitro.(8, 24)  Both observations demonstrate that THZ is not only able to inhibit efflux 
pumps, but also show that THZ can be bactericidal.
To get an understanding of the molecular mechanisms used by M. tuberculosis to manage THZ 
induced cell stress, we quantitatively studied the proteome of M. tuberculosis in vitro with 
and without the continuous presence of THZ. We report the differential abundance of several 
proteins and protein clusters upon THZ treatment, which are involved in the maintenance of 
the cells permeability barrier. In addition, we demonstrate that long-term treatment of M. 
tuberculosis with THZ alters the mycobacterial plasma membrane composition and increases 
the cell envelope permeability, which influences the uptake of anti-mycobacterial compounds. 
In addition to the suggested function of THZ as efflux pump inhibitor, we herewith present data 
that offers a novel explanation to the previously reported synergistic effects between THZ and 
other anti-tuberculosis drugs.
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Material and Methods
Mycobacterial culture conditions
M. tuberculosis H37Rv was re-cultured from frozen stocks in 5 ml Tween-Albumin liquid culture 
broth (Tritium Microbiologie, the Netherlands) at 36°C without shaking until an O.D. at 600 
nm of 0.4 AU was reached. Of the mycobacterial pre-culture, 1 ml was transferred to a 250 
ml Erlenmeyer flask containing 100 ml Tween-Albumin broth, with 0, 4, 6 and 8 mg/l THZ, and 
incubated under shaking conditions at 36°C with constant aeration; see Figure S1a. A >100-fold 
dilution of the pre-culture to prevent the inclusion of death cells for proteomic analysis. The 
mycobacteria used for proteome analyses were continuously treated with 6 mg/l THZ. Once 
these cultures reached an O.D. at 600 nm of 0.6 AU, representing the mid-log phase, the cells 
were washed three times with ice cold PBS, dissolved in 5 ml Lysis-buffer (4% SDS, 100 mM Tris-
HCl, pH 7.6) and heat-killed at 95°C for 10 min. Lysates were stored at -20°C until further usage. 
Thermostability of thioridazine
The thermostability of THZ, over the culture period of approximately two weeks, was assessed 
by pre-incubating culture flasks containing 6 mg/l THZ for 21 days at 37˚C prior to inoculation 
with M. tuberculosis. We compared the growth curves of this pre-incubated culture broth with 
that of freshly prepared culture broth containing 6 mg/l THZ; see Figure S1b. The resemblance 
between the obtained growth curves indicates that the growth rate of M. tuberculosis is 
similar in media containing THZ that is freshly prepared to media containing THZ that was pre-
incubated at 37˚C for 21 days. This demonstrates that THZ is thermostable on the time-scale of 
our experiments, and maintained the majority of its activity over the examined culture period. 
Proteome analysis
Cells were processed as described previously.(35) In brief, heat inactivated cells for proteomic 
experiments were mechanically lysed by bead-beating in a mini bead-beater 16 (BioSpec, 
USA) for 5 min using glass beads. Thereafter, the cells were cooled down on ice for 5 min 
after which the procedure was repeated twice. The cell lysates were cleared from cell debris 
by centrifugation for 1 min at 14,000 g and the supernatant was transferred to a fresh tube. 
Proteins were digested using the filter aided sample preparation (FASP) method. In brief, 100 μg 
of DTT reduced proteins was loaded on a 30 kDa filter. SDS was removed in three washes with 8 
M urea. The proteins were carbamidomethylated, and the excess reagent was removed by three 
additional washes with 8 M urea. Proteins were then digested overnight using endoproteinase 
Lys-C (endoLysC), followed by a four hr digestion using trypsin at RT. The tryptic protein digest 
was desalted on C18 SepPak columns and labelled by reductive amination. A label swap was 
performed between biological replicates to prevent any experimental bias. A total 100 μg of 
labeled peptides were fractionated by strong cation exchange (SCX) on an Agilent 1100 system 
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equipped with an in-house packed SCX-column (320 μm ID, 15 cm, polysulfoethyl A 3 μm, Poly 
LC), run at 4 μl/min. The gradient started with a 10 min run at 100% solvent A 70/30/0.1 (water/
acetonitrile/formic acid), after which a linear gradient reached 100% solvent B (250 mM KCl, 
30% acetonitrile. 0.1% formic acid) in 15 min, followed by 100 % solvent C (500 mM KCl, 30% 
acetonitrile 0.1% formic acid) in the following 15 min. The gradient was held at 100 % solvent 
C for 5 min, then switched back to 100 % solvent A. Fifteen fractions were collected in 1 min 
intervals, lyophilized and reconstituted in 30 μl 95/3/0.1 (water/acetonitrile/formic acid). 
Dissolved fractions were analyzed by on-line nano-HPLC MS with a system consisting of a Agilent 
1100 gradient HPLC system (Agilent, Waldbronn, Germany) as described previously,(35) coupled 
to a LTQ-FT Ultra mass spectrometer (Thermo, Bremen, Germany). Five μl of each fraction was 
injected onto a home-made pre-column (100 μm×15 mm; Reprosil-Pur C18-AQ 3 μm, Dr Maisch, 
Ammerbuch, Germany) and eluted via a home-made analytical nano-HPLC column (50 μmx15 
cm; Reprosil-Pur C18-AQ 3 μm). The gradient was run from 0 to 30% solvent B (10/90/0.1 water/
acetonitrile/formic acid) in 10-155 min. A tip of approximately 5 μm was drawn at the tip of 
the nano-HPLC column to act as electrospray needle. Full scan mass spectra were acquired in 
the FT-ICR with a resolution of 25,000 at a target value of 5*106. The five most intense ions 
were selected and fragmented in the linear ion trap using collision-induced dissociation at a 
target value of 10,000. Peptide and protein identification and quantitation was accomplished 
using MaxQuant 1.4.0.3, as described previously.(35) In brief, the false discovery rate (FDR) was 
set to 0.01. Minimal peptide length was set to 6 amino acids. The first search was performed 
using 20 ppm, while the main search was conducted with 10 ppm. Search of MS/MS spectra 
was performed with 0.6 Da using the Andromeda search engine. Both the first search and the 
main search were carried out against a database of M. tuberculosis H37Rv (3,996 entries). 
In total, 262 common contaminants were included in the searches by Andromeda. Enzyme 
specificity was set as C-terminal to arginine and lysine without proline restriction. A maximum 
of two missed cleavages was allowed. Variable modifications included N-terminal protein 
acetylation, methionine oxidation and corresponding dimethyl labels. Carbamidomethylation of 
cysteine was selected as a fixed modification. Proteins considered for quantification required a 
cumulative peptide count of two, including both unique and razor peptides. A maximum heavy/
light variability of 150% was allowed. Proteins identified by site, which matched against the 
reverse database or were identified as a contamination, were excluded for further analysis. 
Statistical analysis of the outcomes was performed by Perseus using the significance B test 
with a Benjamini-Hochberg FDR 5%. The raw data files and the MaxQuant output files have 
deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the 
dataset identifier PXD001208.
Cell envelope permeability assay
The accumulation of Sytox Orange (Life Technologies, USA), Nile Red (Sigma-Aldrich, the 
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Netherlands) and ethidium bromide (Sigma-Aldrich, the Netherlands) was determined 
essentially as described previously.(36) In brief, M. tuberculosis H37Rv was grown to an O.D. 600 
nm of 0.6 AU, washed three times with PBS, and resuspended in Tween-Albumine culture broth 
(Tritium Microbiologie, the Netherlands) to an O.D. 600 nm of 0.3 AU. Of this cell suspension 
500 μl was inserted into a sealed cuvette. Sytox Orange and ethidium bromide were added to 
final concentration of 100 nM and 6 μM respectively. In addition, the efflux pump inhibitor 
reserpine(37) (Sigma-Aldrich, the Netherlands) was added to a final concentration of 100 µg/ml 
in selected samples. The cell suspensions were incubated at 36°C with occasional mixing for 60 
min. The accumulation of dyes was determined by fluorescence using a Glomax-Multi Jr Single 
tube MultiMode Reader (Promega, USA) with an excitation of 525 nm and emission of 580-640 
nm. The outcomes of the assay were evaluated using a paired t-test.
Analysis of phospholipid derived fatty acids
M. tuberculosis H37Rv was cultured as described above, while constantly being exposed to 
6 mg/l THZ. Preparation and analysis of fatty acid derived methyl ester (FAME) according to 
the manufacturers instruction (Sherlock 6.1 Microbial Identification System,MIDI, USA). In brief, 
cells were washed with ice-cold PBS and resuspended in 1 ml of 15% (w/v) NaOH in 50% (v/v) 
aqueous methanol. This suspension was then incubated for 30 min in a water bath set at 100˚C. 
The saponified samples were allowed to cool to RT in cold water, acidified and methylated by the 
addition of 2 ml reagents consisting out of 54% 6 M HCl and 46% aqueous methanol, followed 
by a 10 min incubation in a water bath set at 80 ˚C. The samples were cooled by handshaking 
the sample tubes in ice-cold water. The methylated fatty acids were extracted with 1.25 ml of 
50% methyl-tert butyl ether in hexane. The suspensions were allowed to mix for 10 min using 
end-over-end rotation. The upper phase was washed with 3 ml of 0.3 M NaOH plus 2.2 M NaCl 
after which the FAMEs were transferred into a gas chromatography sample vial for analysis. 
Separation of FAMEs was performed using a HP6890 gas chromatograph (Hewlett Packard, USA) 
with a fused-silica capillary column (25 m × 0.2 mm) cross-linked with 5% phenylmethyl silicone. 
The operating parameters were set and controlled automatically by the Sherlock 6.1 computer 
program (MIDI Inc., USA). Identification of peaks and assessment of column performance was 
achieved using a calibration standard mix (Microbial ID1200-A) containing nC9 – nC20 saturated 
and 2- and 3-hydroxy fatty acids. Peak areas were determined after careful excision of the 
selected peaks and weighing it on an analytical balance. The outcomes were evaluated using a 
paired t-test.
Lipid analysis
50 ml of mycobacteria were grown in the presence or absence of 6 mg/l of THZ until the 
cultures reached mid-logarithmic phase. Cells were washed three times with ice-cold PBS and 
resuspended in methanol–0.3% NaCl (aqueous) (10:1). Apolar lipids were extracted twice with 
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petroleum ether (bp. 60-80˚C) as described previously.(38) Lipid extracts were dried under a 
stream of nitrogen and weighted. 60 µg of apolar lipid extract, and a PDIM standard (obtained 
through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain H37Rv, Purified 
Phthiocerol Dimycocerosate (PDIM), NR-20328 were spotted onto silica gel 60 thin-layer 
chromatography (TLC) plates (Merck Millipore, Germany), which was then developed three 
times in petroleum ether-ethyl acetate (98:2). PDIM was visualized using 5% phosphomolybdic 
acid in ethanol and gentle heating using a heat gun. 
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Results
Culture considerations and proteome analysis
To obtain a reliable model of protein abundance within THZ exposed M. tuberculosis cells, a 
strongly diluted pre-culture was started, which was treated continuously with THZ until the 
growth reached mid-logarithmic phase. To determine the maximum dosage of THZ that allows the 
growth of M. tuberculosis under the described culture conditions, we inoculated M. tuberculosis 
in the presence of 0, 4, 6 and 8 mg/l THZ; see Figure S1a. THZ partially inhibited the growth of M. 
tuberculosis up to a concentration of 6 mg/l THZ. Exposure of M. tuberculosis to 8 mg/l of THZ 
did not allow for any growth of M. tuberculosis within the examined culture period of 24 days. 
It should be noted that concentrations of 6 mg/l THZ are not clinically achievable within serum. 
However, compared to the serum concentration THZ is >30-fold concentrated within lungs and 
alveolar macrophages.(10) As a consequence, it had been demonstrated that clinically achievable 
serum concentrations of 0.5-1 mg/l and even 0.1 mg/l of THZ can kill intracellular M. tuberculosis.
(16) A concentration of 6 mg/l THZ, as used in our model, fits well within this clinically relevant 
range. All cells were cultured, with or without 6 mg/l THZ, to mid-logarithmic phase, harvested 
and processed according to the protocol outlined in Figure 1a. Proteins were isolated, digested, 
and the obtained peptides were dimethylated, fractionated using SCX chromatography and 
analyzed by nanoLC-MS/MS. A total of 15 SCX fractions were analyzed twice. Two biological 
replicates were analyzed using this approach.
We recently reported how this method yields an unbiased view of the M. tuberculosis proteome.
(35) The cumulative number of unique proteins that was identified and quantified, based on 
at least two peptides was 2,479; see Figure 1b. A total of 2,241 proteins were identified in 
both experiments, corresponding to an overlap of approximately 95% between the biological 
replicates, which is typically achieved in shotgun proteomics when nearly full proteome 
coverage is reached. The obtained quantification values of the 2,241 proteins that have been 
identified in both biological replicates showed a high correlation; see Figure 1c.
Overview of M. tuberculosis protein abundance after long-term in vitro thioridazine exposure
To get an overview of proteins that are differentially abundant due to the influence of THZ, we 
applied strict quantification criteria to our dataset of 2,241 proteins that were identified in both 
biological replicates, as described in the method section. A total of 59 proteins was identified 
to be at least two-fold more abundant and 30 proteins to be at least two-fold less abundant 
upon continuous THZ exposure both with a significance B value ≤0.05; see Table S1 and Figure 
S2. We classified the differentially abundant proteins according to functional categories as 
given by Tuberculist; see Figure 2. Thirty-seven proteins that were categorized to be involved in 
´intermediary metabolism and respiration´ were shown to be differentially abundant. Previous 
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studies already described that phenothiazines inhibit aerobic respiration of M. tuberculosis in 
a NADH-dependent manner.(39) Using InterPro we identified a total of seven proteins with an 
NAD(P)-binding domain to be two-fold more abundant upon treatment with THZ; see Table S1. 
FIGURE 1. Proteomic approach to identify differentially regulated proteins in M. tuberculosis with and 
without continuous thioridazine treatment
A: Schematic design of the experimental approach used in this study. Cells were cultured and processed in 
parallel until dimethylation of the protein digest. In short, M. tuberculosis H37Rv was cultured in the presence 
or absence of THZ until mid-logarithmic phase was reached. Harvesting of the cells was performed by 
centrifugation following three washes with ice-cold PBS. The cells were mechanically lysed using bead-beating 
followed by protein digestion using the FASP procedure. Protein digests were provided with a dimethyl mass 
label, combined and fractionated using SCX. Fifteen fractions were taken, lyophilized and analyzed by LC-MS/MS. 
B: Venn diagram representing the proteins that have been quantified in Biological Replicate 1 and 2. A 
cumulative number of 2,479 proteins were quantified, of which 2,241 were quantified in both analyses. 
C: Comparison of 2,241 normalized protein ratios that were determined in both biological replicates. 
Proteins were colored using a density gradient. The correlation between biological replicates is presented 
by the Pearson r (-0.835). Note: A label swap was performed between both biological replicates.
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FIGURE 2. Functional categorization of proteins that are differentially regulated upon thioridazine 
exposure in vitro
Proteins that were either less (Black filled bars) or more (grey bars) abundant in THZ treated cells compared 
to the control cells were categorized based on their function as given by Tuberculist. None of the functional 
categories showed to be significantly enriched after Chi-square analyses.
The potential inhibition of antibiotic extruding efflux pumps by THZ has been studied repeatedly.
(18-21) In this study we have identified and quantified 15 of the 31 previously listed antibiotic 
efflux pumps,(40) but none of these efflux pumps was observed to be more abundant due to 
long-term THZ exposure; see Table S2. 
Here we examined the proteome of M. tuberculosis after continuous exposure to THZ, whereas 
as a previous transcriptomic study focused on the short, initial response after one, two, four 
and six hours of exposure THZ.(23) A direct comparison of our proteomic dataset with the 
previously reported transcriptomic dataset is difficult due the fact that there is not necessarily a 
correlation between the expression of mRNA and the abundance of a protein in M. tuberculosis.
(41) Nevertheless, we were able to confirm the differential expression of seven out of ten gene 
transcripts that were previously reported to be induced at one, two, four and six hrs after 
THZ treatment, including Rv2710/sigB and the mce4/ Rv3492c-Rv3501c locus; see Table S3. 
Moreover, 21 out of 59 proteins that we have observed to be two-fold more abundant were 
5
THIORIDAZINE ALTERS THE CELL ENVELOPE PERMEABILITY OF MYCOBACTERIUM TUBERCULOSIS | 149
also identified by transcriptomics to be upregulated on at least a single time point. Similarly, 
12 out of 30 proteins that we have observed to be two-fold less abundant were also identified 
by transcriptomics to be downregulated on at least a single time point. Taken together, more 
than 35% of the proteins that we have identified to be differentially abundant using proteomics 
were previously also identified by transcriptomics, despite the variability’s between both study 
designs.
Differential abundance of proteins involved in maintaining the cell envelope permeability barrier
Mycobacteria are known for their unique cell wall, typified by mycolic acids which are unusually 
long-chain fatty acids.(42) This unique mycolic acid bilayer forms an efficient impermeable barrier 
that protects the bacteria from hostile environments, see Abdallah et al. for a comprehensive 
overview of the mycobacterial cell envelope.(43) Using our proteomic approach, we witnessed 
the differential abundance of two protein clusters that are involved in the maintenance of the 
cell envelope permeability barrier upon long-term THZ treatment of M. tuberculosis. A lipid 
family that retained special attention over the years is phthiocerol dimycocerosates (PDIM). 
These C83-103 long lipids alter the plasma membrane of host cells,(44) protect the pathogen 
from nitric oxide,(45),(46) modulate the early innate immune response(45),(46),(47) and lower the cell 
envelope permeability.(48),(36) 
Fourteen proteins are located in the biosynthetic locus of PDIM/Rv2928-Rv2942 and Rv2940c; 
see Figure 3a. Seven of these proteins displayed an upward trend in our dataset upon continuous 
THZ exposure of M. tuberculosis. The increased abundance of multiple proteins in the PDIM 
synthesis locus suggests that THZ treated cells need to put in extra effort to maintain normal levels 
of PDIM in the cell envelope, which prevents the cell envelope from becoming too permeable; 
see Figure S3. Another protein, Rv2190c, which is involved in cell envelope maintenance and 
alteration of PDIM levels, was less abundant in THZ treated M. tuberculosis cells.(49) 
A second cluster of proteins that we observed to be differentially abundant under THZ 
pressure was the mce4 operon, as also described on the mRNA level for short-term treated 
M. tuberculosis; see Figure 3b.(23) The mce4 operon is involved in the uptake of cholesterol, an 
essential nutrient for M. tuberculosis during chronic infection, and thereby an essential virulence 
factor for M. tuberculosis.(50) Similar to PDIM, the accumulation of cholesterol is known to play 
a role in the mycobacterial cell envelope permeability as the build-up of cholesterol increases 
the cell envelope permeability for rifampin in M. tuberculosis.(51) The lower abundance of mce4 
will lower the uptake of cholesterol by M. tuberculosis, which could lead to a decrease of the 
cell envelope permeability.
In line with the differential abundance of the PDIM and mce4 locus, which leads to a decrease 
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in cell envelope permeability, Rv0516c was identified to be threefold less abundant upon 
continuous THZ treatment. Genetic disruption of Rv0516c increases the osmotic resistance in 
M. tuberculosis and enhances the bacterial tolerance to vancomycin, which affects cell envelope 
synthesis.(52) 
 
FIGURE 3. Differential regulation of the PDIM biosynthetic/mce4 cholesterol uptake locus in thioridazine 
exposed M. tuberculosis
A: Open reading frame of the genes involved in the synthesis PDIM are represented by the arrows. The 
proteins that we identified to be approximately two-fold more abundant under THZ pressure in the PDIM 
biosynthetic locus are highlighted in green. 
B: Arrows represent the open reading frames of the genes involved in the uptake of cholesterol. The 
proteins that were less abundant under the continuous pressure of THZ are highlighted in red.
Finally, Rv0129c/Antigen 85c was found to be threefold more abundant in M. tuberculosis 
strains that were continuously treated with THZ. Inactivation of Antigen 85c results in a 40% 
decrease of cell wall bound mycolate.(53) As a consequence of the decreased mycolate content 
in the mycobacterial cell envelope, the permeability towards both the hydrophobic molecule 
chenodeoxycholate and the hydrophilic compound glycerol increases.(53) The increased 
abundance of Antigen 85c might therefore lead to a decrease in cell envelope permeability.
Although mycobacteria possess an efficient permeability barrier, when properly maintained, the 
intrusion of hydrophilic antibiotics may take place via porins.(54) Porins are proteins in bacterial 
outer membranes that enable the non-specific influx of hydrophilic solutes.(55) OmpATb/ Rv0899 
is the most well-known pore forming protein of M. tuberculosis. However, THZ treatment did 
not influence the abundance of this protein; see Table S1. In contrast, the outer membrane 
channel protein, Rv1698, was observed to be approximately two-fold more abundant in our THZ 
treated mycobacterial cells. It was reported that a M. tuberculosis strain harboring a mutated 
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Rv1698 gene, accumulated 100-fold more copper than wild-type M. tuberculosis.(56) The 
increased abundance of Rv1698 upon THZ treatment might therefore be a necessity to prevent 
the accumulation of copper when the cell envelope of M. tuberculosis becomes compromised. 
In summary; we have identified a total of 16 proteins to be differentially abundant upon THZ 
treatment that contribute to a decrease in cell envelope permeability. We hypothesize that 
the proteins in the PDIM synthesis locus, mce4 locus, Rv0516c, Rv1698 and Antigen 85c are 
differentially regulated upon long term exposure of M. tuberculosis to THZ to counteract THZ 
induced cell envelope damage. This hypothesis is supported by electron microscopy images 
published earlier, which clearly show that the cell envelope of M. tuberculosis becomes 
damaged after four hours of THZ treatment.(23)
The effect of thioridazine treatment on the plasma membrane of M. tuberculosis
A recently proposed mechanism of THZ, that was supported by a computer-simulation study, is 
that THZ interacts with lipid-bilayers in bacteria, which causes significant membrane thinning.
(57) This novel insight is in line with previous studies that also showed how THZ and other 
phenothiazines interact with negatively charged phospholipids in erythrocytes,(58) partitions in 
lipid-bilayers and the outer and inner membranes of mitochondria.(59) The induced damage to the 
mycobacterial cell envelope upon THZ treatment as suggested by the proteomic data in this study, 
in light of the latter cited studies, supports the model in which THZ interacts with the bacterial 
plasma membrane. This interaction of THZ with the plasma membrane of M. tuberculosis could 
lead to a more permeable cell envelope which results in a faster accumulation of antibiotics. 
To determine whether THZ alters the composition of the mycobacterial phospholipid bilayer, 
we examined the phospholipid-derived fatty acids (PLFA) of both continuously THZ treated and 
untreated M. tuberculosis. Although a direct effect of THZ on proteins involved in fatty acid 
metabolism has been suggested, this was not reflected in our proteomic dataset.(60) Examination 
of the PLFA profiles derived from continuously THZ treated M. tuberculosis and untreated M. 
tuberculosis cells, we revealed a significant increase in the proportion of tuberculostearic 
acid (10Me-C18:0) in THZ treated cells; see Figure 4. An increase of tuberculostearic acid has 
previously been observed in an ethambutol tolerant strain, when compared to an ethambutol 
susceptible strain.(61) Ethambutol is known to increase the cell envelope permeability towards 
rifampicin in multiple mycobacterial species(62), it therefore might be that the increased 
proportion of tuberculostearic acid is a response of the mycobacteria towards drug-induced 
cell envelope permeability stress.
Tuberculostearic acid is produced by mycobacteria through the methylation of phospholipid 
esterified oleic acid, with S-adenosyl methionine as methyl donor followed by a reduction with 
NADPH as a cofactor.(63) Interestingly, an increase of NAD(P)H has been described for THZ treated 
M. tuberculosis.(64) Furthermore, as mentioned above, we observed a two-fold increased level 
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for seven proteins with an NAD(P)-binding domain; see Table S1. 
FIGURE 4. A larger proportion of tuberculostearic acid is present in thioridazine exposed M. tuberculosis.
Phospholipid-derived fatty acids of untreated M. tuberculosis cells (black bars) and THZ treated cells (grey 
bars) were analyzed. The composition is given as the average percentage of total integrated chromatographic 
areas. Error bars represent the mean ± SEM of the average peak area for each of the independent biological 
triplicates. * P = ≤0.05
Alteration of the mycobacterial cell envelope permeability upon long-term thioridazine treatment
To determine whether the cell envelope permeability of M. tuberculosis is increased 
upon continuous THZ treatment as hypothesized in our study, we used fluorescence 
spectrophotometry to measure the accumulation of several fluorescent compounds over a one 
hour time period. Similar experimental approaches were previously performed using ethidium 
bromide to determine the efflux pump activity of bacteria.(21),(65),(66),(67),(68) 
However, it is not possible to determine the impact of THZ on the efflux pump inhibition solely 
by measuring the accumulation of ethidium bromide, as the total accumulation of ethidium 
bromide is dependent on both efflux pump activity and cell envelope permeability/influx. 
Therefore, we needed to analyze the accumulation of ethidium bromide alongside another 
membrane permeable fluorescent dye that does not act as a substrate for efflux pumps. Sytox 
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Orange, is known as a membrane permeable fluorophore, that, similarly to ethidium bromide, 
emits fluorescence once it intercalates with mycobacterial DNA. In contrast to ethidium 
bromide, Sytox Orange has, to our knowledge, not been used as an efflux pump substrate in 
M. tuberculosis. To assure that Sytox Orange is not susceptible to efflux we monitored the 
accumulation of Sytox Orange and ethidium bromide in the presence and absence of the efflux 
pump inhibitor reserpine. As presented in Figure 5, ethidium bromide is accumulated to higher 
levels in the presence of the efflux pump inhibitor reserpine(37) and THZ, whereas increased 
accumulation of Sytox Orange was solely observed in the presence of THZ. Thus the data 
indicates that Sytox Orange does not act as an efflux pump substrate.
The combination of ethidium bromide and Sytox Orange provides a better understanding of 
cell envelope permeability than the sole usage of ethidium bromide. Since both fluorescent 
compounds were accumulated to higher levels in continuously THZ treated mycobacterial cells, 
compared to untreated cells, the data supports our hypothesis that THZ is able to increase the 
permeability of the mycobacterial cell envelope. 
FIGURE 5. Ethidium bromide and Sytox Orange accumulate faster in thioridazine treated M. tuberculosis.
Untreated M. tuberculosis cells (white filled bars), THZ treated cells (light grey bars), reserpine treated 
cells (dark grey bars) and THZ+reserpine treated cells (black bars) were assessed for the accumulation of 
ethidium bromide and Sytox Orange by fluorescent spectrophotometry. Independent biological duplicates 
were taken and samples were analyzed in duplicate. Error bars represent the mean ± SD of the average 
normalized fluorescence units for each biological replicate. Significant differences in accumulation compared 
to the untreated control group were calculated using two-tailed paired Student’s t-tests. P-values<0.05 
were considered to be significant and are indicated with (*).
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Discussion
The accumulation of antibiotics inside a bacterial cell is crucial for successful treatment. Efflux 
pumps provide an intrinsic mechanism in several bacteria that allows the active secretion of 
drugs.(69) As a result, less of the anti-bacterial compound will be present within the bacteria. The 
inhibition of efflux pumps is a promising development, as inhibition of efflux pumps has been 
shown to increase the drug susceptibility of M. tuberculosis.(40) 
Treatment of M. tuberculosis with THZ results in an increased susceptibility of the pathogen 
towards rifampicin, isoniazid and streptomycin.(9, 10, 20, 28, 70) Furthermore, ethidium bromide, 
a common substrate for efflux pumps, accumulates faster in THZ treated mycobacteria.(21) 
Therefore, it has been suggested that THZ inhibited efflux pumps, which leads to an increase 
of intracellular drug accumulation that could explain the synergistic effects between THZ and 
other antibiotics. Based on the data obtained in the current study we propose an alternative 
molecular mechanism that connects the outcomes of several other studies. 
Using a proteomic approach, we demonstrated the differential abundance of 16 proteins that 
are known to fulfill a function in the maintenance of the mycobacterial cell envelope. These 
observations support a previous study that demonstrated THZ induced cell envelope damage.(23) 
In fact, we confirmed the differential of SigB on the protein level, that was previously reported to 
be induced on the mRNA level in the response to THZ.(23) More importantly, our proteomic data 
points to several molecular processes that might are utilized by M. tuberculosis to compensate 
for THZ induced cell envelope damage. Further studies are warranted to elucidate the role of 
these proteins in response to THZ stress that might be caused by a direct interaction of THZ 
with the plasma membrane of M. tuberculosis.(57) There is no experimental evidence that THZ 
binds to the plasma membrane of M. tuberculosis. However, in our study we demonstrate that 
the composition of the mycobacterial plasma membrane is altered upon long-term exposure to 
THZ; see Figure 4. 
Based on the proteomic response of M. tuberculosis to THZ we hypothesized that THZ 
compromises the mycobacterial cell envelope, which allows for rapid accumulation of several 
antibiotics. To support this hypothesis we performed a fluorescent spectrophotometry based 
accumulation assay. To this end, we have selected two fluorophores with unique properties; 
ethidium bromide and Sytox Orange. Ethidium bromide was used to monitor both cell envelope 
permeability and efflux pump activity, whereas we demonstrated that the accumulation of Sytox 
Orange is solely dependent on cell permeability; see Figure 5. Using this experimental setup 
we demonstrated that THZ treated cells accumulate more Sytox Orange and ethidium bromide 
than untreated cells, which supports our hypothesis that the cell envelope of M. tuberculosis 
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becomes more permeable after THZ treatment; see Figure 5. 
Synergistic effects between antibiotics, due to alteration of the cell envelope permeability, 
have previously been observed for ethambutol, which increases the accumulation of rifampicin 
in multiple mycobacteria: M. aurum, M. smegmatis and M. tuberculosis.(62) In addition, it has 
also been shown in M. marinum that the susceptibility towards multiple antibiotics increases 
once the cell envelope permeability was significantly increased.(36, 71) The THZ induced cell 
envelope permeability could explain the synergistic effects between THZ and other drugs in M. 
tuberculosis as described previously.(9, 10, 20, 28, 70)
The exceptional cell envelope of M. tuberculosis provides the pathogen with an intrinsic form 
of antibiotic tolerance.(43) By permeabilizing the cell envelope antibiotics can more readily 
enter the cell and accumulate to a bactericidal concentration. In fact, due to the increased 
permeability of the cell envelope to old drugs and new anti-tuberculosis antibiotics, not only 
would the old drug(s) be restored to an effective therapeutic level, the dose levels of new but 
toxic anti-tubercular compounds may be significantly reduced.
Regarding the accumulation of ethidium bromide, we did not observe a synergistic effect 
when we combined THZ with the efflux pump inhibitor reserpine, at the concentrations and 
timespan examined; see Figure 5. However, the observation that Sytox Orange accumulates 
to higher levels in THZ treated cells than reserpine treated cells demonstrates that there is a 
role for cell envelope permeabilizing agents next to efflux pump inhibitors. As demonstrated, 
some compounds only accumulate to high intracellular levels through the induction of cell 
permeability. 
In the here described model we demonstrate that THZ induces cell envelope permeability. 
The corresponding proteomic data revealed that proteins involved in the synthesis of PDIM 
and uptake of cholesterol are differentially abundant during THZ treatment. Similarly, we 
demonstrated that the relative content of tuberculostearic acid increases in the plasma 
membrane upon exposure to THZ. Both the differential abundance of these proteins and the 
alteration of the plasma membrane composition can play a vital role to counter act the THZ 
induced cell envelope permeability. The extent to which these changes contribute to THZ 
tolerance in M. tuberculosis requires further assessment.
The increase in cell envelope permeability upon THZ treatment is an alternative explanation for 
the synergistic effects of THZ with other antibiotics that has so far only been attributed to the 
inhibition of efflux pumps. Nevertheless, there remain two conceivable hypotheses in which THZ 
inhibits mycobacterial efflux pumps. First, the THZ induced cell envelope permeability might 
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reduce the proton motive force, which indirectly inhibits efflux pumps by denying its source 
of energy.(72),(73),(74) Secondly, the THZ induced alteration of the phospholipid bilayer might also 
result in a membrane-mediated inhibition of efflux pumps by THZ as suggested previously.(57)
It is important to note that both the indirect inhibition of efflux pumps and an increase of cell 
envelope permeability can contribute to a more rapid accumulation of antibiotic compounds in 
the cell. Cell envelope influencing agents like THZ may therefore increase the efficacy of other 
drugs significantly.
Finally, permeabilization of the cell envelope could lead to the loss of metabolites, ions and 
thereby the loss of, for example, the proton motive force which will ultimately lead to cell death. 
Thereby, the permeabilization of the mycobacterial cell envelope by THZ could also explain why 
THZ is active against metabolically inactive cells.(29)
Conclusion
By analysing the proteome of THZ treated M. tuberculosis cells we observed the differential 
abundance of 16 proteins that are involved in the maintenance of the mycobacterial permeability 
barrier. We further demonstrated that long-term THZ treatment yields a relatively permeable 
M. tuberculosis cell envelope. Finally, we also showed how the plasma membrane composition 
of M. tuberculosis is altered under the influence of THZ. This renewed insight in the working 
mechanism of THZ offers a better understanding on the molecular basis of this promising new 
antibiotic, which will hopefully result in a more efficient use of this drug, possibly in combination 
with other efflux pump inhibitors. 5
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replicates with additional information. This table can be downloaded on the website of the journal: https://
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abundance ratios in the reported proteomic data set. This table can be downloaded on the website of the 
journal: https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.5b01037
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FIGURE S1. Growth patterns of M. tuberculosis H37Rv treated with thioridazine. 
(A) Exposure of M. tuberculosis to 0(control),4,6 & 8 mg/L thioridazine. 
(B) Growth curves of media containing 6 mg/L thioridazine media that has been pre-incubated for 21 days 
at 37˚C (stability) and media containing 6 mg/L that has freshly been prepared. 
5
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FIGURE S2. protein ratio distribution comparison of thioridazine treated and untreated M. tuberculosis 
H37Rv. Normalized Log2 transformed protein ratio’s plotted against the summed Log2 peptide intensity for 
both biological replicates. Data points are colored based on their significance B values. Turquois is >0.5, blue 
>0.25, red >0.1, yellow >0.05 and green <0.05. Note: a label swap was performed between both biological 
replicates.
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FIGURE S3. Thin Layer Chromatohraphy analysis of phthiocerol dimycocerosate(PDIM) abundance in M. 
tuberculosis H37Rv. Apolar lipids were extracted, analysed on silica gel TLC plates and three times developed 
in petroleum ether:ethyl acetate (98:2). I: a spot of PDIM standard, II/III: spots of untreated M. tuberculosis 
H37Rv, IV/V: spots of thioridazine treated M. tuberculosis. 
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Identification of phylogenetic relationships 
in the Mycobacterium genus by direct 
comparison of shared spectral content 
6
Abstract
The degree of pathogenicity and antibiotic susceptibility differs greatly between species of 
the Mycobacterium genus. Correct identification of mycobacteria is therefore a necessity to 
discriminate harmless mycobacteria from clinically relevant species. To overcome limitations of 
current phenotypic and molecular identification methods, we examined the potential of tandem 
mass spectrometry to identify species and determine phylogenetic relationships between 
various mycobacteria. Mass spectrometry data were acquired using a standard proteomics 
configuration, after which the shared spectral content between samples was determined. 
The resulting phylogenetic tree was constructed out of 11 species that were represented 
by 29 unique isolates, and Escherichia coli as an outgroup. Comparison of the species-level 
clustering with the conventional mycobacterial identification methods based on 16S rRNA and 
rpoB sequencing showed the increased discriminatory power of the here described technique. 
Thereby, we demonstrate that the number of shared tandem mass spectra can be used as a 
direct measure of phylogenetic relatedness. Furthermore, this method does not require any 
prior knowledge of the sample or the availability of genomic information, which makes it 
applicable to virtually any organism. 
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Introduction
Mycobacterium tuberculosis, the causative agent of tuberculosis, is the best known member 
of the Mycobacterium genus. Next to the M. tuberculosis complex, the genus consists of more 
than 140 so called nontuberculous mycobacterial (NTM) species and this number is still growing.
(1) Approximately 25 non-tuberculous mycobacteria, previously also referred to as ‘atypical 
mycobacteria’ or ‘mycobacteria other than tuberculosis’ (MOTT), are potentially pathogenic to 
either humans or animals.(1, 2) 
The correct identification and classification of clinical mycobacterial isolates is important for 
proper diagnosis, treatment and epidemiological surveillance of mycobacteria.(3) A variety of 
molecular and phenotypic methods is available for the identification of M. tuberculosis complex 
sub-groupings and NTM species, yet each of these methods has its own limitations.(4) 
Traditional biochemical and phenotypic assays that were utilized for the identification of 
mycobacteria were replaced by molecular diagnostics. 16S rRNA gene sequencing was 
introduced in the early 1990’s as the gold standard to determine phylogenetic relationships 
between a variety of micro-organisms, including mycobacteria.(5) However, 16S rRNA sequencing 
lacks the required resolution to discriminate between some groupings of NTM, especially for 
rapid growing species.(6, 7) 
Sequencing of the rpoB gene might be more suitable to study phylogenetic relationships 
between NTMs, compared to sequencing of 16S rRNA genes.(8, 9) RpoB sequencing can be more 
discriminative than 16S rRNA sequencing, but is still prone to misidentifications, presumably 
due to horizontal gene transfer events.(10) Furthermore, identification of species using rpoB 
sequencing is limited due to the absence of sequence data for the less frequent encountered 
NTM in the GenBank database.(9) 
Despite the above mentioned limitations, single gene based molecular identification is widely 
accepted and generally applied to study phylogenetic relationships between mycobacteria. In 
addition, the analysis of clinical specimens using matrix assisted laser desorption ionization 
time-of-flight (MALDI-TOF) technology is gaining popularity due to the minimal turnaround time, 
ease of sample preparation and low cost per sample.(11, 12) This phenotypic identification method 
compares proteome compositions to discriminate between species.(13) However, the MALDI-
TOF approach is not able to discriminate all (sub)species and does not provide interpretable 
spectral information.(12, 14, 15) Since spectra are solely acquired from molecules within the range 
of 2-20 kDa, identification is largely dependent on a limited number of features that mainly 
consist of the generally well conserved ribosomal proteins.(16) Since these methods fully rely on 
a small number of nucleotides or protein sequences, they can readily oversimplify the species 
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phylogeny. Therefore, it remains challenging to identify mycobacteria and re-construct their 
phylogeny with a single, straightforward, affordable, non-targeted assay.
LC-MS/MS analysis of an entire bacterial proteome or selected proteins can be used for the 
identification of micro-organisms, as reviewed recently.(17) In these approaches, proteins are 
proteolytically digested and the resulting peptide are separated by HPLC. The peptides eluting 
from the HPLC are ionized, detected and fragmented for analysis. Identification of the peptides 
is subsequently established by matching the obtained tandem-MS spectra against theoretical 
fragment data. There are several advantages to LC-MS/MS analysis of bacteria as the method 
provides detailed information that could reveal minor differences between species while 
only using inexpensive consumables for the preparation of samples.(18, 19) However, correct 
identification of species requires the presence of fully annotated databases, which is to date 
still limiting. (18) 
We previously demonstrated that phylogenetic relationships between primates can be established 
using a direct pairwise analysis of tandem mass spectra derived from trypsinized serum samples.
(20) One of the promising features of this approach is that it functions independently of genomic 
information. Furthermore, following standard proteomics procedures, one can readily acquire 
thousands of tandem mass spectra that all serve as features to discriminate between species 
and construct a phylogenetic tree. Similar approaches have already successfully been used for 
the authentication of commercial fish products(21) and tick blood meals derived from vertebrate 
species.(22) 
In this study, we further examined the potential of tandem mass spectrometry for the 
identification of mycobacterial species, both of NTM as the closely related M. tuberculosis 
complex (sub)species. By comparing the shared spectral content between various species, 
we demonstrate that phylogenetic relationships can be revealed with this technique and that 
closely related species can be discriminated without prior knowledge or information of the 
organism to be analysed.
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Materials and Methods
Mycobacterial culture conditions
The following mycobacterial species, derived from clinical isolates, were cultured in mycobacterial 
growth indicator tubes (MGIT) and incubated until positive growth was detected using the 
BACTEC MGIT  960 (Becton Dickinson, USA): Mycobacterium gordonae, Mycobacterium szulgai, 
Mycobacterium kansasii, Mycobacterium avium, Mycobacterium malmoense, Mycobacterium 
marinum, Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium canettii, 
Mycobacterium abscessus and Mycobacterium fortuitum. Each of these species was represented 
by two or three unique, clinically derived, isolates. Approximately 0.2 ml was inoculated onto 
7H10 medium agar plates (Tritium Microbiologie B.V., the Netherlands) and incubated at 36 °C 
until colony formation was visible, except for M. marinum isolates, which were incubated at 30 
°C. A 1-μl inoculation loop full of mycobacterial biomass, collected from one to three colonies, 
was transferred to 0.5 ml of lysis-buffer (4% SDS, 100mM Tris-HCl) and heat-inactivated at 100 
°C for 15 minutes. Cell lysates were frozen at -70 °C until further usage. Biological duplicates 
were taken from each isolate.
Molecular diagnostics
Authenticity of the NTM samples was determined using INNO-LiPA Mycobacteria v2 (Fujirebio, 
Belgium) with additional partial 16S rRNA sequencing for M. szulgai and the M. tuberculosis 
complex samples was identified with the GenoType MTBC method (Hain lifescience, Germany) 
with additional variable number tandem repeat (VNTR) typing for M. canettii.(23)
Partial 16S rRNA and rpoB sequencing were performed as described previously.(9) In brief, 16S 
rRNA gene sequence analysis started from E. coli position 28 (479 bp, including the hypervariable 
regions A and B).(5, 24) Partial sequencing of the rpoB gene was performed using previously 
published primers.(25) Analyses of the 16S rRNA and rpoB gene sequences was performed using 
Bionumerics version 7.5 software (Applied Math, Belgium). Phylogenetic trees constructed 
using the Unweighted Pair-Group Method with Arithmetic Mean (UPGMA) distance calculation.
Protein sample preparation
Samples were essentially processed as described previously.(26) Briefly, mycobacterial cell lysates 
were mechanically disrupted by bead-beating in a mini bead-beater 16 (BioSpec, USA) for 5 
min using glass beads of 0.4-0.6 mm (Sartorius, Germany). Thereafter, the cells were cooled on 
ice for 5 min and further disrupted by two more rounds of bead-beating. The cell lysates were 
separated from cell debris by centrifugation for 1 min at 14,000xg and the supernatant was 
transferred to another tube. Proteins were digested using the filter aided sample preparation 
(FASP) method.(27) DTT reduced proteins were loaded on a 30 kDa filter. SDS was removed in 
three washes with 8M urea. The proteins were carbamidomethylated, and the excess reagent 
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was removed by three additional washes with 8M urea. Proteins were then digested overnight 
using endoproteinase Lys-C (endoLysC), followed by a four hrs digestion using trypsin at RT. 
Tryptic peptides were desalted on C18 SepPak columns (Waters, USA) and dissolved at 125 ng/
µl for LC-MS/MS analysis.(28)
Liquid chromatography- tandem mass spectrometry Q-Exactive
Samples were analysed on a nanoLC-MS/MS system consisting of an Easy nLC 1000 gradient 
HPLC system (Thermo scientific, Bremen, Germany) that was coupled to a Q-Exactive mass 
spectrometer (Thermo scientific, Bremen, Germany). SCX fractions were injected onto an in-
house packed precolumn (100 μm × 15 mm; Reprosil-Pur C18-AQ 3 μm, Dr. Maisch, Germany) 
and eluted via a homemade analytical nano-HPLC column (15 cm × 50 μm; Reprosil-Pur C18-AQ 
3 μm). The gradient was run from 0% to 30% solvent B (10/90/0.1 water/acetonitrile/formic 
acid) in 10 minutes. A tip with a ~5 μm internal diameter was drawn at the end of the nano-HPLC 
which acted as the electrospray needle of the MS source. The Q-Exactive mass spectrometer 
was operated in top10-mode. Parameter settings were; resolution 70,000 at an AGC target value 
of 3e6, a maximum fill time of 20 ms (full scan), and resolution 17,500 at an AGC target value of 
1e6 with a maximum fill time of 80 ms for MS/MS. The RAW data files have been deposited to 
the ProteomeXchange Consortium via the PRIDE partner repository and can be accessed with 
the dataset identifier PXD003488.
Spectral annotation using Proteome Discoverer
Peptides and proteins were identified and quantified using Proteome Discoverer 1.4 (Thermo 
scientific, Bremen, Germany) using the SEQUEST HT algorithm. The false discovery rate (FDR) 
was set to 0.01 using Percolator.(29) The precursor tolerance was set 10 ppm, while MS/MS 
spectra were searched using 20 mmu mass tolerance. Trypsin specificity was set as C-terminal 
to arginine and lysine without proline restriction. A maximum of two missed cleavages was 
allowed. Methionine oxidation was selected as variable modification. Carbamidomethylation of 
cysteine was selected as a fixed modification. All spectra were matched against a FASTA database 
of M. tuberculosis reference strain H37Rv (3,996 entries), and a database composed out of 
common contaminants (116 entries). The Proteome Discoverer output files, which provide 
access to all annotated spectra, have been deposited to the ProteomeXchange Consortium via 
the PRIDE partner repository that can be accessed with the dataset identifier PXD003488.
Molecular phylogenetics using compareMS2
The Q-Exactive raw files were converted into Mascot Generic Format (mgf) files using Proteome 
Discoverer 1.4. The similarity between mgf-files was determined using compareMS2.(20) Pairwise 
comparisons between tandem mass spectra was performed by compareMS2 for precursors 
differing less than 0.01 Th and recorded within 600 scans from each other. Spectra were 
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considered to be shared between samples when compareMS2 calculated a dot product larger 
than 0.8., which corresponds to a false discovery rate of approximately 1%.(30) The fraction of 
dot product above 0.8 was loaded into a distance matrix that was exported in the MEGA format.
(31) Phylogenetic trees were constructed using UPGMA algorithm.
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Results & discussion
Sampled features of the mycobacterial proteome
Mycobacteria were cultured on solid media and processed as outlined in Figure 1. The data 
acquired for all species, biological replicates and technical replicates were of similar quality, 
based on visual inspection of the total ion chromatograms and number of tandem mass spectra; 
supplemental Figure 1. Each dataset consists out of roughly 2,500 tandem mass spectra, which 
all serve as features to discriminate between the various species. Spectra acquired from the 
well-annotated M. tuberculosis H37Rv (32, 33) were interpreted using the SEQUEST HT algorithm in 
Proteome Discoverer. The peptides identified were derived from 578 to 630 unique proteins. In 
contrast to the MALDI-TOF based technology, in which only proteins in the mass range of 2-20 
kDa are sampled,(13) we also identified proteins larger than 20 kDa proteins; supplemental Figure 
2a. The inclusion of a protein digestion step in the here reported method enabled acquisition of 
tandem mass spectra from both small and large proteins. The ability to acquire features that are 
derived from the entire mass range of the proteome is likely to result in enhanced discriminatory 
power compared to the limited mass range sampled by the MALDI-TOF approach.
Mass spectra were acquired using a top 10 data dependent acquisition (DDA) approach, which 
automatically selects the ten most intense peptides for fragmentation. As expected, our short, 
10 min  DDA method showed a strong preference for highly abundant proteins; supplemental 
Figure 2b.(34) This bias for high abundant proteins is advantageous as the identification of 
abundant proteins requires less sensitivity and allows for reproducible sampling between 
different untargeted LC-MS/MS runs using DDA approaches.
Discriminatory power of CompareMS2 compared to 16S rRNA and rpoB sequencing
CompareMS2 software was used to determine the number of shared tandem mass spectra 
between the various samples analysed.(20) CompareMS2 pairs tandem mass spectra generates 
a similarity score between two spectra, which is expressed as a dot product; Figure 2. Tandem 
mass spectra with a dot product greater than 0.8 were considered to be shared between 
species. The number of shared tandem mass spectra between the various samples was 
converted into a distance matrix to generate a phylogenetic tree; supplemental Figure 3A&B. 
The approach described here discriminates between the rapid growing mycobacteria; M. 
fortuitum and M. abscessus, and slow growing mycobacteria. Furthermore, all NTMs analysed 
clustered on the species level. Moreover, there was very limited variation between the biological 
and technical replicates analysed. The position of M. malmoense in the vertical dimension 
differs between both technical replicates. However, the calculated distance from M. malmoense 
to either M. marinum or M. avium in the horizontal dimension is comparable in both technical 
replicates.
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FIGURE 1. Experimental design. Mycobacteria were cultured on solid agar until colonies were observed. 
Colonies were dissolved in 4% SDS and heat-killed. The cells were mechanically lysed by bead-beating, 
after which the proteins were digested using the FASP procedure.(27) Spectra of intact peptide and tandem 
mass spectra of fragmented peptides were acquired on a Q-Exactive mass spectrometer after which the 
percentage of shared tandem mass spectra between datasets was calculated using compareMS2.(20)
Compared to 16S rRNA and rpoB sequencing, we observed that our approach is the only assay 
than can sufficiently discriminate between the M. tuberculosis complex members M. bovis, M. 
canettii and M. tuberculosis while it is also capable to discriminate between various NTMs; 
supplemental Figures 3C&D. Similarly, the MALDI-TOF method is only able to identify members 
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of the M. tuberculosis complex on the complex level, but lacks the discriminatory power to 
separate individual members at the species level.(12) 
FIGURE 2: Mirror plots of two tandem mass spectra derived from M. tuberculosis (black, top) and M. 
marinum (red, bottom). The similarity between spectra was calculated using SpectraST 5.0, and reported as 
a dot product.(37) Spectra with dot product close to 1.0 are almost indistinguishable (A&B). Spectra with 
a dot product of 0.8 are still recognizably similar (C). Spectra with a dot product well below 0.8 are not 
considered to be shared or considered to originate from the same precursor peptide (D).
FIGURE 3: In silico analyses of the two-spectra dot product distribution between two M. tuberculosis H37Rv 
biological replicates with different precursor mass tolerances. Both the high- and low-resolution datasets 
follow the same distribution when a dot product greater than 0.8 is used as a cut-off, indicating that low-
resolution mass spectrometers can be used to study and reconstruct phylogenetic relationships.
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The effect of instrument resolution
CompareMS2 uses the precursor mass of a peptide to compare their corresponding tandem 
mass spectra pairwise. In our case, compareMS2 only processed tandem mass spectra of 
which the precursor differed less than 0.01 Th. The usage of high resolution, high accuracy 
mass is becoming more prevalent in the field of proteomics. High resolution instruments offer 
considerable advantages for the analysis of proteomic samples of increased complexity, but this 
high quality data comes with a price tag.(35) To examine the added benefits of a high resolution 
precursor scan for the identification of mycobacterial species by shared spectral content, we 
analysed our high resolution data with less resolution in silico. 
To investigate the impact of mass measurement accuracy, we modified two MGF files derived 
from biological replicates of M. tuberculosis H37Rv using Gaussian distributed random numbers 
from http://random.org with zero mean and a standard deviation of 0.5 Th. These Gaussian 
randomised MGF files were processed with compareMS2 using a precursor mass tolerance of 1.0 
Th; a mass precision that is readily achieved with a more affordable ion trap mass spectrometer. 
The original high resolution MGF files were processed with a 0.01 Th precursor mass tolerance. 
For both datasets we used a fragment mass bin size of 0.2 Th.
The relative wide precursor mass tolerance of 1.0 Th did result in more low scoring two-spectra 
dot products, i.e. tandem mass spectra that score lower than 0.8; Figure 3. However, both the 
high- and low resolution data follow the same distribution when a dot product of 0.8 was used 
as a cut-off.   
Reconstruction of the phylogeny using either 0.01 Th or 1.0 Th precursor mass tolerance did 
not affect clustering, since solely the spectra pairs with a dot product greater than 0.8 were 
used for clustering; supplemental Figure 4. This observation underlines the robustness of the 
method, but also indicates that more affordable low resolution mass spectrometers can be 
used to examine the species’ phylogeny in a reliable way.(36) This hypothesis is strengthened 
by a previous study that demonstrated the power of spectral matching for the identification of 
commercial (processed) fish products on a low resolution ion trap.(21)
It should be noted that both the identification of fish products, as well as the identification 
of mycobacterial species was performed without any filtering of the data or optimization of 
the processing workflow. Thereby, the method shows to be inherently robust. In addition, 
the described methodology functions without any prior knowledge of the sample, thereby 
circumventing the need of organism specific consumables such as primers, which are required 
for molecular diagnostic assays. Therefore, we anticipate that the method is directly transferable 
to other organisms.
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Conclusion
To date, the identification of NTM and species within the M. tuberculosis complex has been 
limited to specialized laboratories that often rely on a variety of molecular assays. This study 
demonstrates a straightforward and rapid proteome-based method that can differentiate 
between closely-related mycobacterial species and even construct phylogenetic relationships. 
Compared to other MS-based phenotypic typing approaches, this method brings the following 
advantages: it requires no prior knowledge of the organism to be analysed (e.g. specific primers), 
the method can be transferred to virtually all (micro-)organisms, all acquired tandem mass 
spectra can be used for clustering and identification, the acquisition of tandem mass spectra 
can be performed on both high and low resolution instrumentation, and the method can easily 
be implemented in a typical proteomics laboratory. 
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Supporting information
FIGURE S1: total number of mass spectra acquired on the Q-Exactive for each of the species analysed. Error 
bars represent the standard deviation of biological variation within the grouped species.
 
FIGURE S2: The spectra acquired for M. tuberculosis H37Rv were searched using the SEQUEST HT peptide 
search engine. Proteins that were molecular weight (A) and the estimated abundance (Schubert et al., 2013) 
(B) compared to complete the M. tuberculosis H37Rv proteome. (Cole et al., 1998) Error bars represent the 
standard deviation between biological replicates.
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FIGURE S3: Phylogenetic trees of selected mycobacteria were established using compareMS2.(Palmblad 
and Deelder, 2012) Two technical replicates were analysed (A&B) and compared with 16S rRNA (C) and 
rpoB (D) sequencing. 
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FIGURE S4: Phylogenetic tree constructed out of 11 Mycobacterium species, represented by 29 unique 
isolates, and E. coli using the UPGMA hierarchical clustering method on approximately 2000 tandem 
mass spectra that were acquired on the Q-Exactive for each of sample, in biological duplicates. The trees 
were constructed using compareMS2 with either 0.01 Th (A) and 1.0 Th (B) precursor mass tolerance. The 
distances were calculated using the formula: #(spectra)/#(spectra|dot>0.8)
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The ongoing spread of (multi-)drug resistant Mycobacterium tuberculosis presents a major 
burden on the management of tuberculosis (TB).(1) Early detection of drug resistance or drug 
tolerance can be essential to minimize the spread of resistant strains. Furthermore, a better 
knowledge of interstrain variation, mechanisms of action of anti-TB drugs and mycobacterial 
drug tolerance will facilitate the development of improved diagnostic assays, new drug targets 
and novel drug treatment strategies. In this thesis, we made use of mass spectrometry-based 
proteomics as an unbiased hypothesis generating tool to study protein regulation in M. 
tuberculosis in relation to the development and transmission of drug resistance. The (major) 
novel findings described in this thesis are summarized and discussed in this Chapter; Box 1. 
BOX 1: Summary of novel findings described in this thesis.
In this thesis, we examined to what extent regulation of the M. tuberculosis proteome 
contributes to drug tolerance, a (sub-)lineage specific phenotype and the anti-TB 
mechanism of antibiotics. The main findings are listed below:
 − Chapter 2 & 4 a gap is bridged between the M. tuberculosis Beijing sub-lineages 
genotype and phenotype by identifying the differential abundance of Rv0450c/ 
MmpL4 and Rv3283/sseA in modern Beijing strains relative to other clinically relevant 
M. tuberculosis lineages.
 − In Chapter 3 it is demonstrated that the DosR dormancy regulon is actively induced 
by M. tuberculosis Beijing B0/W148 upon rifampicin treatment. Furthermore, it is 
demonstrated that the M. tuberculosis Beijing B0/W148 strain displays a pre-dormant 
phenotype prior to rifampicin treatment.
 − In Chapter 4 it is demonstrated that next to M. tuberculosis Beijing B0/W148, also 
M. tuberculosis H37Rv induces the dormancy regulon upon rifampicin treatment. 
Additionally, it is shown that the proteinaceous regulators of dormancy are a priori 
more abundant in M. tuberculosis Beijing strains compared to other clinically relevant 
M. tuberculosis strains.                                                                                                                                                                                                                                                   
 − In Chapter 5 a novel mechanism of action for the potential new antibiotic thioridazine 
is described.
 − In Chapter 6 we demonstrate that phylogenetic relationships between closely related 
mycobacteria and M. tuberculosis strains can be reconstructed based on their 
phenotype using tandem mass spectrometry.
7
190 | CHAPTER 7
Proteomic analysis of M. tuberculosis
In order to establish a comprehensive, representable proteomic view of M. tuberculosis using 
mass spectrometry, mycobacterial proteins need to be extracted from the cell. Reproducible, 
unbiased extraction of an entire mycobacterial proteome is hampered by the thick, lipid-rich 
cell wall surrounding mycobacteria.(2, 3) To obtain a representative extract of the mycobacterial 
proteome, we made use of a chemical disruption, using sodium dodecyl sulfate, combined with 
heat treatment and mechanical disruption by means of bead-beating. Based on the identified 
recovered proteins, we demonstrate that this procedure yields a reproducible extraction of 
the mycobacterial proteome without a bias towards a protein’s physiochemical properties and 
cellular localization (Chapter 2).
The proteomic coverage in a proteomics experiment is dependent on several variables, 
including pre-fractionation of the proteome and the type of mass spectrometer used. Within 
this thesis, we made use of a Thermo Scientific LTQ-FT Ultra hybrid mass spectrometer and 
a Thermo Scientific Q-Exactive quadrupole orbitrap mass spectrometer. As expected, the 
Q-Exactive outperformed the LTQ-FT Ultra in total number of identified proteins; Table 1. The 
Q-Exactive is a newer generation of mass spectrometer, that can generate more high resolution 
mass spectra per second, which resulted in more peptide identifications and ultimately more 
protein identifications. 
In the proteomic dataset generated with the Q-Exactive mass spectrometer, we reproducibly 
quantified a total of 2,429 proteins with ≥2 peptides per protein and a 1% false discovery rate 
(Chapter 4). Thereby, this proteomic dataset covers ±60% of all proteins theoretically present 
in M. tuberculosis and ±80% of the expressed proteome reported to date.(4-6). Considering that 
we analyzed a homogenous culture of M. tuberculosis cells that was in mid-logarithmic growth 
phase, we assume that for example stationary growth phase specific proteins were likely to be 
absent, or in quantities too low to be detected.(7) 
The comprehensive, unbiased proteome-wide quantifications performed in this thesis were 
obtained after pre-fractionation of the digested proteome to decrease complexity and thereby 
increase proteomic coverage. However, with the availability of new bioinformatic tools and 
even faster scanning mass spectrometers, pre-fractionation of mycobacterial protein digests 
can possibly be omitted. One novel powerful approach to study unfractionated proteomes is 
the data-independent acquisition (DIA) method SWATH (Sequential Window Acquisition of all 
THeoretical Mass Spectra).(8)
Analysis of the M. tuberculosis proteome using SWATH allowed for the quantification of up to 
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2,458 proteins in a single LC-MS/MS run on a Sciex TripleTOF 5600 mass spectrometer.(6) Using 
SWATH, M. tuberculosis proteomes can be quantitatively studied with a high-throughput, but 
SWATH also has several disadvantages.  A major drawback of SWATH assays is that the method 
is not compatible with conventional proteomic database search alghorithms. The generation of 
a SWATH assay specific proteomics library requires a major investment. For the generation of 
the M. tuberculosis SWATH library, a total of 17,463 peptides were selected, synthesized and 
analyzed by data-dependent acquisition (DDA) on a TripleTOF 5600 mass spectrometer.(5, 6) The 
resulting tandem mass spectra were compiled into a SWATH assay library. Albeit very powerful, 
this SWATH library resource is only of use for researchers that have acces to a TripleTOF mass 
analyzer or other mass spectrometers that produce peptide fragmentation patterns similar to 
the curated tandem mass spectra stored in the SWATH library.
Due to the limitations of DIA/SWATH analysis, DDA remains to be an attractive alternative. 
Even more than DIA, DDA analysis of complex samples relies on the acquisition speed of the 
mass analyzer. The ongoing development of mass spectrometers continues to lead to new 
mass spectrometers with increased resolution and acquisition speed. For example, with the 
introduction of the Thermo Scientific Orbitrap Fusion mass analyser, comprehensive analysis of 
the Saccharomyces cerevisiae proteome could be achieved using a single 95 minute analysis.
(9) Considering the fact that the S. cerevisiae proteome consists of 6,100 theoretical proteins, 
compared to M. tuberculosis producing 4,000 proteins, and the fact that the dynamic range 
of the proteome in S. cerevisiae is an order of magnitude larger than that of M. tuberculosis, 
we can conclude that the observable proteome of S. cerevisiae is more complex than that of 
M. tuberculosis.(5, 10, 11) Therefore, we would anticipate that comprehensive DDA proteomic 
analysis of M. tuberculosis can be achieved within 95 minutes using the latest generation of 
mass spectrometers. 
Despite the ongoing development of mass spectrometers, the current, state-of-the-art, 
equipment is sufficiently powerful to comprehensively study the proteome of M. tuberculosis and 
address scientific questions. The development and implementation of new mass spectrometers 
with increased resolution and acquisition speed will be of limited added value to the M. 
tuberculosis proteomics research field that performs bottom-up proteomic analysis, i.e. faster 
mass spectrometer will mainly allow for a higher sample throughput. However, the development 
of novel fragmentation techniques, that are orthoganol to the commonly used fragmentation 
method collision induced dissociation, will be of more interest as the characterization of (semi-)
intact proteins and post-translational modifications become increasingly important.(12-14)
In the cell, proteins can engage into highly specific interactions that affect the cellular phenotype. 
With the hardware available to identify and quantify these proteins within a reasonable 
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timeframe, the generated mass spectrometry data should be analyzed to add biological 
meaning to data and generate new hypotheses. Proteomic analysis is heavily dependent on 
downstream software solutions, both for the identification & quantification of proteins and 
interpretation of the large datasets generated. The functional interpretation of quantitative 
proteomic datasets can be performed using pathway and protein-protein interaction analysis. 
Pathway analysis refers to a type of data analysis that aims to identify (de)activated biologicals 
pathways typically including; signalling pathways, gene regulatory pathways and metabolic 
pathways.(15) The interpretation of proteomic datasets by either network or pathway analysis 
requires prior information of the proteins of interest, such as protein-protein interactions, a 
proteins cellular localization and its molecular function. For well-studied organisms, this type of 
data can be derived from well curated scientific publications.
Regarding the functional assignment of the proteins present in M. tuberculosis, relatively little 
pre-existing functional biological information is present. This is well illustrated by the functional 
categorization of the M. tuberculosis proteome as performed by Tuberculist, a regularly 
updated database of M. tuberculosis proteins, where a  quarter of the proteome is categorized 
as hypothetical.(16) Despite the, mainly bioinformatic, attemps to assign these hypothetical 
proteins to a molecular function, specific functional information is limited for most of the M. 
tuberculosis proteome.(17) More information on this aspect will improve the functional biological 
interpretation of new and previously published proteomic datasets, and thereby further 
advance our understanding of cellular processes in M. tuberculosis. Now that the analytical 
hardware reached a level of maturity that is sufficient for the rapid, comprehensive study of M. 
tuberculosis proteomes, it is highly conceivable that the availibity of protein functionality data 
will become the next bottleneck at the frontier of M. tuberculosis proteomics.
TABLE 1: Overview of the proteomics analyses performed and proteins identified in this thesis. Proteins 
identified contain ≥2 peptides/ protein and 1% False Discovere Rate (FDR).
Chapter M. tuberculosis Strains Multiplex SCX fractions
Bio./Tech. 
duplicate
Total no. of 
fractions analysed Mass analyzer
Total no. of 
proteins identified
2 Atypical and Typical Beijing 2 3 x 15 No/ Yes 90 LTQ-FTICR Ultra 2392
3 Typical Beijing 2 5 x 15 Yes/ Yes 300 LTQ-FTICR Ultra 2534
4 Typical Beijing & H37Rv 3 2 x 15 Yes/ Yes 60 Q-Exactive 2903
5 H37Rv 2 1 x 15 Yes/ Yes 30 LTQ-FTICR Ultra 2479
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Metabolic reprogramming of M. tuberculosis in response to 
rifampicin treatment
M. tuberculosis has a wide variety of molecular tools that can increase the cells’ tolerance to 
drugs and thereby prevent rapid drug induced killing of the pathogen (Chapter 1). In this thesis, 
we set out to identify the mechanisms that come to play in M. tuberculosis during the initial 24 
hrs of rifampicin exposure (Chapter 3 & Chapter 4). As described in Chapter 3, we reasoned that 
short-term exposure of the pathogen to rifampicin will yield a more accurate representation 
of the in vivo situation than long-term rifampicin exposure due to the short half-life time of 
rifampicin in vivo.(18)
Although we aimed to identify the molecular tools that contribute to the development of 
rifampicin resistance, we did not study rifampicin resistant strains. Strains that have acquired 
a rifampicin resistance conferring mutation will no longer be susceptible to the drug. As a 
consequence, it is not to be expected that a rifampicin resistant mutant will regulate stress 
induced proteins or any of the molecular tools that provide drug tolerance when the cells are 
exposed to rifampicin. Therefore, we reasoned that the physiology and proteome of a drug 
resistant strain will not provide information on the proteins required to develop an enduring 
drug tolerant phenotype.
 
Rifampicin targets rpoB, an enzyme whose RNA polymerase activity is required for the synthesis 
of proteins.(19, 20) However, in this thesis we demonstrated that despite the presence of high 
levels of rifampicin, M. tuberculosis still manages to regulate the abundance of proteins in the 
initial 24 hrs after the start of rifampicin exposure. Strikingly, when we exposed M. tuberculosis 
Beijing B0/W148 to 16 µg/ml of rifampicin for 24 hrs, we did observe the increased abundance 
of DosR dormancy proteins (Chapter 3). Using DosR proteins, M. tuberculosis can enter a 
metabolicly hypoactive latent state where the pathogen is less susceptible to antibiotics which 
act as inhibitors of active cellular or metabolic processes.(21) In this thesis, we did not only 
describe the proteomic changes induced by rifampicin exposure, but using cellular assays, we 
demonstrated that, following the induction of DosR dormancy proteins, rifampicin exposed 
cells develop a more dormant phenotype (Chapter 3).
To determine whether this reponse is shared by other M. tuberculosis strains, we also exposed 
M. tuberculosis H37Rv, a laboratory M. tuberculosis strain, to rifampicin (Chapter 4). Similar 
to the results obtained after exposure of M. tuberculosis Beijing B0/W148 to rifampicin,  we 
found that M. tuberculosis H37Rv also induces dormancy proteins as a response to rifampicin 
treatment. Thereby, the outcomes of this thesis suggest that transition to dormancy, as 
a response to rifampicin induced stress, is conserved throughout various M. tuberculosis 
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genotypes, although this may be more pronounced in genotypes such as the Beijing family, that 
is often associated with the spread of drug resistant TB.(22-28)
If rifampicin treatment induces the transition into a dormant phenotype, it will eventually make 
the pathogen less susceptible to a variaty of antibiotics, since the mechanism of action of most 
drugs share the requirement for growth or active metabolism.(21) The increased tolerance of the 
pathogen during dormancy will lead to extended survival times of the cells during treatment, but 
the pathogen can still be killed by antibiotics. However, dormant M. tuberculosis cells maintain 
the same mutation rate as actively growing cells.(29) Thereby, dormancy increases the window of 
opportunity of the pathogen to establish a drug resistant genotype, which can ultimately result 
in relapses of drug resistant M. tuberculosis.
The dramatic effects of drug induced dormancy are not limited to the in vivo situation. In 
vitro, drug susceptibility testing aims to determine the growth inhibitory concentrations of 
antibiotics, known as the minimal inhibitory concentration (MIC). Since mycobacterial growth 
in a known concentration of a given antibiotic is the only measure of these assays, it cannot 
diagnose a situation in which growth is actively inhibited by the pathogen to prevent killing. 
As a consequence, the read-out of the assay does provide the tester with a growth limiting 
concentration of the antibiotic examined, but it does not provide a measure of antibiotic 
tolerance. Therefore, the currently available drug susceptibility testing is not capable of 
diagnosing bacteria more prone to escape treatment and develop drug resistance.
As an alternative to MIC testing, it has been suggested to supplement current microbial drug 
susceptibility testing with minimum duration for killing (MDK) testing.(30) The combination of MIC 
and MDK values can be very powerful to determine mycobacterial tolerance to specific drugs 
and combinatorial therapy. However, the time required to perform both MIC and MDK testing 
for slow growing M. tuberculosis cells would significantly increase diagnostic turnaround times. 
Ideally, in the future, the abundance of phenotypic markers of drug tolerance, as the DosR 
proteins identified in this thesis, can be rapidly monitored to provide a quantitative measure of 
drug tolerance. 
Finally, it is known that a wide variety of stimuli can induce dormancy, including nitric oxide, 
acidity, nutrient deprivation and hypoxia.(31-34) Therefore, we hypothesized that the observed 
DosR regulated metabolic reprogramming can be part of a general stress response for M. 
tuberculosis (Chapter 3 & Chapter 4). In support of this hypothesis, it was recently reported 
that the DosR protein Rv0081 is involved in the mycobacterial response to isoniazid, rifampicin, 
moxifloxacin, mefloquine and bedquiline.(35) Thereby, it is conceivable that not only rifampicin, 
but also other antibiotics can induce a more dormant phenotype in M. tuberculosis, indicating 
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that the impact of the findings presented in this thesis can have a much broader impact than we 
can foresee with our current knowledge. 
The regulators of dormancy are more abundant in the emerging 
M. tuberculosis Beijing genotype
In Chapter 3, we demonstrated that M. tuberculosis Beijing B0/W148 is actively inducing a 
more dormant phenotype as a mechanism to circumvent killing by rifampicin. Furthermore, in 
Chapter 4 we observed a similar response to rifampicin in M. tuberculosis H37Rv. In addition, 
we also observed that out of the 23 identified DosR regulon proteins, ten were significantly 
more abundant prior to drug exposure in M. tuberculosis Beijing B0/W148 than M. tuberculosis 
H37Rv (Chapter 4). Finally, we found that the M. tuberculosis Beijing B0/W148 cultures posses 
a highly homogenous, close to dormant, phenotype (Chapter 3). To determine whether the a 
priori high abundance of DosR proteins is a Beijing specific trait, we examined the abundance 
of eight DosR proteins in five of the globally most prevalent M. tuberculosis (sub-)lineages; 
atypical Beijing, typical Beijing, East-African Indian, Haarlem and Central Asian strains (Chapter 
4). Strikingly, we observed that the proteinaceous regulators of dormancy, Rv3132c/devS and 
Rv3133c/devR, are more abundant in the M.tuberculosis Beijing genotype than in any of the 
other clinically relevant M. tuberculosis lineages examined. 
In Chapter 4, we demonstrated that M. tuberculosis Beijing B0/W148 induces three-fold more 
copies of the DosR protein Rv2031c/hspX within the initial 24 hrs of rifampicin exposure than 
H37Rv. This observation is an indication that M. tuberculosis Beijing B0/W148 transitions faster 
to dormancy than M. tuberculosis H37Rv. It is tempting to assume that the quantity of DosR 
proteins is a direct reflection of a pathogen’s potential to switch to a fully dormant state. 
However, this conclusion can only be drawn based on cellular assays, where the induction of 
dormancy, and phenotypic markers of dormancy, correlate with the quantity of DosR proteins 
present. Nevertheless, in Chapter 3 we did demonstrate that M. tuberculosis Beijing strains 
posses a pre-existent dormant phenotype during logarhitmic growth, indicating that the cells 
are always prepared to enter a fully dormant state.
The a priori high abundance of DosR proteins that are required for the response to rifampicin 
and pre-existing dormant phenotype in M. tuberculosis Beijing, provide a potential advantage 
over other strains to establish an enduring drug tolerant phenotype. Therefore, we reasoned 
that part of the success of M. tuberculosis Beijing strains might be attributable to the constant 
high abundance of dormancy proteins. As the abundance of DosR proteins is conserved in 
the M. tuberculosis Beijing lineage, it is plausible that phenotype associated drug tolerance is 
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conserved throughout entire M. tuberculosis genotypes. In the case of M. tuberculosis Beijing 
it has been demonstrated that this specific genotype is more tolerant to rifampicin, which 
correlates with the specific pre-dormant phenotype we described in this thesis.(22, 23)
It should be noted that the results in this thesis are obtained in an in vitro model of M. tuberculosis. 
Although the here described results impact in vitro M. tuberculosis drug susceptiblity testing, 
the in vivo impact and validaty of these findings remain to be examined. However, the dormancy 
regulon has been pinpointed in this thesis as a key factor in drug tolerance and hence most 
likely in resistance development. Using targeted proteomic approaches, these proteins can 
potentially be quantified in patient sputum or in an in vivo M. tuberculosis infection model.
Finally, in view of the importance of DosR for mycobacterial persistence and the findings 
presented in this thesis, it can be concluded that DosR proteins are promising drug targets.
(36, 37) It could be speculated that if novel drugs designed to target the DosR dormancy regulon 
and prevent the pathogen from entering dormancy, TB treatment times can potentially be 
reduced due to synergism with other antibiotics and even MIC-testing can improve with regard 
to forecasting drug tolerance.(35) 
 
M. tuberculosis Beijing sublineages specific traits
In Chapter 2 & Chapter 4, we demonstrated that the abundance of DosR proteins is conserved 
between the more ancient “atypical” Beijing and more modern “typical” Beijing strains. 
Nevertheless, both sublineages differ in their capacity to cause and spread active disease, leading 
to global prevalence of the typical Beijing strain, except for Japan.(38-40) Therefore, we hypothesized 
that there are selective advantages present in the more modern typical Beijing strain, which 
resulted in the dominance of this sublineage over other M. tuberculosis strains (Chapter 2). 
Genetically, the atypical and typical Beijing strains are highly related, with a mere total of 31 
non-synonymous single nucleotide polymorphisms (nsSNPs) that separate the two sublineages.
(41) Since the genome of M. tuberculosis can be seen as the blueprint for the proteome of the 
organism, it could be that the polymorphisms present in the genome can be displayed in the 
proteome.
By systematically comparing the proteomes of well characterized M. tuberculosis Beijing 
sublineages, we identified four proteins to be differentially abundant between typical and 
atypical Beijing strains: Rv0450c/MmpL4, Rv1269c, Rv3137, and Rv3283/sseA. By analysing 
enzymatic activity and the expression of mRNA of these genes in a large cohort of 29 clinically 
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derived Beijing strains, we could confirm the differential regulation of Rv0450c/MmpL4 and 
Rv3283/sseA in the M. tuberculosis Beijng sublineages (Chapter 2). In Chapter 4 we further 
compared the abundance of Rv0450c/MmpL4 and Rv3283/sseA in five clinically prevalent 
M. tuberculosis genotypes and found that Rv0450c/MmpL4 is always highly abundant in M. 
tuberculosis typical Beijing, whereas Rv3283/sseA is always less abundant in typical Beijing 
strains, relative to all other M. tuberculosis (sub-)lineages examined.
For Rv3283/sseA, we were able to bridge the observed typical Beijing specific proteomic 
phenotype with the typical Beijing specific genotype. It is known that typical Beijing strains 
posses a typical Beijing specific nsSNP in Rv3283/sseA.(41) In Chapter 2, we described how this 
nsSNP impacts protein stability, and as result, we demonstrate in Chapter 3 that once protein 
production is inhibited by the presence of rifampicin, the abundance of Rv3283/sseA rapidly 
declines due to the instability of the protein. 
The relatively low abundance of Rv3283/sseA in the typical Beijing strains could provide the 
sub-lineage with an advantage over other genotypes, as a Rv3283/sseA deficiency was reported 
to promote enhanced growth of M. tuberculosis in macrophages relative to wild-type M. 
tuberculosis.(42) Thereby, the inheritable differential abundance of Rv3283/sseA in typical Beijing 
strains presents a potential factor that provides the sublineage with a selective advantage.
Regarding Rv0450c/MmpL4, there is no typical Beijing specific nsSNP described in the gene of 
this protein. However, Rv0450c/MmpL4, together with Rv0451c/MmpS4 or Rv0677c/MmpS5 
and Rv0676c/MmpL5, are required for the secretion of iron-scavenging siderophores in M. 
tuberculosis.(43) The typical Beijing specific nsSNP present in Rv0676c/MmpL5 does, using the 
bioinformatic algorhitims used in this thesis, not impact the functionality or half-life time of 
the protein (Chapter 2). Nevertheless, considering the shared functionality of Rv0450c/MmpL4 
and Rv0676c/MmpL5, it is plausible that increased levels of Rv0450c/MmpL4 are present to 
compensate for the mutated Rv0676c/MmpL5 in typical Beijing strains. Since both Rv0450c/
MmpL4 and Rv0676c/MmpL5 play an important role in mycobacterial iron metabolism, our data 
suggest a unique role for iron metabolism in typical Beijing strains. 
The importance of iron metabolism in M. tuberculosis Beijing strains has been stressed before. 
From the host’s perspective, it has been demonstrated that patients with a mutation in 
SLC11A1/NRAMP1, a divalent transition metal transporter involved in human iron metabolism, 
have been associated with increased odds of contracting M. tuberculosis Beijing.(44) Adaption of 
the mycobacterial iron metabolism to the altered situation in the host is evidence for the co-
evolution of M. tuberculosis Beijing and humans in the region. 
In Chapter 3, we found more evidence linking iron metabolism to the success of M. tuberculosis 
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typical Beijing strains. Rv2986c/HupB, also known as iron-regulated protein (Irep-
28), was observed to be phosphorylated during rifampicin treatment. Rv2986c/HupB can 
positively regulate the biosynthesis of siderophores.(45, 46) Next to Rv2986c/HupB, we also found 
Rv3458c/rpsD to be increasingly phosphorylated during initial exposure to rifampicin (Chapter 
3). Similar to Rv2986c/HupB, Rv3458c/rpsD plays a role in the pathogens iron metabolism.(47) 
Thereby, we were not only the first to link the regulation of post-translational modifications to 
drug treatment, but also support the correlation between iron metabolism and drug tolerance.
(48)
Finally, others recently reported that Rv1346/MbtN, an acyl-CoA dehydrogenase that is 
involved in the production siderophores, was significantly more abundant in the M. tuberculosis 
Beijing strains, compared to the other M. tuberculosis lineages examined.(49) Eventually, iron 
metabolism and dormancy are related. M. tuberculosis cells that enter dormancy, or a metabolic 
hypoactive state, attempt to increase their iron storages.(50, 51) The link of iron metabolism with 
dormancy fits our overall, re-occurring, picture that iron metabolism is an important feature 
of M. tuberculosis Beijing strains, especially typical Beijing strains, which requires further 
investigation.  
Dormancy and iron metabolism are potentially related within M. tuberculosis Beijing, with 
even a genomic link between the typical Beijing specific nsSNP in Rv0676c/MmpL5 and iron 
metabolism (Chapter 2). In relation to the typical Beijing genome and dormancy, there is a typical 
Beijing specific mutation present in the DosR gene Rv2027c/DosT.(52) It has been reported 
that the presence of this mutation correlates with an increased abundance of Rv3133c/devR 
mRNA, where typical Beijing strains express on average 12-fold more Rv3133c/devR transcripts 
than atypical Beijing strains. However, both in our comparative proteomic (Chapter 2) and 
parallel reaction monitoring (Chapter 4) studies, we did not find this relation on the protein 
level. Nevertheless, the presence of a typical Beijing specific mutation in a DosR regulon protein 
strengthens the hypothesis that there is a unique relation between the genotype of typical 
Beijing strains in relation to dormancy and iron metabolism.
Now that we are bridging the gap between the typical Beijing specific genotype and phenotype, 
we can supplement molecular differentiation between Beijing sub-lineages using genotypic 
markers of which we know they more closely reflect a sub-lineage specific phenotype; Rv0676c/
MmpL5, Rv2027c/DosT and Rv3283/sseA.
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Thioridazine, the magic bullet for dormant tuberculosis?
Antibiotics are essential for curative treatment of TB patients and prevention of dissemination of 
the disease. Despite the presence of effective antibiotics, M. tuberculosis is increasingly found to 
be resistant to one or several antibiotics.(53) In this thesis, we reasoned that antibiotic tolerance, 
and thereby resistance, is at least partially caused by dormancy (Chapter 3 & Chapter 4). 
As we described in Chapter 4, dormancy is related to the M. tuberculosis Beijing genotype 
and can be induced by anti-TB treatment regimens. Also other factors can induce dormancy, 
including nitric oxide, acidity, nutrient deprivation and hypoxia.(31-34) As a result, in vivo M. 
tuberculosis often transitions itself in its dormant state. Since most antibiotics target replicating 
metabolically active cells, they loose activity once the cellular metabolism is down regulated. 
The ideal novel antibiotic would not only target metabollicaly active cells, but also the dormant 
forms of M. tuberculosis.(54-58) 
Several phenothiazine neuroleptics, such as thioridazine, exhibit in vitro and in vivo activity 
against M. tuberculosis.(59) Thioridazine has already been successfully used, off-label, in 
combination with third-line antibiotics for compassionate therapy of patients presenting 
with extensively drug resistant infections of TB in Buenos Aires.(60) In this and other studies, 
thioridazine has proven to work synergistically with other antibiotics.(61-63) 
The synergy between thioridazine and other antibiotics has been attributed to the potential 
inhibition of drug secreting efflux pumps by thioridazine. The inhibition of efflux pumps was 
thought to increase the accumulation of antibiotics, which could explain the synergy between 
thioridazine and other drugs.(64) However, the inhibition of drug efflux pumps solely does not 
fully explain the reported bactericidal effects of thioridazine, leaving the mode of action of 
thioridazine unknown. Using an unbiased proteomic approach, we set out to unravel the 
molecular mechanism of this potential new anti-TB component by examining the impact of 
continuous thioridazine exposure on the proteome of M. tuberculosis (Chapter 5). 
Long-term exposure of M. tuberculosis to thioridazine requires the drug to be thermostable over 
a culture period of approximately two weeks. To determine the thermostability of thioridazine, 
we designed a straightforward, easy to implement, bioassay that demonstrated the stability of 
thioridazines’ anti-TB activity over a period of 21 days (Chapter 5).
By analyzing the proteomic composition of thioridazine treated and untreated cells, we 
discovered that under the influence of thioridazine several proteins, including two large clusters 
of proteins involved in the maintenance of the cell wall permeability barrier, are differentially 
regulated. Our study data did not provide evidence for the differential regulation of specific 
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mycobacterial efflux pumps that are potentially inhibited by thioridazine. 
Following our proteomic data that suggested a difference in cell envelope permeability, we 
assessed the accumulation of fluorescent dyes in M. tuberculosis over time. Our findings show 
that long-term thioridazine exposure of M. tuberculosis increased the accumulation of both 
hydrophilic and hydrophobic fluorescent compounds. Furthermore, using gas chromatography, 
we demonstrated that treatment of M. tuberculosis with thioridazine altered the composition of 
the mycobacterial plasma membrane, similarly to other cell envelope permeabilizing drugs.(65) 
The observed increase of cell envelope permeability upon thioridazine treatment explains the 
reported synergistic effects and increased accumulation of other antibiotics when thioridazine 
was included in multidrug treatment regimens, i.e. drugs can more easily cross the mycobacterial 
cell envelope after thioridazine treatment. Although the hypothesis that thioridazine treatment 
leads to higher intercellular drug concentrations has not changed in this study, the more exact 
knowledge of its mode of action is a step forward and could facilitate further development of 
this class of drugs for therapy of multidrug resistant pulmonary infections of TB. In fact, due to 
the increased permeability of the cell envelope after thioridazine exposure, old drugs can be 
accumulated to an effective therapeutic level, and also the dose levels of new, but toxic, anti-TB 
compounds may be significantly reduced.
The mechanism of action described for thioridazine in Chapter 5 does not only explain 
why thioridazine acts synergestically with other antibiotics, but also serves as a plausible 
explanation for the effectivity of thioridazine to both metabolically active and hypoactive 
cells, as thioridazine seems to directly target the cell envelope.(54, 66) Despite reported adverse 
events associated with the usage of thioridazine, the need for novel antibiotics could justify the 
risk associated with  usage of this repurposed drug for the treatment of drug resistant TB.(67) 
However, the development of less toxic, more potent thioridazine analogues, will bring the 
routine usage of thiordazine closer to the clinic, which could ultimately result in more effective 
treatment of drug tolerant, dormant and to dormant transitioning M. tuberculosis.(68)
Differentiation of mycobacterial species using tandem mass 
spectrometry
The mycobacterium genus, including M. tuberculosis, consists out of more than 140 species.
(69) The various mycobacterial species cause various diseases, some leading to morbidity and 
mortality, but not all mycobacteria are of clinical significance, and not all mycobacteria are 
susceptible to the same antibiotics.(69, 70) In order to properly diagnose and treat patients 
infected with a Mycobacterium, the pathogen needs to be correctly identified.(71) However, the 
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occurrence of >140 Mycobacterium species, of which some species are genetically very closely 
related, hampers the routine identification with a single test. 
In Chapter 6, we demonstrated that using a rapid proteomics-based method, phylogenetic 
relationships between closely related mycobacterial species can be established by directly 
comparing tandem mass spectra derived from a proteolytic digest of the mycobacterial 
proteome. The method brings the following advantages compared to other currently employed 
mycobacterial typing approaches; prior knowledge of the species to be identified is not required 
when performing this untargeted assay (e.g. specific primers), the workflow can be applied to 
virtually all (micro-)organisms, all acquired tandem mass spectra can be used for clustering of 
species, the acquisition of tandem mass spectra can be performed on both high and low resolution 
mass spectrometers, and the technique can easily be implemented in a proteomic laboratory. 
Ideally, the method would not only be capable of species identification as demonstrated in 
Chapter 6, but it would also be able to discriminate between antibiotic susceptible, tolerant 
and resistant strains. However, since drug resistant bacteria could differ from drug susceptible 
bacteria by as little as a single mutation, it would be difficult to predict drug resistance using an 
untargeted method as described in this thesis. Theoretically, a single mutation could alter the 
physiology of a cell and thereby the proteome, making identification of drug resistant strains 
a possibility. However, as such data is not available in literature, other approaches should be 
explored.
As discussed above, current in vitro drug susceptibility testing methods often determine the 
growth inhibitory concentrations of antibiotics, the MIC. Since the outgrowth of the pathogen 
in a pre-determined drug concentration is the only measure of these assays, it is not possible 
to identify drug tolerant bacteria which inhibit their own growth to prevent killing as we 
presented in Chapter 3 & Chapter 4. As a consequence, based on the outcomes of these types 
of drug susceptibility assays, one can solely conclude whether a strain is drug resistant, i.e. drug 
resistant strains will grow in high concentrations of antibiotics, whereas drug susceptible strains 
will not be able to grow in the presence of antibiotics. Theoretically, the in Chapter 6 described 
mycobacterial typing method can be applied to discriminate between bacterial drug responses, 
as discussed below.
It is conceivable that rifampicin treatment will not inhibit the production of new proteins in 
rifampicin resistant strains. Therefore, it is to be expected that the proteome of a rifampicin 
resistant strain will not change dramatically during rifampicin treatment. In contrast, rifampicin 
treatment of fully drug susceptible cells will lead to cell death and might eventually even 
lead to cell lysis, which will result in a proteomic signature that differs from that of drug 
resistant, viable, cells. Finally, drug tolerant cells that will persist during drug treatment, but 
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stop growing, will need to adjust their metabolism and thereby their proteome, described in 
Chapter 3 & Chapter 4. As a result, drug susceptible, tolerant and resistant cells are likely to 
present a different proteome after drug exposure. Therefore, it would be of interest to perform 
a traditional phenotypic drug susceptibility assay of which the cultures are also analysed using 
the described compareMS2 method.
If the pathogen is able to grow in the presence of an antibiotic, we can state that the pathogen 
is drug resistant, as can be determined using current drug susceptibility testing. If there is no 
growth, the pathogen can be either drug susceptible or drug tolerant. In this situation, the mass 
spectrometer can be used to determine whether the cells are drug tolerant, based on their 
proteomic signature. As a control, the bacteria could be transferred to fresh cultured broths 
without antibiotics, so non-killed, drug tolerant cells can be re-cultured, as also described in 
Chapter 3. However, the re-culture of cells would take significantly longer than the identification 
of drug tolerant cells using tandem mass spectra. Thereby, phenotypic identification methods, 
as compareMS2, could shorten the diagnostic turn-around times significantly.
Although the hypothetical situation outlined above could lead to the discrimination of drug 
tolerant and drug susceptible strains, it is to be expected that in a cultured population both drug 
tolerant and drug susceptible strains are present due to the heterogeneity of cell cultures, even 
with highly defined culture conditions.(72) However, as recently reported for meat products, the 
described compareMS2 method is capable to determine the relative composition of a sample 
containing meat derived from two or more species.(73) Thereby, the method has, theoretically, 
the potential to not only discriminate between closely-related mycobacterial species, but also 
determine the relative composition of drug susceptible, tolerant or resistant cells present 
within a single culture.
The limitations and possibilities of the method should be further examined before it can reach 
its full potential and being considered for routine use in the clinic. However, based on the data 
presented in Chapter 6, we can conclude that the approach has the potential to advance our 
understanding of phenotypic relationships between mycobacterial species. Furthermore, the 
principles of this method can provide accurate species identification and could be of help in 
directing rapid, accurate and effective patient treatment in the future.
Concluding remarks
The research presented in this thesis has increased our understanding of the mechanisms that 
provide rifampicin tolerance, the limitations of drug susceptibility testing, inter- and intra-strain 
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variation in M. tuberculosis, thioridazine’s mechanism of action and potential new diagnostic 
methods. The hypotheses generated, tested and confirmed in this thesis were the result of 
unbiased proteomic approaches that allowed for novel insights into the regulation of the M. 
tuberculosis proteome in well-defined experimental settings. Although we found that the 
phenotype M. tuberculosis Beijing lineage is more equipped to withstand antibiotic treatment, 
the outcomes of this thesis indicate that if we advance our understanding of the etiology of 
drug resistance in M. tuberculosis, improved treatment strategies and diagnostic methods will 
be on the horizon.
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Tuberculose (TB) is een ernstige infectieziekte die veroorzaakt wordt door Mycobacterium 
tuberculosis. Wereldwijd worden er jaarlijks ruim 10 miljoen nieuwe gevallen van actieve TB 
gediagnosticeerd. Ondanks dat er sinds de jaren 50 meerdere medicijnen op de markt zijn ge-
komen om TB succesvol te behandelen, eist deze ziekte nog altijd vele mensenlevens, met een 
geschat aantal sterfgevallen van 890.000 mannen, 490.000 vrouwen en 140.000 kinderen per 
jaar. Hiermee is TB wereldwijd de meest dodelijke bacteriële infectieziekte. Buiten deze hoge 
sterftecijfers zijn er naar schatting wereldwijd nog ca. twee miljard individuen die een latente 
vorm van TB bij zich dragen, waarbij M. tuberculosis in een soort slapende toestand aanwezig 
is. Van deze twee miljard mensen zal uiteindelijk 3-30% actieve TB ontwikkelen en deze gevallen 
kunnen opnieuw voor verspreiding van de ziekte zorgen. Hoewel TB wereldwijd nog steeds veel 
slachtoffers eist, is er in de Westerse wereld sinds halverwege de 20ste eeuw, met de introduc-
tie van antibiotica, een gestage afname van het aantal TB infecties. 
Momenteel is TB in het algemeen goed te behandelen met  werkzame antibiotica. De huidige 
eerstelijns antibiotica worden echter al ruim 50 jaar gebruikt voor de behandeling van TB. Tij-
dens dit tijdsbestek zijn er antibiotica resistente vormen van TB ontstaan. Wereldwijd wordt 
momenteel in 3.5% van alle TB gevallen een vorm van TB gevonden die resistent is voor tenmin-
ste rifampicine en isoniazide, de twee belangrijkste eerstelijns antibiotica voor de behandeling 
van TB. Deze vorm van antibiotica resistente TB staat bekend als Multidrug Resistant  TB (MDR-
TB). Wanneer er sprake is van additionele resistentie tegen fluoroquinolonen en aminoglycosi-
den wordt deze vorm van TB extensively drug resistant (XDR-TB) genoemd. Tenslotte is er ook 
totally drug resistant TB (TDR-TB); een verzamelnaam voor TB gevallen die resistentie hebben 
ontwikkeld tegen alle beschikbare TB antibiotica waar in een bepaalde setting op getest kan 
worden. Vanwege het beperkte aantal nieuwe anti-TB medicamenten dat op de markt komt,  is 
er een groeiende angst dat MDR-TB, XDR-TB en TDR-TB uitbraken vaker voor zullen komen en 
moeilijker te bestrijden worden.
MDR-TB gevallen komen relatief vaak voor in Centraal-Azië en Oost-Europese landen. Zo is be-
schreven dat in Wit-Rusland bij 35% van alle nieuwe TB gevallen er sprake is van MDR-TB. Dit 
betekent dat resistente vormen van TB actief worden overgedragen. De verspreiding van MDR-
TB wordt in Wit-Rusland, Europa, Zuid-Afrika en grote delen van Azië  vaak geassocieerd met 
het Beijing genotype van M. tuberculosis, dat in 1995 door het RIVM werd beschreven. Hoewel 
dit genotype genetisch niet veel verschilt van andere M. tuberculosis stammen, vertonen stam-
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men van het Beijing genotype een hogere  antibiotica tolerantie, een hogere pathogeniciteit 
en een afwijkende inductie van immuunresponsen in diverse gastheren, waaronder de mens.
Vanwege de toenemende  antibioticaresistentie bij TB is het belangrijk om verdere verspreiding 
van resistente bacteriën te voorkomen. Verbetering van de huidige diagnostiek, behandelstra-
tegieën en de ontwikkeling van nieuwe medicijnen kunnen hiertoe bijdragen. 
 
Dit proefschrift
Eiwitten zijn relatief grote biomoleculen die verantwoordelijk zijn voor allerlei processen in de 
bacteriële cel, zoals energiehuishouding, celdeling, infectie van de gastheer en ontwikkeling van 
antibioticaresistentie. Het proteoom, bestaande uit de eiwitten die aanwezig zijn in de cel op 
een specifiek moment, bepaalt voor een groot deel de eigenschappen van de cel. Het onder-
zoek dat beschreven is in dit proefschrift werd uitgevoerd om een completer beeld te krijgen 
van de mycobacteriële eiwitten die van belang zijn voor de ontwikkeling van antibioticaresisten-
tie en verspreiding van TB. Daarnaast is er gekeken naar toepassingen in de diagnostiek.
Een M. tuberculosis genotype dat zich de laatste decennia snel verspreid heeft is de ‘moderne’ 
of ‘typische’ Beijing lineage. Deze typische Beijing genotype familie is in een veelheid aan  stu-
dies geassocieerd met antibioticaresistentie, de inductie van een alternatieve immuunrespons 
en een verhoogde prevalentie, terwijl deze genotype familie genetisch zeer sterk geconserveerd 
is. Tezamen zijn dit sterke aanwijzingen dat de typische Beijing genotype familie een evolutio-
nair voordeel heeft ten opzichte van andere M. tuberculosis families. 
In hoofdstuk 2 is onderzocht of er eiwitten aanwezig zijn in het proteoom van de typische Be-
ijing genotype familie die deze stammen een evolutionair voordeel geven. Hiervoor is het prote-
oom van typische Beijing isolaten vergeleken met het proteoom van atypische Beijing isolaten. 
De atypische, of ‘ancient’  Beijing familie is evolutionair gezien van alle M. tuberculosis families 
het meest verwant aan de typische Beijing genotype familie. De atypische Beijing genotype 
familie is echter niet zo sterk geassocieerd met een verhoogde prevalentie en antibioticaresi-
stentie als de typische Beijing strain.
Uit de resultaten bleek dat het proteoom van de onderzochte typische en atypische Beijing 
isolaten in grote mate overeenkomstig zijn. Slechts vier eiwitten kwamen in verschillende rela-
tieve hoeveelheden voor in stammen van beide families: Rv0450c/MmpL4, Rv1269c, Rv3137, 
and Rv3283/sseA. Transcriptionele en functionele analyse van deze vier eiwitten in een cohort 
van 29 klinische Beijing isolaten liet zien dat typische Beijing isolaten meer Rv0450c/MmpL4 
tot expressie brengen dan de geteste atypische Beijing isolaten. Rv0450c/MmpL4 is betrokken 
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bij de ijzerhuishouding van M. tuberculosis. De verhoogde aanwezigheid van Rv0450c/MmpL4 
eiwit en mRNA in typische Beijing isolaten is een eerste verklaring waarom individuen met een 
mutatie in SLC11A1/NRAMP1, een eiwit dat betrokken is bij de ijzerhuishouding in de gastheer, 
een verhoogde kans op een infectie met Beijing stammen hebben. 
In tegenstelling tot Rv0450c/MmpL4, was het eiwit Rv3283/sseA verminderd aanwezig in de on-
derzochte typische Beijing isolaten. Uit de bioinformatische analyse, beschreven in hoofdstuk 
2, blijkt dat de verminderde aanwezigheid van Rv3283/sseA in typische Beijing isolaten ten op-
zichte van atypische Beijing isolaten veroorzaakt wordt door een specifieke mutatie in typische 
Beijing stammen, die een instabiliteit van het eiwit veroorzaakt. Daarmee demonstreert deze 
studie een direct verband tussen het afwijkende genotype en fenotype van typische Beijing 
stammen ten opzichte van de nauwverwante atypische Beijing stammen.
De bevinding dat de relatieve kwantiteit van Rv0450c/MmpL4 en Rv3283/sseA verschilt tussen 
typische en atypische Beijing isolaten is een eerste stap om de hogere prevalentie van typische 
Beijing stammen te verklaren aan de hand van het mycobacteriële fenotype. Echter biedt het 
nog geen verklaring voor de correlatie met antibioticaresistentie. Om erachter te komen welke 
eiwitten een rol spelen bij de initiële respons van typische Beijing stammen op antibiotica is in 
hoofdstuk 3 een typische Beijing stam blootgesteld aan een hoge concentratie rifampicine, één 
van de belangrijkste eerstelijns antibiotica voor de behandeling van TB.
Gedurende de eerste 24 uren na blootstelling aan rifampicine steeg de relatieve hoeveelheid 
van zogenaamde ‘dormancy regulon encoded genes’ (DosR) in het proteoom van typische Be-
ijing stammen opvallend veel. DosR genen komen sterk verhoogd tot expressie komen wanneer 
de bacterie in een zuurstofarm milieu terecht komt. Door de aanwezigheid van DosR eiwitten 
zal M. tuberculosis snel in een latente of ‘dormancy’ fase terechtkomen, waarin deze minder 
vatbaar is voor antibiotica. Door blootstelling aan rifampicine steeg niet alleen de relatieve 
hoeveelheid DosR eiwitten. Na het bestuderen van fenotypische dormancy markers bleek ook 
dat de gehele kweekpopulatie van het onderzochte typische Beijing isolaat een pre-dormant fe-
notype heeft dat nog ‘meer’ dormant wordt na blootstelling aan rifampicine. De bevinding dat 
DosR eiwitten een belangrijke rol spelen bij de initiële respons van typische Beijing stammen op 
antibiotica is nieuw en is een nog niet eerder beschreven manier van M. tuberculosis om op een 
actieve manier fenotypische antibiotica tolerantie te ontwikkelen. 
In hoofdstuk 4 is onderzocht of de initiële respons van typische Beijing stammen op rifampicine 
uniek is, of dat deze reactie ook waar te nemen is bij andere M. tuberculosis stammen. Om deze 
onderzoeksvraag te beantwoorden is eerst het proteoom van een typische Beijing stam vergele-
ken met het proteoom van M. tuberculosis controle stam H37Rv, zowel voor- als na blootstelling 
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aan rifampicine. In beide M. tuberculosis stammen nam de relatieve hoeveelheid DosR eiwitten 
toe in de eerste 24 uur na blootstelling aan rifampicine. Echter, de relatieve hoeveelheid van 
meerdere DosR eiwitten was al hoger in typische Beijing stammen voordat rifampicine werd 
toegevoegd aan de kweek. Ook steeg de relatieve hoeveelheid van meerdere DosR eiwitten 
sneller in de onderzochte typische Beijing stam dan bij andere stammen. De verhoogde aanwe-
zigheid van DosR eiwitten in typische Beijing stammen, nog voordat de bacterie in aanraking 
is gekomen met een antibioticum, duidt erop dat de typische Beijing stammen te allen tijde 
voorbereid zijn om effectief in een dormancy stadium over te gaan.
Om te bepalen of typische Beijing stammen relatief grote hoeveelheden DosR eiwitten bevatten 
t.o.v. andere stammen, werden meerdere DosR eiwitten gekwantificeerd in 27 klinische M. tuber-
culosis  isolaten, afkomstig van vijf van de meest voorkomende M. tuberculosis geotype families. 
De regulatoire DosR eiwitten waren verhoogd aanwezig waren in zowel typische als atypische  Be-
ijing stammen. Deze observatie duidt op een evolutionair voordeel voor de gehele M. tuberculosis 
Beijing familie. Dit biedt deze specifieke M. tuberculosis genotype familie de mogelijkheid om te 
persisteren tijdens behandeling met antibiotica en resistentie te selecteren. Daarom staat de in 
dit proefschrift beschreven observatie mogelijk in direct verband met de associatie tussen Beijing 
stammen en antibioticaresistentie in diverse regio’s in de wereld, waaronder Europa en Azië.
De bevinding dat eiwitten van het DosR regulon verhoogd aanwezig zijn in Beijing stammen 
biedt niet alleen een mogelijke verklaring voor de associatie tussen dit genotype en antibiotica-
resistentie, maar geeft ook een nieuwe kijk op huidige antibioticaresistentie testen. Een veelge-
bruikte test voor het bepalen van antibioticaresistentie is de Minimum Inhibitory Concentration 
(MIC) test. Hierbij wordt de antibioticaconcentratie bepaald waarbij de M. tuberculosis bacterie 
stopt met groeien. De aanname is dat boven de MIC de bacterie niet meer groeit omdat de 
concentratie antibiotica toxisch of remmend is voor het pathogeen. De bevindingen beschre-
ven in dit proefschrift laten zien dat M. tuberculosis blootstelling aan antibiotica kan overleven 
doordat deze in een stadium van dormancy over gaat om zich te beschermen tegen de invloed 
van antibiotica, om later alsnog opnieuw uit te groeien. De mogelijkheid bestaat zelfs dat de 
bacterie vele malen hogere concentraties van antibiotica kan tolereren. Concluderend kan ge-
steld worden dat een MIC bepaling uitsluitend iets zegt over de laagste concentratie waarbij 
bacteriële groei geremd wordt, maar dat deze niet noodzakelijkerwijs direct verband houdt 
met het overleven van het pathogeen onder invloed van antibiotica. Deze observatie dient als 
mogelijke verklaring voor de vele TB relapsen na ‘geslaagde’ behandelingen.
Vanwege de toenemende mate van antibioticaresistentie wereldwijd en het feit dat de meeste 
beschikbare antibiotica met name werkzaam zijn tegen metabool actieve en delende myco-
bacteriën is het belangrijk om de zoektocht naar nieuwe antibiotica voort te zetten. Dit wordt 
A
NEDERLANDSTALIGE SAMENVATTING | 217
verder onderstreept door de in dit proefschrift beschreven bevindingen dat blootstelling aan 
antibiotica ook direct antibiotica tolerantie kan veroorzaken door het induceren van dormancy. 
Een medicijn dat mogelijk geschikt is voor de behandeling van dormant TB, MDR-TB, XDR-TB 
en mogelijk zelfs TDR-TB, is thioridazine. Thioridazine is een antipsychoticum dat met succes 
off-label gebruikt is voor de behandeling van XDR-TB patiënten en in vitro actief is tegen zowel 
metabool actieve als metabool inactieve, dormant, M. tuberculosis. Buiten de anti-TB activiteit 
van thioridazine, werkt dit middel synergistisch met reeds bestaande eerstelijns antibiotica. De 
theorie voor het werkingsmechanisme is dat het de effluxpompen (afvoerpompen) van bacteri-
en zou remmen, waardoor er een stapeling van stoffen als antibiotica zo ontstaan. Hoewel het 
potentieel van thioridazine als nieuw middel voor de behandeling van TB is aangetoond, zoals 
blijkt uit zowel in vitro als in vivo data, is het exacte mechanisme van thioridazine onbekend. 
In hoofdstuk 5 is onderzocht op welke manier thioridazine M. tuberculosis weet te bestrijden en 
waarom dit middel met name goed werkt in combinatie met andere antibiotica. Door het bestu-
deren van het M. tuberculosis proteoom in de aan- en afwezigheid van thioridazine is ontdekt 
welke eiwitten betrokken zijn bij het in stand houden van het pathogeen. De theorie als basis 
voor deze studie was dat eiwitten die differentieel tot expressie komen tijdens de behandeling 
met thioridazine betrokken zijn bij cellulaire processen die moeten compenseren voor de door 
het antibioticum toegebrachte schade. 
Meerdere van de eiwitten die differentieel gereguleerd werden tijdens behandeling met
thioridazine bleken betrokken bij het produceren en in stand houden van de celenvelop. Aan 
de hand van de gegenereerde proteomics data en beschikbare literatuur kwam de hypothese 
tot stand dat thioridazine de celenvelop van M. tuberculosis beschadigt. Analyse van de vetzuur 
compositie in de plasmamembraan van M. tuberculosis liet zien dat behandeling met thiori-
dazine de relatieve hoeveelheid ‘tuberculostearic acid’ beïnvloedt, hetgeen kan wijzen op een 
verandering van de celenvelop permeabiliteit. 
Als de celenvelop van M. tuberculosis permeabeler wordt, betekent dit dat antibiotica gemakkelij-
ker de cel in komen om hun anti-TB functie uit te oefenen. Om te testen of langdurige blootstelling 
van M. tuberculosis aan thioridazine de permeabiliteit van de celenvelop inderdaad beïnvloedt, 
werd een cellulair assay ontwikkeld waarmee cel permeabiliteit en efflux pomp activiteit gemeten 
kan worden, omdat beide mechanismes bijdragen aan de accumulatie van componenten in de cel. 
Uit deze data bleek dat thioridazine de celenvelop permeabiliteit beïnvloedt, maar er werd geen 
direct bewijs gevonden dat thioridazine de activiteit van efflux pompen remt.
Aan de hand van de data uit hoofdstuk 5 kan worden beredeneerd dat thioridazine M. tubercu-
losis kan doden doordat deze zich richt op de mycobacteriële celenvelop. Een verhoogde per-
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meabiliteit van de celenvelop zorgt er ook voor dat andere antibiotica makkelijker accumuleren 
in de cel. Nu er een beter beeld is van het mechanisme van thioridazine kan dit hopelijk leiden 
tot beter, efficiënter gebruik van dit medicijn, of derivaten van dit veelbelovende medicijn.
Tenslotte is er binnen de studies in dit proefschrift gekeken hoe massaspectometrie gebruikt 
kan worden voor de identificatie van mycobacteriën. Binnen het Mycobacterium geslacht zijn 
momenteel meer dan 140 species beschreven. Hoewel alle species binnen hetzelfde geslacht 
vallen als M. tuberculosis, zijn niet alle mycobacteriën van klinisch belang en zijn niet alle spe-
cies gevoelig voor dezelfde antibiotica. Identificatie van het mycobacteriële species is van be-
lang om tot een juiste behandeling van de patiënt te komen en de epidemiologie te begrijpen. 
In hoofdstuk 6 laten wij zien dat de mate van verwantschap tussen nauw verwante mycobacte-
riën bepaald kan worden met behulp van massaspectometrie. De in dit proefschrift beschreven 
methode vergelijkt het aantal overeenkomstige tandem massaspectra tussen verschillende pro-
teolytische digesten van de onderzochte mycobacteriële species. De voordelen van de beschre-
ven methodologie ten opzichte van bestaande diagnostische technieken is dat er geen a priori 
kennis van het te identificeren pathogeen nodig is, de methode naar alle waarschijnlijkheid kan 
worden toegepast op andere micro-organismen, alle tandem massaspectra gebruikt kunnen 
worden voor het clusteren van de verschillende species en dat de methode werkt op zowel hoge 
als lage resolutie massa spectrometers. 
De limitaties en verdere mogelijkheden van de methode beschreven in hoofdstuk 6 en hoofd-
stuk 7 zullen verder onderzocht moeten worden voordat overwogen kan worden of deze bena-
dering in een klinische setting toegepast kan worden. Desalniettemin kan op basis van de in dit 
proefschrift beschreven informatie geconcludeerd worden dat deze methode de potentie heeft 
om onze kennis omtrent de fenotypische verwantschap tussen de verschillende mycobacteri-
ele species te vergroten. Hoewel er in hoofdstuk 6  uitsluitend een ‘proof of principle’ van de 
methode is gedemonstreerd, zou het principe van deze techniek gebruikt kunnen worden voor 
snellere en accurate identificatie van pathogenen. Uiteindelijk zal dit kunnen leiden tot een 
effectievere behandeling van patiënten met infecties van nontuberculeuze mycobacteriën in 
de toekomst.
Conclusie
Het onderzoek beschreven in dit proefschrift biedt inzicht in de moleculaire mechanismes die 
betrokken zijn bij het ontstaan rifampicine tolerantie; de limitaties van de huidige antibiotica 
gevoeligheidstesten; inter- en intra-stam variatie binnen de M. tuberculosis genus; het anti-my-
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cobacteriële mechanisme van thioridazine en potentiële nieuwe diagnostische methoden voor 
identificatie. Deze bevindingen onderstrepen dat antibioticaresistentie niet enkel een genetisch 
probleem is, maar dat eiwit regulatie een belangrijke rol speelt bij de totstandkoming van an-
tibioticaresistentie. Hoewel dit proefschrift aantoont dat het fenotype van Beijing stammen er 
voor zorgt dat dit pathogeen relatief goed bestand is tegen veel van de momenteel beschikbare 
antibiotica, laten de uitkomsten van dit proefschrift ook zien dat wanneer kennis met betrek-
king tot het ontstaan van antibioticaresistentie wordt vergroot, nieuwe verbeterde diagnosti-
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bedankt dat jullie mij lieten zien dat er meer in het leven is dan pipetteren.
Mamma, dankzij jouw onvermoeibare steun en hulp ben ik in de mogelijkheid gekomen om 
aan een promotietraject te beginnen. Pappa, je hebt mij meer dan eens gezegd dat je naast 
je schoenen zou lopen van trots mocht ik op een dag promoveren. Hoe erg ik het ook vind dat 
je er niet bij kan zijn, denk ik warm terug aan alle momenten die wij samen hebben gedeeld 
en die uiteindelijk hebben geleid tot dit moment. Als ouders staan jullie aan de basis van dit 
proefschrift, ik hoop dat jullie zo trots op mij zijn als ik op jullie ben.
Lieve Talitha, het moeilijkste deel van het proefschrift is misschien wel op papier zetten hoe 
dankbaar ik ben voor alles wat je de afgelopen jaren voor mij hebt gedaan. Hoewel ik altijd 
enthousiast ben als het over mijn promotieonderzoek gaat, weet jij als geen ander dat er ook 
moeilijkere momenten zijn geweest. Jouw liefde, onvermoeibare geduld en steun, ook als ik 
weer eens een weekend aan dit proefschrift spendeerde, zijn de belangrijkste redenen dat het 
tot een afgerond geheel is gekomen. Ik ben dan ook blij de laatste zin van mijn proefschrift te 
hebben geschreven, zodat ik vanaf nu mijn vrije tijd met jou en onze kudde kan doorbrengen!
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